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ABSTRACT

A RETROSPECTIVE DATA ANALYSIS IN VETERANS WITH INFLAMMATORY
BOWEL DISEASE: USING WAGNER’S CHRONIC CARE MODEL
TO EXPLORE MEDICATION ADHERENCE

By
Lori K. Rizzo
August 2014

Dissertation supervised by Dr. Alison M. Colbert

Background
Medication adherence in inflammatory bowel disease (IBD) ranges between
7-72%. Increased healthcare utilization has been associated with non-adherence in IBD.
Wagner’s Chronic Care Model (CCM) posits that care coordination between primary and
gastroenterology (GI) specialty care could improve adherence and healthcare utilization.

Methods
Guided by the CCM, a retrospective analysis was conducted in veterans with IBD to:
describe medication adherence rates; describe healthcare utilization measured by ER visits and
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inpatient admissions; and describe care coordination measured by primary care and GI specialty
care use. A secondary study aim was to explore the relationships between those key outcome
variables and select demographic/health history characteristics.
A local Veteran’s Affairs database was used to extract a cohort of individuals with
Crohn’s disease and ulcerative colitis for fiscal year (FY) 2011. Medical utilization and IBD
medication refills were collected. A dichotomized medication possession ratio (MPR .80) was
used in logistic regression to identify factors affecting medication adherence. Logistic regression
was also used to examine factors affecting ER visits, inpatient utilization, and care coordination.

Results
The cohort consisted of 165 White male veterans 75 with Crohn’s disease and 89 with
ulcerative colitis. The overall rate of adherence was 50.9% with a median MPR of .82.
Regression models did not render any statistically significant predictors of adherence. ER
utilization was significantly associated with adherence (OR=.314, 95%CI=.111-.886, p=.029)
and care coordination (OR=45.73,95%CI=9.053-231,p=.001) in multivariate analysis. Inpatient
admission was associated with: younger age (OR=.108,95%CI:.019-.609,p=.012), adherence
(OR=.113,95%CI=.014-.939,p=.044), IBD diagnosis (OR=.117,95%CI=.017-.784,p=.027), and
care coordination (OR=11.89,95%CI=1.228-115,p=.033). Logistic regression identified
statistically significance associations with care coordinated between primary and GI specialty
care and the following factors: taking both a 5-ASA and immunomodulating medication
(OR=5.122,95%CI=1.874-14.00, p=.001), younger age (OR=.905,95%CI=.871-.940,p=.001),
and having a comorbidity (OR=2.643,95%=1.171-5.965,p=.027).
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Conclusions
No predictors of medication adherence emerged. However, the CCM element of care
coordination provided additional insight into the healthcare utilization of veterans with IBD as
statistically significant associations between care ER visits and hospitalization were identified.
Further inquiry into the influences of medication adherence and healthcare utilization in this
population is warranted.

key words: adherence to medication, Wagner’s chronic care model, coordination of care,
veterans, inflammatory bowel disease
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Chapter 1
Introduction
Chapter 1 provides an overview for this dissertation study. This chapter includes study
background, purpose, aims, as well as operational definition of variables. Additionally, the
chapter encompasses study assumptions and limitations. Finally, this chapter concludes with
study significance to nursing.

1.1 Background of the Study
Chronic illness affects nearly one-half of those residing in the United States including
those who suffer with inflammatory bowel disease (IBD), a set of chronic inflammatory diseases
of the GI tract with symptoms that exacerbate and ameliorate (Robert Wood Johnson
Foundation, 2013). IBD affects 1.5 million Americans (Kappleman, Moore, Allen, & Cook,
2013) , approximately 45,000 of whom are veterans who utilize Veterans Affairs (VA) for
chronic illness care of this disease (Hou, Kramer, Richardson, Mei, & El-Serag, 2013).
Medication Adherence
Long-term medication administration is required in IBD for disease control that is
tenuous (Peppercorn, 2012). There are no allowable gaps in treatment, making strict medication
adherence critical to successful disease control (Regueiro, 2012a). A systematic review
demonstrated that medication adherence in IBD is problematic and in the range of 7-72%
corresponding to rates in other chronic disease (C. A. Jackson, Clatworther, Robinson, & Horne,
2010; Krueger, Berger, & Felkey, 2005). However, little is known about medication adherence
rates for veterans with IBD who access healthcare through the VA. This gap in scientific
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knowledge supported the primary line of inquiry for this study exploring the rates of medication
adherence in this cohort.
Over 50 years of medication adherence research exists. However, the topic only came to
the forefront in IBD in the last 20 years and remains inconsequential in the minds of clinicians
who fail to recognize the need for assessment of medication adherence as part of routine chronic
illness care in this population (Trindade, Morisky, Ehrlich, Tinsley, & Ullman, 2011).
Furthermore, a review of the literature conducted for this study, demonstrated that those who do
conduct an assessment, utilize non-validated tools, calling into question the reliability of the
results from this type of inquiry. Therefore, adherence science in IBD continues to stymie.
The majority of adherence research in IBD has taken place in the last five years, using
cross-sectional design, conducted in small samples of specialty IBD clinic patients throughout
the world. Modifying factors affecting medication adherence in IBD are not distinctive, existing
in many chronic diseases and include lack of knowledge regarding illness and treatment,
discordance in the physician-patient relationship, low health literacy, pill burden, and depression
(C. A. Jackson et al., 2010). Several noteworthy, unique, condition specific factors found to
affect adherence included disease duration, remission status, disease type (CD versus UC), new
patient status, timing of last colonoscopy, and taking immunosuppressants (C. A. Jackson et al.,
2010) . The literature presents conflicting data for non-modifiable risk factors for non-adherence
in most diseases, including IBD, such as age, gender, and race, supporting closer examination of
these demographics in this study.
Over a decade ago, the international community (National Council on Patient Information
and Education, 2007; National Institutes of Health, ; World Health Organization, 2003)
recognized medication adherence in chronic disease as a healthcare crisis that today, continues to
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consume scarce healthcare resources (Lachaine, Yen, Beauchemin, & Hodgkins, 2013) . Despite
international recognition, scientific stalemate persists because uncertainty remains about how
best to define and measure medication adherence. After years of intensive review, the
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced a call
to action to standardize both the definition and measurement of medication adherence. These
efforts were aimed at improving the quality of adherence research so that results could be
compared across studies to move science forward (Cramer et al., 2008). While no “gold
standard” to measure adherence exists, IBD experts deemed use of pharmacy refill data as the
criterion measure in this cohort, specifically the calculation of the Medication Possession Ratio
(MPR) (S. Kane et al., 2012). This recommendation is corroborated by ISPOR (Peterson et al.,
2007) and supports the retrospective research design chosen for this study.
Chronic Care Model
Initially, the patient was at the center of non-adherence research. However, as
understanding of the concept evolved, the complexity of treatment adherence emerged,
demonstrating that healthcare systems providing services were not meeting the treatments needs
of those with chronic disease (Wagner, 1998). As a result, adherence research began to change
its focus from individual behaviors to examination of healthcare systems as a whole. Treatment
deficiencies were the genesis for the Chronic Care Model (CCM) that provides a framework for
chronic illness care based on best practices that accounts for intricate systematic influences on
the delivery of healthcare (Wagner, Austin, & Von Korff, 1996).
Additionally, as acknowledged by global adherence experts, congruent with the CCM,
the impact of healthcare systems outside the U.S. on medication adherence in IBD cannot be
understated (World Health Organization, 2003). A study conducted by (Robinson, 2001)
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demonstrated the potential influences of the health system on adherence in IBD in a study
conducted to examine the rates of non-adherence in European countries. Reported rates of nonadherence varied widely between countries: France 13%, Italy 25%, UK 33%, and Germany
46%. That said, at least 50% of adherence research in IBD has occurred outside the U.S. with
virtually no investigations conducted in the U.S. evaluating systematic effects. Therefore, a
discrepancy in the literature exists regarding not only the effects of healthcare delivery in the
U.S. on adherence in IBD, but also the effects of a closed system such as the VA has on
medication adherence in this population. This supports the use of the systems based framework
chosen for this study. The results of this investigation aid in rectifying informational inequality
existing in IBD adherence research.
Moreover, in 2003, (World Health Organization, 2003) acknowledged that little research
on the effects of healthcare teams and system-related factors on adherence exists, which, a
decade later, remains true in patients with IBD, supporting further study in this arena (Shah,
Tinsley, & Ullman, 2011) . Therefore, the CCM provides the framework for this study exploring
the influences of the Veterans Affairs (VA) healthcare system in veterans with IBD.
Specifically, the effects of primary and specialty care in this population.
Primary care is at the Model’s center since this is the origin of chronic care in this
country, including in the VA, because primary care acts as a gatekeeper to access VA specialty
care (Kizer, 1996). Moreover, with the advent of evidence based medicine and the development
of clinical practice guidelines, primary care is at the forefront of preventing and treating chronic
illness (Starfield, Shi, & Macinko, 2005) . However, experts in chronic disease management
propose coordination of care between primary and specialty care as a mechanism to attain
optimal health (Shi & Singh, 2012).
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For this study, gastroenterology was the specialty of focus, consulted through primary
care, for the management of IBD. The literature suggests that organizational variables such as
number of visits to primary and specialty care, as well as continuity of care, may have far greater
impacts on treatment adherence than any other intervention (Albaz, 1997). One of the main
functions of primary care is the coordination of care between primary and specialty care service
lines (Shi & Singh, 2012) . Coordination of care between these two departments was the CCM
element of interest in this study as it relates to medication adherence and healthcare utilization in
this population, as the role of care coordination is requisite to improve adherence in chronic
disease and was not formally explored in IBD. (MacColl Institute for Healthcare Innovation,
2010; World Health Organization, 2003) .
Care coordination is integral to delivery of chronic illness care in the Veterans Health
Administration (VHA), a multifaceted agency governing the largest integrated benefits system in
the world, the VA, providing services to honorably discharged members of the U.S. Armed
Services (Kizer & Dudley, 2009) . VHA adopted the CCM in the late 1990s as a vehicle for
transformation of this closed healthcare system (Perlin, J. B, Kolodner, R. M., & Roswell, R. H.,
2004). Care coordination, a priority in VHA, occurs through the “medical home” model that
consists of an interdisciplinary team of health professionals housed in primary care with requisite
consultation to specialists as warranted (Shi & Singh, 2012) . VA efforts are consistent with the
plan for coordination of care set forth by the (MacColl Institute for Healthcare Innovation, 2010)
from which the CCM originates.
Intuitively, coordination of primary and specialty care should equate with improved
health outcomes. However, the results from a recent Cochrane review (S. M. Smith, Allwright, &
O'Dowd, 2009) conducted to assess the effectiveness of care coordination between primary and
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specialty care in chronic disease management, were conflicting. Overall, no consistent
improvement in outcomes across disease states materialized with the exception of medication
adherence that indicated significant benefit with care coordination in this realm, supporting the
need for further inquiry into the effects of care coordination on medication adherence for which
no data exists in veterans with IBD (Neugaard, Priest, Burch, Cantrell, & Foulis, 2011).
This study builds on existing research by conducting the first medication adherence
assessment of veterans to offer a critical evaluation of systematic influences of the VA on
coordination of care, medication adherence, and healthcare utilization in patients with IBD. The
results of this study may inform clinical practice as well as national health policy on the manner
in which chronic illness care occurs in veterans with IBD.
Healthcare Utilization
Evidence suggests that when chronic illness is sub optimally treated, complications may
worsen leading to increased consumption of healthcare resources such as ER services, inpatient
admissions, as well as office visits (N. H. Miller, 1997), suggesting that higher levels of
medication adherence may reduce healthcare costs, assuming the medication was appropriately
prescribed (Sokol, McGuigan, Verbrugge, & Epstein, 2005). Repeatedly, research has
demonstrated that those with IBD who do not follow prescribed medication regimes are at
increased risk for disease relapse, up to five times that compared to those who adhere (Bhatt,
Patil, Joshi, Abraham, & Desai, 2009; S. V. Kane & Hanauer, 2000; S. Kane, Huo, & Magnanti,
2003) . A disease flare, perhaps compelled by non-adherence to therapy, could influence the
need for health services. Direct healthcare costs estimates are $3.1 billion for CD and $2.1 billion
for UC (Kappleman et al., 2011).
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World adherence experts (World Health Organization, 2003) provide support for
examination of healthcare utilization concurrently with medication adherence rates as this data
works synergistically to accurately inform health outcomes and future interventions. Additional
support for this study emanates from two recently published papers from IBD experts
(Kappelman, Palmer, Boyle, & Rubin, 2010; Shah et al., 2011) that identified gaps in the
literature regarding patterns of healthcare utilization in this cohort for which a dearth of
information exists due to the decentralized nature of the healthcare system in the U.S.
(Kappleman et al., 2011). Therefore, this study began to explore the relationship between
medication adherence and healthcare utilization in veterans with IBD as the consequence of
these relationships are unknown.

1.2 Purpose of Study
The purpose of this descriptive, retrospective data analysis was to convey medication
adherence rates of veterans with IBD and to examine the relationships between care
coordination, medication adherence, and healthcare utilization.

1.3 Specific Aims
The primary aim for this study was as follows:
1.

Described medication adherence, healthcare utilization, and care coordination of
veterans with inflammatory bowel disease (IBD) who employ Veterans Affairs
(VA) healthcare at one Veterans Affairs Medication Center (VAMC).

Secondary study aims were as follows:
1.

Examined the association between medication adherence adjusted for
care coordination, age, IBD diagnosis, comorbidity, and IBD medication in
veterans with IBD who employ VA healthcare.
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2.

Explored the relationship between healthcare utilization adjusted for medication
adherence, age, IBD diagnosis, IBD medication, coordination of care and
comorbidities in veterans with IBD who employ VA for healthcare.

1.4 Definition of Terms
Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is a set of conditions including, ulcerative colitis (UC)
and Crohn's disease (CD), that cause chronic inflammation of the GI tract (Peppercorn, 2012).
The ICD-9 code of 555.x for CD and 556.x for UC identified subjects with said disease in this
study (Thirumurthi, Chowdhruy, Richardson, & Abraham, 2010).
Medication Adherence
Researchers have posited many definitions of medication adherence. This study used the
definition of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
that defines medication adherence as the "extent to which a patient acts in accordance with the
prescribed interval, dose, and dosing regimen (Cramer et al., 2008, p.46). Adherence is reported
as a percentage of total number of doses taken (if prospectively measured) or therapy-days
available (if retrospectively measured), in relation to the time period of observation during which
compliance is measured" (Burrell, Wong, & Ollendorf, 2005, p.194). Medication adherence was
assessed using VA pharmacy refill data to calculate a rate of adherence using the medication
possession ratio (MPR) defined as: “the sum of the days’ supply of medication divided by the
number of days between the first fill and the last refill plus the days’ supply of the last refill”
(Sikka, Xia, & Aubert, 2005, p. 449). The terms "adherence" and "compliance" are
indistinguishable in the literature. For this study, the two terms were synonymous.
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Healthcare Utilization
Healthcare utilization was the “use of healthcare resources” (Bernstein et al., 2003, p.1).
For this investigation, the following healthcare services represented healthcare utilization:
emergency department visits and inpatient admissions
Emergency Department Visit
Emergency department (ED) visit was defined as the “direct personal exchange between
a patient and a physician or other healthcare provider working under the physician’s supervision,
for the purpose of seeking care and receiving personal health services” (Bernstein et al., 2003,
p.129). For this study, the total number of ED visits in FY 2011 represented healthcare utilization
of ED services as measured by clinic stop code 77 for any diagnosis.
Inpatient Admission
An inpatient admission was “an admission to an inpatient service of a hospital for
observation, care, diagnosis, or treatment” (Bernstein et al., 2003, p.130). Inpatient admissions
were measured as the total number of inpatient admissions for FY 2011.
Outpatient Department Visit
An outpatient department (OPD) visit was “the direct, personal exchange between an
ambulatory patient seeking care and a physician or other healthcare provider to render personal
health services within a hospital facility” (Bernstein et al., 2003, p.130). OPD visit measurement
consisted of clinic stop codes for primary and specialty (Gastroenterology) care.
Primary Care
Primary care was defined as the provision of "integrated, accessible healthcare services
by clinicians who are accountable for addressing a large majority of personal healthcare needs,
developing a sustained partnership with patients, and practicing in the context of family and
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community" (Vaneslow, Donaldson, & Yordy, 1995, p.192). Identification of healthcare
utilization occurred using a clinic stop code, “a required field in the VA OPC Hospital Location
file that assigns a number representing a type of care or Service/treating Specialty” (Zivin et al.,
2010) . The clinic stop codes of 323, 301, 322, 348, 350, 170, 634, and 172 represented primary
care for this study.
Specialty Care
Specialty care was the "delivery of care to individuals based on a certain physiological
system or clinical condition or based principally on the age of patients" (S. M. Smith et al., 2009,
p.3). Specialty care referred to Gastroenterology as measured by clinic stop code 151.
Care Coordination
Care coordination was the “deliberate organization of patient care activities between two
or more participants (including the patient) involved in a patient’s care to facilitate the
appropriate delivery of healthcare services. Organizing care involves the marshaling of personnel
and other resources needed to carry out all required patient care activities, and is often managed
by the exchange of information among participants responsible different aspects of care”
(McDonald et al., 2007, p.41). The literature characterizes the term “shared care” as tantamount
with coordination of care, as was the case for this study (Starfield, 2003). The stop codes for
primary care (323, 301, 322, 348, 350, 170, 634, 172) and gastroenterology (specialty care, 151)
represented care coordination. Coordination of care was assumed when the patient had clinic
stop codes for both primary and specialty care.
Comorbidity
Comorbidity was the "presence of additional diseases in relation to an index disease in
one individual" (Valderas, Starfield, Sibbald, Salisbury, & Roland, 2009, p.359) measured by
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ICD-9 code as reported by (Deyo, Cherkin, & Ciol, 1992), originating from (Charlson, Pompei,
Ales, & MacKenzie, 1987). The index disease in this study was IBD. Therefore, measurement of
this construct provided information regarding the influences of diseases additional to IBD on
healthcare utilization in the population of interest.
Demographic Variables
Demographic variables included age, gender, and race/ethnicity. VA administrative
databases provided this information.

1.5 Assumptions
The assumptions for this study were as follows:
1.

Patients who obtained prescriptions for IBD medications consumed the
medication starting the first day of the fill, used the drug as prescribed, and
consumed all medications obtained. Patients were not stock piling medication,
skipping doses, or giving their medications away.

2.

When measuring adherence by drug class or by condition, patients were adherent
as long as they received medication from a drug class for a specific condition,
regardless of dose titration, switching, as well as adding or dropping medications.

3.

Medications prescribed for IBD were appropriate for treating the intended
condition.

4.

The diagnosis of IBD, as documented by ICD-9 code, was accurate.

5.

Patients used VA for healthcare services only.

6.

Patients received the correct number of tablets equating to the days’ supply
of fill per dosing instructions.
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7.

Patients were assumed to have care coordinated if both primary and specialty GI
clinic stop codes were present.

1.6 Limitations
The limitations of this study were as follows:
1.

Because the study was limited to veterans who utilized the VA for healthcare, the
findings may not be generalizable to veterans who do not use the VA for
healthcare or to the civilian population.

2.

Patients may have filled prescriptions for IBD medications outside the VA
pharmacy.

3.

Observations made about adherence in this study were not sufficient to
characterize the patients' adherence to all medications in his/her regime.
Calculated adherence only applied to those medications taken for IBD.

4.

Since data extraction occurred from administrative data sets, information captured
may be incomplete and data of unknown quality.

5.

Patients may have accessed healthcare services outside the VA Healthcare
System.

6.

Feasibility did not allow a multi-method approach to data collection that included
both a self-report and an objective measure, as considered state-of-the-art in
measuring adherence behavior (World Health Organization, 2003).

7.

Local VA databases did not contain the Sig for medications. Therefore, the
researcher was unable to compare the number of tablets dispensed against the
dosing instructions to ensure accuracy of prescription refills.
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1.7 Significance to Nursing
Non-adherence to medication is an international healthcare crisis resulting in increased
morbidity and mortality in many chronic illnesses including IBD (World Health Organization,
2003). Current understanding of medication adherence acknowledges this construct as
multifaceted requiring a multidisciplinary team approach to disease management. Yet, who the
members of such a team should be, and the definitions of their roles, are not evident. Much of the
published literature regarding coordination of care in patients with IBD hales from the position
of specialty care synchronization. Little knowledge exists concerning the outcomes of shared
care across the primary/specialty care continuum in patients with IBD, particularly rates of
medication adherence and healthcare utilization patterns in this cohort.
A recent synthesis of the literature suggested that nurses are the crucial link between
primary care and specialty care coordination in the chronic disease management of IBD
(Hernandez-Sampelayo et al., 2010). Support of this notion came from a case study conducted in
the VA that explored the role of the nurse in coordinated shared medical appointments between
primary and specialty care using the CCM as a guiding framework (Watts, Hynes, & Kopp,
2003). Furthermore, the American Academy of Nurse Practitioners and the White House also
recognized the unique, integral role nurses play in chronic illness care by endorsing the expanded
role of nurse practitioners in chronic disease treatment of our Nation’s veterans in a collaborative
effort known as Joining Forces (American Academy of Nurse Practitioners, 2012).
This study began to describe the impact of coordination of care on medication adherence
and healthcare utilization in patients with IBD. Armed with knowledge regarding the effects of
coordination of primary and specialty care on medication taking behavior and resource
utilization, nurses are poised to make significant impacts on patient care and to advocate
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allocation of scare healthcare resources. Nurses contribute to the chronic illness care in IBD by
generating effective interventions and changing health policy in this population about which,
currently, little information exists.
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Chapter 2
REVIEW OF LITERATURE
2.1 Introduction
This chapter presents the theoretical foundation for this study as well as the current state
of knowledge of the disease state under consideration, along with a comprehensive discussion
surrounding the nomenclature and measurement of adherence as it relates to the population of
interest. A summary show casing the gaps in the literature rounds out this chapter.

2.2 Conceptual Framework: The Chronic Care Model
Chronic illness affects more than 133 million individuals in this country with
approximately half of these individuals experiencing more than one chronic illness
(Bodenheimer, Chen, & Bennett, 2009). Research suggests that system(s) in which individuals
obtain care for chronic illness are not conducive to meeting care needs of this vast group and
result in deficient management of the most common chronic illnesses (Bodenheimer et al., 2009).
In response to these deficiencies, (Wagner et al., 1996) generated a model to improved care for
chronic conditions, the Chronic Care Model (CCM).
In broadest terms, the CCM seeks to encompass systems change by examining the
interactive relationship between three key areas of influence on chronic illness care: the
community, the healthcare system, and the provider organization. Primary care is the principal
location of chronic illness care and is therefore, the focus of the Model.
The CCM places a self-motivated patient at the center of chronic care delivery as a method to
improve disease management and to prevent complications. However, primary care collaboration
between the patient, healthcare provider, and the healthcare system provides the underpinning for
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the Model that posits resultant mutual goals, requisite skills for self-management, and improved
chronic illness outcomes.
In 1998, the initial CCM contained six key elements that work in tandem to produce high
quality outcomes: community; the health system; self-management support; delivery system
design; decision support; and clinical information systems as depicted in Figure 2.1. The
MacColl Center expanded the CCM into its current format in 2003, to include the previous six
domains as well as five new elements. Expanded Model elements include patient safety (in
health system), cultural competency (in delivery system design), care coordination (in health
system and clinical information systems), community policies (in community resources and
policies), and case management (in delivery system design) as illustrated in Figure 2.2.

The Community
The element of Community involves the mobilization of community resources to meet
patient needs. By accessing existing assets, healthcare systems expand the depth and breadth of
services provided. Ultimately, healthcare institutions, in collaboration with local, state, and
national agencies, would act as advocates for patients with chronic disease to affect policy.
Self-Management Support
The self-management component of the CCM consists of patient engagement in: 1)
activities that promote health; 2) interactions with healthcare providers and adhering to advised
treatment recommendations; 3) ongoing self-assessment with resultant medical decision making;
and 4) managing the effects of disease to participate in activities of daily living (Von Korff,
Gruman, Schaefer, Curry, & Wagner, 1997). The self-management support plan of care is
revised through a collaborative team process (MacColl Center & 1996-2013, 2013) (MacColl
Center, 2013).
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Figure 2.1. Representation of the Chronic Care Model. Reprinted from "Chronic Disease
Management: What Will It Take to Improve Care for Chronic Illness?" by E. H. Wagner,
August/September 1998, Effective Clinical Practice, 1, p. 4. Copyright 1998 by the American
College of Physicians. Reprinted with permission.

The Health System
The Health System in the CCM represents an organization that has identified chronic
illness care as a priority and views improvement of this care as a fluid process that will continue
to evolve. The organization recognizes that comprehensive institutional change provides the
foundation for effective care delivery and has origins at all staff levels with support from senior
leadership. Collaboration across the institution is fundamental.
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Figure 2.2. Expanded Representation of the CCM. Copyright 1996-2012 .The MacColl Center.
The Improving Chronic Illness Care program is supported by The Robert Wood Johnson
Foundation, with direction and technical assistance provided by Group Health's MacColl Center
for Health Care Innovation. Reprinted with permission.

Delivery System Design
The configuration of healthcare delivery in the CCM necessitates creation of prepared,
proactive practice teams. The system providing treatment becomes proactive by providing
evidenced based care that shifts the focus from acute to chronic illness care. Multidisciplinary
practice teams communicate regularly about the care of a defined group of patients and often
consult professionals outside of a single practice (Starfield et al., 2005).
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Decision Support
The decision support component of the CCM necessitates an educational foundation for
members of the practice team to allow for the appropriate development of a treatment plan.
Clinical reminders and standing orders support implementation of practice standards in medical
decision-making. Evidenced based guidelines drive treatment decisions, serve to reduce
inconsistencies in clinical practice, and provide standards for optimal chronic care. By sharing
practice guidelines, healthcare providers encouraged patients to participate in disease
management and treatment adherence. Patients are educated about disease process by employing
methods that have demonstrated effectiveness. Decision support also incorporates access to
medical specialty expertise.
Clinical Information Systems
Comprehensive clinical information systems are an essential attribute to effective disease
management. A critical component of clinical information systems, patient registries generated
from an electronic medical record (EMR) allow tracking of individuals with particular chronic
disease states. Once the registry is establish, clinical reminders permit practice teams to address
condition specific needs. In turn, the EMR can track performance of the team regarding the
accomplishment of clinical goals. Additionally, the EMR coordinates care between services
across a healthcare system as well as sharing information with patients.

Summary
Successful disease management relies on relations between individuals, healthcare
providers, systems, and adherence to recommended protocols. Evidence suggests that clinical
outcomes for individuals with chronic disease are suboptimal, due to interactions focused on
urgent treatment needs rather than on long-term disease and symptom control, attributed to
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widespread deviation from standard medical practice and lack of patient self-management skills.
The CCM imparts a template for healthcare organizations to achieve high quality chronic illness
care. Core changes to primary care, the location most frequently providing chronic disease
management, are required to attain optimal disease management.
The Model has identified characteristics that are common among successful disease
treatment programs in the literature. These characteristics are synergistic and include consistently
planned follow-up, systematic assessments, acquisition of self-management proficiency, access
to disease expertise, and supportive information systems. Implementation of all Model elements
results in productive interactions between a prepared, proactive practice team and an informed,
activated patient. Preparation of the clinical team incorporates chronic disease expertise as well
as the resources to manage conditions effectively. An informed patient is one who possesses the
knowledge and self-efficacy to capitalize on exchanges with clinical team members. Productive
interactions involve the generation of a patient-centered, collaborative plan of care utilizing
effective clinical treatments. Ultimately, use of CCM elements, renders coordinated services that
are patient-centered, timely and efficient, as well as evidence based and safe. An application of
the Model to this study follows.

2.3 Application of Theory to Study
The literature contains five decades of extensive medication adherence inquiry. When
research in the field began, the patient was the center cause for deviation from prescribed
treatment regimes. As such, initial theoretical models explained the construct from the
perspective of changing individual behaviors. Models such as the Health Belief Model and
Transtheoretical Model, as well as the Theory of Reasoned Action, self-efficacy, and the Theory
of Planned Behavior pervade the literature in attempts to predict behavior leading to non-
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adherence based on individual functioning. However, as the discipline evolved, the complexity
of medication adherence became apparent, such that examining individual actions was not
sufficient to address the magnitude of this problem, even with the use of intricate conceptual
frameworks.

Figure 2.3. Application of Wagner’s Chronic Care Model in Veterans with IBD

Therefore, corresponding with the current state of knowledge, a comprehensive system
model, the CCM, was the guiding framework for this study. This multidimensional Model
addressed how elements of chronic illness care organization within a healthcare system produce
improved outcomes. In this study, only one element of chronic illness care was reviewed, the
prescribing of medications for veterans with IBD, coordinated between primary care and
specialty care. The outcome variable was medication adherence. Congruent with the CCM,
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prescribing IBD medication, coordinated between primary and specialty care, may improve
medication adherence as well as healthcare utilization as depicted in Figure 2.3.
The CCM provides healthcare systems with salient mechanisms to address the challenges
of chronic illness care as evidenced by extensive testing of the Model throughout the world that
have yielded promising results (Coleman, Austin, Brach, & Wagner, 2009). Further support of
the Model was generated by a meta-analysis performed by (Tsai, Morton, Mangione, & Keeler,
2005) which demonstrated that interventions containing one component of the CCM improved
clinical outcomes and processes of care. However, the literature does not present a clear picture
of the impact individual Model elements contribute to effective chronic care. Influenced by the
disease considered and the characteristics of both the organization under study and the
population the organization serves, the effect of single Model elements may fluctuate (SperlHillen et al., 2004) . This supports research examining just one element of the CCM, in this
case, coordination of care between primary and specialty care in the VA healthcare system in
veterans with IBD. This was the first study to use the CCM in veterans with IBD to explore the
relationships between medication adherence, healthcare utilization, and coordination of care in
the VA system. The significance of this study was in identifying potential points of intervention
in the chronic illness care of this population.

2.4 Inflammatory Bowel Disease
Inflammatory bowel disease is comprised of two major disorders: Crohn's disease (CD)
and ulcerative colitis (UC). These disorders have both distinct and overlapping characteristics.
However, the pathogenesis of these disorders remains poorly understood. Theories of
environmental exposure, genetic influence and autoimmune dysregulation subsist.
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Both CD and UC are chronic inflammatory conditions of the GI tract typified by
relapsing and remitting symptoms. Representations of CD include transmural inflammation with
skip lesions that can occur anywhere from the oral pharynx to the anus which often lead to
scarring and obstruction. Whereas, the inflammation found in UC is contiguous, superficial,
usually involves the rectum, and is limited only to the mucosal layer of the colon, thereby unable
to cause fibrosis of colonic tissue.
Epidemiology
In North America, the incidence rates for ulcerative colitis range from 2.2 to 19.2 cases
per 100,000 with a prevalence of 238 per 100,000 (Molodecky et al., 2012).The incidence rates
of Crohn's disease range from 3.1 to 20.2 cases per 100,000 with a prevalence of 201 per
100,000. This equates to approximately 1.2 million with IBD in the U.S. (Kappleman et al.,
2013).
In North America the prevalence rates of IBD in Hispanics is 4.1% per 100,000 and in
Asians 5.6% per 100,000. These rates are much lower when compared to the rates for White
individuals of 43.6% per 100,000 and African American individuals at 29.8% per 100,000
(Baumgart & Carding, 2007). Additionally, both CD and UC are more common in Jews than
non-Jews (Acheson, 1960).
Current statistics demonstrate that IBD accounts for approximately 45,000 veterans who
access VA healthcare services for the chronic illness care of this disease (Hou et al., 2013). This
study reported the prevalence of IBD in a national VA sample from 1998-2009 the results of
which demonstrated an IBD occurrence primarily in men (>90%) with 50% of this cohort falling
between the ages of 55 to 74.
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Smoking effects both CD and UC in dichotomous ways. The risk of developing CD is
twice as likely in smokers versus nonsmokers (Silverstein, Lashner, Hanauer, Evans, & Kirsner,
1989). While current smokers have a 40% lower risk of developing UC than nonsmokers.
Interestingly, former smokers are 1.7 times more likely to develop UC when compared to those
who have never smoked (Boyko, Koepsell, Perera, & Inui, 1987). Smoking cessation in UC has
been associated with an increase in disease activity as well as hospitalization.
Other risk factors implicated in the occurrence of IBD include diets high in processed,
fried, and sugary foods, obesity, GI infections, breast feeding, antibiotic usage, antiinflammatory medication, oral contraceptives, Isotretinoin, and having an appendectomy
(Peppercorn, 2012).
Clinical Manifestation
A comparison of the clinical manifestations of CD and UC are found in Table 1.The
clinical manifestations of CD are more variable compared to those with UC and consist primarily
of prolonged diarrhea, with or without gross bleeding, fever, weight loss and crampy abdominal
pain. While UC typically presents with intermittent rectal bleeding in patients with mild disease
confined to the rectum (proctitis). In moderate UC, inflammation extends to the splenic flexure
(left-sided colitis) and the patient experiences frequent bloody diarrhea (up to 10x daily), mild
anemia, abdominal pain, and fever.
In patients with severe disease, often inflammation extends the entire length of the colon
to the cecum (pancolitis), bloody bowel movements number > 10 per day, and the patient may
require a blood transfusion. Additionally, rapid weight loss leading to poor nutritional status may
result in severe cases. If the inflammation in UC is severe enough, the process may extend
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beyond the mucosa to involve the muscle layers of the colon causing impaired colonic motility
and possible perforation (Peppercorn, 2012).
A recent review article was published by (Peyrin-Biroulet, Loftus, Colombel, &
Sandborn, 2010) who examined the natural history of adult CD from 1935 through 2008. The
results showed that while the disease remained stable over time with approximately 10% of the
cohort experiencing prolonged periods of remission, half of all patients had intestinal
complications within 20 years of diagnosis. The annual incidence of hospitalization was 20%.
Additionally, half of the patients required surgery within 10 years of diagnosis with a
postoperative risk of recurrence in the 44-55% range 10 years out.
Diagnosis
The diagnosis of CD is established with endoscopic findings and/or imaging studies in
patients with a history consistent with the disease. Colonoscopy, with intubation of the terminal
ileum, establishes the diagnosis of ileocolonic CD. Inflammation occurs in patches with normal
colonic mucosa between lesions. Usually, the rectum is not affected. Colonic biopsies confirm
the diagnosis with inflammation found on the small bowel biopsy. Imaging studies are typically
done to assess for small bowel activity not evaluated by colonoscopy and include an upper GI
with small bowel follow through, Ct, Ct enterography, MRI, and MR enterography.
Initially, flexible sigmoidoscopy establishes the diagnosis of UC (Peppercorn, 2012).
Inflammation is in a contiguous pattern with rectal involvement. Biopsy confirms the diagnosis.
Colonoscopy is usually not the first line exam in the severely ill patient due to risk for
megacolon or perforation. In this country, diagnosis of UC does not depend on imaging studies.
However, in Europe, ultrasonography provides information regarding the extent of colitis
(Peppercorn, 2012) .
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Table 1
Comparison of Crohn’s Disease and Ulcerative Colitis
Crohn’s Disease

Ulcerative Colitis

Inflammation may occur anywhere in the
digestive tract and is in patches, the
rectum is spared

Inflammation only occurs in the large
intestine, is continuous, and typically
affects the rectum

Ulcers in digestive track are deep and may
extend into all layers of the bowel wall

Mucus lining of large intestine may have
ulcers, but they do not extend beyond the
inner lining

Bleeding from the rectum during bowel
movements is not common

Bleeding from the rectum during bowel
movements is common

Symptoms
Diarrhea
Weight Loss
Joint Pain
Anemia

Bloody Diarrhea
Weight Loss
Joint Pain
Anemia from severe rectal bleeding

Treatment
The goal of treatment is to induce remission, assessed by a variety of methods that
include patient subjective report of convalescence in symptoms, blood studies, as well as
improvement on colonoscopic exam. However, treatment for IBD is convoluted requiring
individualized application of current therapies due to disease heterogeneity. IBD typically has a
relapsing, remitting path that requires continuous, particularized, therapy adjustment. Some
individuals will have a quiescent disease course, while others have much more aggressive
disease. Treatment considerations include the extent of disease, cost of therapy, patient
compliance, and risk for toxicity. Because of disease and treatment complexity, there is no
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consensus among discipline experts about how best to treat these patients. Many guidelines
subsist with no one platform universally adopted. Therefore, the most current evidenced based
practice recommendations provided guidance for the following discussion.
Treatment of CD
Generally, two approaches for the treatment of mild to moderate Crohn’s disease: step-up
therapy and top-down therapy are widely recognized as illustrated in Figure 2.4 (Farrell &
Peppercorn, 2012). The most favored approach is step-up therapy that involves using
medications that are the least potent, with fewer side effects, first. Medications with more toxic
side effects follow, if initial therapy fails. Conversely, top-down therapy starts with potent
therapies early on in disease course. Outpatient treatment with oral medication is appropriate for
most individuals with mild to moderately active Crohn’s disease. However, inpatient
management is usually required for those with severely active disease.
Administration of oral medication depends upon the site of disease. Gastroduodenal
disease occurs in less than 5% of CD patients, the treatment for which is prednisone. The ileum
is the site most commonly involved in CD, the initially treatment for which is a 3-4 week course
of an oral 5-aminosalicylate (5-ASA) medication such as mesalamine or sulfasalazine (Farrell &
Peppercorn, 2012). Using a 5-ASA as an initial treatment in CD is controversial as studies
evaluating its efficacy in this population are mixed.
If patients do not respond to the 5-ASA trial, treatment with either metronidazole alone or
in combination with ciprofloxacin is next advised (Sartor, 2012). The mechanism of action of
antimicrobials in IBD is not transparent with theories of intestinal bacterial overgrowth or
possible microperforation speculated. Four weeks of tapering, oral steroid therapy follows a
failed course of antibiotics to treat recalcitrant symptoms.
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For intractable cases of CD, treatment consists of immune modulating medication such as
azathioprine, 6-mercaptopurine (6MP), or methotrexate that has a response rate of 60-70% in
small bowel and colonic disease (Farrell & Peppercorn, 2012). Reaction to these medications
typically takes three to six months during such time the patient may need concomitant therapy
with oral steroids. These medications have been associated with malignancy, bone marrow
suppression, and hepatotoxicity. Therefore, close monitoring of biochemical parameters is
required.

Step-up Versus Top-Down Therapy
Step-up Therapy

Top-down Therapy
5-ASA

Anti
TNF
Immune
Modulator

Immune
Modulator
Anti
TNF

5-ASA

Figure 2.4 Step-up versus Top-down Therapy for Treatment of Crohn’s Disease
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In a step-up approach, use of anti-TNF agents, also known as biologics, such as
infliximab, adalimumab, and certolizumab represent the top tier of treatment and are not
recommended as first line therapy but rather to be used in refractory cases and are often used in
conjunction with immune modulating medications (Farrell & Peppercorn, 2012) . Due to
immunocompromise with these medications, screening for hepatitis B and C as well as for TB, is
advisable prior to initiation of therapy. Many possible serious side effects from anti-TNF
medications are possible that include heart failure, malignancy, and demyelinating disease
(Stone, 2012). As a recent systematic review demonstrated, it is unclear whether exposure to
both immunomodulators and biologics simultaneously exponentially increases cancer risk
(Kotlyar et al., 2011).
Approximately 10 to 20 percent of patients experience a prolonged remission after initial
diagnosis (Solberg et al., 2007). Additionally, a recent review of the literature (Lichtenstein,
Hanauer, Sandborn, & Practice Parameters Committee of American College of
Gastroenterology, 2009) provided insight into the state of knowledge regarding treatment
outcomes in this population. Important treatment statistics generated from the study analysis
included:


patients in remission for one year have an 80% chance of maintaining remission in
subsequent years



patients with active disease in the past year have a 70% chance of remaining active
in the next year



13% of patients will have a period from relapse, while 20% have annual relapses,
and 67% have a combination of years of relapse and remission with less than 5% of
patients having a continuously active disease course.
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Treatment of UC.
Similar to CD, treatment for UC focuses on the location of the inflammation. For example,
treatment of proctitis, a disease limited to the distal 10 to 15cm of the colon, present in
approximately 30% of patients, consists of a topical 5-ASA or steroid suppository (Farrell &
Peppercorn, 2012). Treatment for disease extending into the left side of the colon consists of 5ASA or steroid enema at bedtime, with response seen in four to six weeks (Farrell & Peppercorn,
2012). Treatment for non-responders consists of a second morning enema. Finally, therapy for
non-responders to the aforementioned treatments consists of oral 5-ASA preparations that take
three to six weeks to exert maximal benefit.
Deployment of tapering oral prednisone occurs for those with severe UC. However,
chronic oral steroid use is not beneficial due to multiple deleterious effects such as weight gain,
osteoporosis, diabetes, hypertension, cataract development, and mood swings. Additionally,
there is no evidence that oral steroids maintain remission. Therefore, immune modulating
medication as described, are added for those unable to wean off steroid. If no response occurs
with immune modulating medication and/or the patient is unable to tolerate steroid wean, the
final drug choices used to treat severe UC, prior to considering colectomy, include IV
cyclosporine and Infliximab. However, the role of these medications in treating complicated
cases of UC remains contentious.
Complications
CD and UC share a number of extraintestinal manifestations that correlate with the
amount of inflammatory activity present. For example, arthritis such as ankylosing spondylitis
that affects large joints, occurs in approximately 20% of patients and is the most common
extraintestinal complication (Peppercorn, 2012). Eye involvement that exhibits as uveitis or iritis
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occurs in 5% of patients (Peppercorn, 2012). Similarly, primary sclerosing cholangitis, also
present in 5% of patients, is a consideration when alkaline phosphatase and gamma glutamyl
traspeptidase (GGT) are elevated. Erythema nodosum and pyoderma gangrenosum, two common
skin conditions, arise in 10% of patients (Peppercorn, 2012).
Several vitamin deficiencies plague patients with IBD, who experience impaired vitamin
D and calcium absorption that may result in bone loss related to steroid use. Additionally,
pernicious anemia can result from severe ileal inflammation since vitamin B12 is absorbed in the
distal 50-60cm of ileum (Peppercorn, 2012).
IBD patients are at risk for renal stones. Calcium oxalate and uric acid kidney stones can
result from steatorrhea and diarrhea (Obialo et al., 1991). Uric acid stones also result from
dehydration and metabolic acidosis. Although rare, an additional renal complication includes
secondary amyloidosis.
Pulmonary complications, although less likely, also exist in this population related to
underlying inflammation but may be influenced by the medications used to treat the disease
(Black, Mendoza, & Murin, 2007). Lung manifestations include pulmonary embolism,
sarcoidosis, and interstitial lung disease.
Individuals with both CD and UC are at increased risk for colorectal cancer when
compared to the general population. However, the data in this regard are disparate with much
more known about this risk in UC and with no consensus regarding the timing of surveillance
colonoscopy declared. Furthermore, a reduction in mortality due to colonoscopic surveillance
has not materialized (Peppercorn & Odze, 2012) . Despite this, the general recommendation is to
perform annual colonoscopy after eight years of disease duration in those with disease that
extends beyond the hepatic flexure and after 12 years for those with left sided colitis (Peppercorn
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& Odze, 2012). These surveillance exams do not preclude interim colonoscopic evaluations to
assess disease extent as warranted.
Because IBD is an illness that tends to onset during the child bearing years, pregnancy
and infertility are concerns that need addressed. Overall, decreased rates of fertility occur for
both men and women with IBD (Walsh, Mabee, & Trivedi, 2011). For men, changes in fertility
are associated with medication, methotrexate and 6MP, which resolved with cessation of the
medication. Similarly, women experience decreased rates of fertility while taking methotrexate
as well. Men and women should be counseled about the abortifacient and teratogenic effects of
methotrexate and be advised to use two type of birth control while taking this medication (Walsh
et al., 2011). While IBD improves during pregnancy, an individualized plan of care coordinated
by an experienced gastroenterologist is critical for successful birth outcomes.

Summary
Inflammatory bowel disease is comprised of a set of conditions that cause chronic
inflammation in the GI tract for 1.5 million Americans including approximately 45,000 veterans
who access VA for healthcare services. The symptoms of IBD and the medications used to treat
the disease can be debilitating and are a drain on scarce healthcare resources.
Two recently published papers (Shah et al., 2011) and (Kappleman et al., 2011) raise
concerns about the quality of treatment for IBD noting significant variations in clinical practice
that contribute to a misappropriation of therapy. Authors of both articles identified gaps in the
literature regarding comprehensive evaluation of chronic illness care for this population that
includes variations in prescribing practices as well as patterns of healthcare utilization. Not only
did the results of these review articles support the need for additional research in medication
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adherence and healthcare utilization in this cohort, the authors advise using a framework such as
the CCM to do so which provided strong support for this study.

2.5 Medication Adherence
Chronic illness that requires prolonged treatment with medications affects more than 40%
of individuals in this country and is the principal variable affecting treatment outcomes
(Hoffman, C., & Schwartz, K., 2008). A meta-analysis demonstrated that rates of medication
adherence in chronic disease varies and is in the range of 4.6% to 76% (DiMatteo, 2004).
While adherence to long-term therapies for chronic illness has been extensively
deliberated for the last 50 years, a consistent profile of factors affecting adherence, or a single
strategy that guarantees compliance, has not materialized. Furthermore, how to best define and
measure this construct remains elusive. A discussion in this regard follows.

Defining Medication Adherence
Terminology and definitions of medication adherence used in research vary. The most
common terms used are adherence, compliance, concordance, and persistence. The connotation
of medication-taking language is widely debated (Osterberg & Blaschke, 2005; Steiner &
Earnest, 2000). However, there is no consensus in the literature about how best to define this
concept. Without homogeneity in construct description, it is problematic to compare research
findings. Thus, advancement of knowledge in this field stymies.
In 2008, a paper presented standardization of the terms and definitions used when
referring to medication-taking behavior. This publication was based on three years of
international appraisal of this topic conducted by the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) (Cramer et al., 2008) in which
investigations conducted over the last half-century were considered. In an effort to comply with
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standardization, the definitions generated from this report will serve to characterize adherence
for this study.
The term compliance is purported to be offensive to patients when compared to the term
adherence. However, after extensive review of this consideration, the authors concluded that no
scientific support for the assumption that the term adherence is a less disparaging term or
preferred by patients exists. Therefore, medication adherence was synonymous with compliance
and was defined as “the extent to which a patient acts in accordance with the prescribed interval
and dose of a dosing regime” (Cramer et al., 2008).

Measuring Medication Adherence
Similar to defining medication adherence, no “gold standard” for measuring this
conception exists in scientific publication (S. Kane et al., 2012). Methods for measuring
medication adherence are direct and indirect. Each measure elucidates a different aspect of this
construct, making choice of the appropriate mechanism for research dependent upon study
methodology and research questions.
This section presents a discussion of the advantages and disadvantages of the most
frequently used methods of direct measures to include: observed therapy, measurement of
medicine metabolite, and measurement of serology biologic marker, and indirect measures of:
patient self-report, pill counts, pharmacy refill records, and electronic medication monitoring
(Osterberg & Blaschke, 2005). Each of these methods, when used in isolation, often yields
inaccurate and unreliable data (MacLaughlin et al., 2005). For this reason, use of a subjective
and an objective measure to corroborate research findings are advised (Turner & Hecht, 2001).
Because of limited resources, deployment of a corroborating source did not occur for this study.
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Direct Measures
Directly Observed Therapy
Randomized control trials most often use the method of directly observing a patient
receive medication where this type of intensive intervention warrants. However, its applicability
in routine clinical settings is limited due to the expensive, labor-intensive nature of this data
collection method. Although considered the most accurate means of measuring medication
adherence, this method is not full proof as the patient could feign swallowing medication and
then remove it from their mouths once the observation period had ceased.
Measurement of Medicine Metabolite
Biologic fluids can identify medication use during a stipulated period. However, presence
or absence of a drug metabolite cannot fully substantiate adherence. Serum and urine drug levels
do not explain medication consumption. For example, consider “white-coat compliance”, a
phenomenon where by the patient may exhibit adherence that corresponds with a clinic visit
(Feinstein, 1990). Further complicating the use of this measure, are the variations that exist in
individual’s absorption, metabolism, and excretion that affect drug levels.
Measurement of Serology Biologic Marker
Biologic markers are compounds added to target or placebo medications used in clinical
trials and extend similar inadequacies as medicine metabolites. Isotopes, phenobarbital, digoxin,
and phenol red are examples of markers that have been used (Farmer, 1999) .

Indirect Measures
Patient Self-Report
Soliciting input from individuals via self-report is crucial to understanding adherence
because patients ultimately decide whether to comply with treatment protocols. Self-report
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measures are the most common, cost effective, convenient method of assessing medication
adherence and include patient diaries, patient interviews, and validated adherence questionnaires
(Sakthong, Chabunthom, & Charoenvisuthiwongs, 2009). The basic premise of this measure is
simply asking the patient if they have been adherent to a drug regime. A caveat to this is that
patients often times overestimate their adherence (Wang et al., 2004). Similarly, clinicians
generate inaccurate assessments of patient compliance as well (Osterberg & Blaschke, 2005).
Confirmation of findings in studies of medication adherence using a self-report method is
advised (Morisky, Green, & Levine, 1986). Despite this recommendation, there are few studies
available in the literature that compare self-report to objective criteria such as electronic
monitoring (Wang et al., 2004).
Self-report methods have been widely used throughout the last several decades to
measure adherence in a variety of chronic illness. However, due to the number of methods used
to interview and retrieve information from patients, as well as the lack of psychometric
properties of such tools, comparing results across studies can be arduous.
Pill Counts
Second only to self-report, pill counting is the most common method to measure
medication adherence that involves counting the number of dosage units
(tablets/capsules/drops/puffs) the patient has not taken by the scheduled appointment. A
comparison of returned units with the number of units received by the patient in the most recent
prescription and the length of time since the medication was dispensed takes place (Farmer,
1999). Calculation of medication adherence occurs by subtracting the number of units returned
from the number of units issued which calculates the amount of medication used by the patient
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during the observation period that can then multiplied by 100 to determine the percentage of
adherence.
Once thought to be a viable mechanism for measuring medication adherence due to ease
of use and cost effectiveness, pill counting has fallen out of favor due to overestimation of
compliance (Cramer et al., 2008). This method of measuring medication adherence gives no
insight of ingestion of medication by the patient. Patients can easily manipulate the results of the
data collection. A phenomena known as "pill dumping" may occurs whereby patients ingest large
amounts of medication immediately preceding a clinic visit (Rudd et al., 1989). Additionally,
patients may not return all residual medications in an attempt to hide their behavior. Even when
assessments are accurate, pill counts cannot explain reasons for non-adherence.
Pharmacy Refill Records
Use of prescription refill records to assess medication adherence has become the most
common measure of this construct in the last decade (Ho, Bryson, & Rumsfeld, 2009). The
advent of the electronic medical record has provided opportunity to access pharmacy data for
research purposes. Because this was the chosen data collection method for this study, a detailed
discussion occurs further on in this review.
The accuracy of this measure depends in large part if patients are filling prescriptions
within a closed pharmacy system (i.e. patients are obtaining medication from a single pharmacy)
such as VA (Osterberg & Blaschke, 2005). Measuring medication adherence using electronic
claims can be problematic if patients obtain prescriptions from multiple sources. Additionally,
pharmacy records do not provide any information about medication consumption. Patients may
order refills of medications as scheduled and stockpile them.
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Electronic Medication Monitoring
The last four decades have witnessed use of electronic monitors to record the time and
date when patients open a prescription container (Osterberg & Blaschke, 2005). The most
commonly used device is the Medication Event Monitoring System (MEMS) which costs
approximately $100 per monitor, inhibiting its use in routine clinical practice and large studies
(Balkrishnan, 2005). When the device communicates to the appropriate computer software, it
has the ability to identify non-adherent behaviors such as drug holidays, pill dumping, and white
coat compliance (MacLaughlin et al., 2005). However, electronic monitoring cannot document
whether the patient actually ingested the medication after opening the container. Despite this
fact, electronic monitoring is considered to provide the most reliable adherence data (Osterberg
& Blaschke, 2005).

Measuring Medication Adherence Using Administrative Databases
Administrative data are data files assembled for billing of healthcare services (Hess,
Raebel, Conner, & Malone, 2006). VA has been keeping such records related to medication
refills for over the last twenty years. About the time of electronic medical record development,
researchers at VA facilities proposed a method of measuring medication adherence using
pharmacy refill records. This method was borne from frustration with the limitations of other
methods that were available at that time. The VA, as a closed pharmacy system (i.e. the
assumption that patients only receive medications from one pharmacy), provided the ideal
laboratory for this type of data collection method.
In 1980, (Inui, Carter, Pecoraro, Pearlman, & Dohan, 1980) used VA pharmacy data to
assess for correlations between refill data and mean diastolic blood pressure in a group of
patients taking hydrochlorothiazide as well as the resting pulse in patients taking propranolol
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(N = 419). The results indicated that hydrochlorothiazide compliance significantly correlated
with mean diastolic blood pressure (r = -.63, p<0.05). The results further suggested a correlation
between resting pulse and compliance with propranolol (r = -.41, p <0.05).
Subsequently, while the use of administrative data to measure medication adherence was
evolving as a viable data collection method, substantive growth was not recognized in this field
until the sentinel paper was published in 1988 which introduced a variety of new concepts into
the literature that have expanded considerably over the years (Steiner, Koepsell, Fihn, & Inui,
1988). Following, will be a discussion of the history of this method year to date. Table 2
contains simulated data generated to provide a reference for the various mathematical
calculations.
MED-INT/MED-TOTAL/MED-OUT/REG-TOTAL/REG-OUT
In 1988, (Steiner et al., 1988) introduced the concepts of: Medication-Interval (MEDOUT); Medication-Total (MED-TOTAL); Medication-Out (MED-OUT); Regimen-Total (REGTOTAL);and Regime-Out (REG-OUT) in a study that sought to validate a data collection
method using VA refill data that incorporated changes in drugs or dosages, variable refill
intervals, as well as regimens of multiple medications. The investigation examined compliance to
long-term medications used to treat hypertension and seizure disorder.
MED-INT is the ratio of the days' supply obtained at the beginning of a specific time
interval to the days lapsed before the next fill. Days' supply, the equation numerator, is
calculated, as the number of pills dispensed divided by the number of pills prescribed per day.
For example, Patient B taking Sulfasalazine for UC 500mg, two tablets three times daily, who
obtains a thirty day supply of medication for the 4th refill during the observation period, the
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quantity of pills dispensed would be 180, divided by 6 for number doses in a day, and finally
dividing by 30, the number of days in a refill interval:
(Quantify of pills dispensed 180) / (pills per dose 2 x doses per day 3)
Days in refill interval (30)
the Medication Interval in this example is 1. The applicability of this equation in clinical
practice has limited use since it only provides adherence information for one refill which cannot
then be extrapolated to draw conclusions about the patient's overall adherence to a drug regime.
For a series of refills, the MED-TOTAL equation provides a method to calculate an overall
measure of compliance. The MED-TOTAL calculation is the total supply of pills
dispensed divided by the total number of days in the refill period. Expanding on the example
above, to examine a six-month refill period for both Patients A and B, the equation would
resemble the following:
Sum of days' supply dispensed (180 days x 6 months)
Sum of days in all refill intervals (180 days x 6 months)
The MED-TOTAL is 1, indicating perfect adherence during the six month observation period.
This example reveals the limitations of this calculation. Both Patients A and B receive a score
that represents perfect adherence. However, Patient A has a gap in treatment because instead of
the patient filling the medication after 90 days had elapsed, the patient fills the medication 100
days after the previous refill, signifying a 10-day gap when the patient was without medication.
The third concept presented by (Steiner et al., 1988) is that of MED-OUT that represents the total
number of days without medications divided by the total days of observation. As discussed
above, in the example of Patient A taking Sulfasalazine, the 2 nd refill
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Table 2
Simulated Pharmacy Refill Data
Patient A

Drug

Quantity

Days Supplied

Date

Days Elapsed

Sulfasalazine 500mg

540

90

10/01/2010

0

Sulfasalazine 500mg

540

90

04/06/2011

100

Sulfasalazine 500mg

540

90

07/01/2011

185

Sulfasalazine 500mg

540

90

09/30/2011

275

Drug

Quantity

Days Supplied

Date

Days Elapsed

Sulfasalazine 500mg

540

90

10/01/2010

0

Sulfasalazine 500mg

540

90

12/29/2010

90

Sulfasalazine 500mg

540

90

04/28/2011

210

Sulfasalazine 500mg

180

30

07/27/2011

300

Sulfasalazine 500mg

180

30

08/26/2011

330

Sulfasalazine 500mg

180

30

09/25/2011

360

Patient B

Fairman, K. & Motheral, B. (2000). Evaluating medication adherence: Which measure is right
for your program? Journal of Managed Pharmacy. 6(6). 499-504. Reprinted with permission.
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demonstrates that the patient went 10days without medication. To calculate MED-OUT for this
individual:
(Sum of days without medication) 10
(Sum of days in the observation period) 180
or 0.05. For the individual who never runs out of medication before obtaining a refill, MEDOUT will equal zero.
This calculation is not sensitive to changes in doses that would alter the supply of drug on
hand. Such that, if this patient were instructed to increase the medication interval from three
times daily to four times daily, this reason for the patient to be out of medication would not be
readily apparent by performing this calculation.
The final two concepts put forth by (Steiner et al., 1988), REG-TOTAL and REG-OUT
mirror MED-TOTAL and MED-OUT. While the latter equations represents medication
adherence as it relates to one drug, the former can be used to examine compliance as it relates to
an entire regime since it is recognized that patients may adhere to varying degrees with different
medications in the same treatment regime.
To obtain REG-TOTAL and REG-OUT , the MED-TOTAL and MED-OUT are
calculated for each drug in the individuals regime respectively, summed and then divided by the
total number of observation days for each drug.
The authors validated MED-TOTAL and MED-OUT by demonstrating a correlation
between the measures and Dilantin serum levels, correspondingly, (r = 0.31, p = 0.03, 95% CI
0.04 to 0.54) and (r = -0.40, p = 0.004, 95% CI -0.14 to -0.61). Expectedly, the MED-OUT
correlation was negative because serum Dilantin levels decrease if the patient is without
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medication. The investigators attempted to validate REG-TOTAL and REG-OUT by examining
all hypertensive medications each individual in the study was taking and comparing these
calculations to diastolic blood pressure. There was a correlation found between compliance and
diastolic blood pressure for both REG-TOTAL and REG-OUT. However, neither reached a
statistically significant level, (r = -0.14, p = 0.23, 95% -0.35 to 0.09) and (r = 0.17, p = 0.15, 95%
CI -0.06 to 0.39) respectively.
CSA,CSG,CMA,CMG,DSA,DSG,DMA,DMG
Research of medication adherence using pharmacy refill data continued to grow
throughout the 1980s and 1990s. (Steiner & Prochazka, 1997) expanded on their 1988 work by
performing a systematic review of the literature from 1969 through 1994 to examine the state of
knowledge regarding the use of administrative databases to measure compliance. In all, the
authors examined 41 studies from the U.S., UK, Australia, and Finland that employed refill
compliance measures. Twelve of the 41 studies reviewed occurred in VAMCs that meant that
VA pharmacy data informed these studies.
The researchers created a new typology that introduced three new categories into the
literature to describe refill measures. The categories included: 1) the distribution of the adherence
variable was continuous (C) versus dichotomous (D); 2) the number of refill intervals was either
single (S) or multiple (M); and 3) the measure either assessed the time period over which drugs
were available to the patient (A) or the time intervals during which gaps in medication
possession occurred (G). From this review, the authors generated new classifications by
grouping studies by typology.
The first category presented by (Steiner & Prochazka, 1997) is that of continuous, singleinterval measures of medication availability (CSA). Similar to MED-INT that provides minimal
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information on a patient's overall adherence to a drug regime, CSA is of limited clinical
usefulness, as it too, gives little insight into adherence. None of the studies in this review
utilized CSA as a measure for compliance.
The second typology offered by the authors is continuous, single-interval measures of
medication gaps, CSG. This calculation provides information about gaps in adherence for 1 refill
only, typically 30, 60, or 90 days. For example, if a patient fills a medication for 30 days and the
observation period is for a total of 90 days, this leaves a gap in the treatment of 60 days. CSG is
calculated: 60/90 = 0.67. When no gaps in treatment occur, CSG will be zero. Analogous to both
CSA and MED-INT, CSG will have limited pertinence in medication adherence research due to
its confined scope of measurement. The data presented by (Steiner & Prochazka, 1997) did not
include any studies that utilized this equation.
The third classification generated is CMA that is a continuous, multiple-interval measure
of medication availability. This measure is comparable to MED-TOTAL and provides
information on mean adherence over all refill intervals. Dividing the sum of the days' supply
obtained over a series of refill intervals by the total days from the beginning to end of the
observation period provides the calculation for CMA. For the patient taking Sulfasalazine who
refills this medication every 30 days for 6 months, the CMA would be 1 (180/180), which
demonstrates perfect adherence. Any number > 1 constitutes an oversupply of medication.
Over 50% (23) of the studies in this review used CMA as a measure of adherence. Of these, 11
collected data using VA administrative databases to examine a large variety of medications with
4 of the 11 studies observing adherence for 6months and the remaining studies reviewing data
for 12 months or more. The mean CMA for the 11 studies was .87 indicating a high level of
compliance.
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The fourth concept in this review is the continuous, multiple-interval measure of
medication gaps (CMG). This corresponds with MED-OUT and documents the amount of time a
patient is without medication. CMG calculation consists of dividing the total number of days in
treatment gaps by the duration, in days, of the observation period. The denominator in this
equation can be a specific date at the end of the observation period or the date of the last
medication fill. If the former is used, all gaps are "embedded" within a series of refills. If the
latter is used, a "terminal gap" is present after the last fill. This measure assumes that gaps in
treatment correspond to a lack of adherence rather than a temporary or permanent dose change
made by the provider.
Eight studies in this review examined medication adherence using CMG, the majority of
which were studies conducted in the VA. The mean CMG for these studies was 0.17 indicating
small gaps in treatment, i.e. higher levels of adherence. The remaining four equations, DSA,
DSG, DMA, DMG, are simply dichotomous measures generated from their continuous
counterparts, CSA, CSG, CMA, and CMG.
Dichotomous cutoffs were used to differentiate between complaint versus partially
compliant or complaint versus noncompliant individuals. The investigations in this review did
not offer clinical or pharmacological justification for the choice of a threshold value. Often the
cutoff of .80 represents the ceiling (Esposti et al., 2004). Therefore, those with a calculated
adherence of .80 and above are adherent. Whereas those with a score < .80, would be categorized
as partially compliant or non-compliant.
Medication Possession Ratio
Included in the review conducted by (Steiner & Prochazka, 1997), however not explicitly
addressed, was the construct of Medication Possession Ratio (MPR). (Sclar et al., 1991)
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introduced the MPR into the literature and defined it as the number of days’ supply obtained by
the patient during an observation period. The ultimate outcome is a ratio of 1:1 representing
perfect adherence. This equation provides comparable data to MED-TOTAL and CMA in that it
provides information about adherence to a drug regime over time.
Considerable research was generated from the preliminary (Sclar et al., 1991)
investigation during the next 15 years utilizing the MPR as a method for measuring medication
adherence. Consequently, while many adherence measures that used pharmacy refill data exist in
the literature during this period, the MPR sustained and gained popularity. The definition of
MPR had expanded from what has previously been described into the following: “the sum of the
days’ supply of medication divided by the number of days between the first fill and the last refill
plus the days’ supply of the last refill” (Sikka et al., 2005).
MPR was the measure of medication adherence used in a recent study conducted by
(Lockwood, Steinke, & Botts, 2009) that examined this concept and readmission rates in the 12
months following discharge, in a sample (N = 82) of Veterans with Posttraumatic Stress Disorder
(PTSD), released from an inpatient psychiatric stay for such. Local pharmacy data was used to
measure adherence to psychiatric medication regimes, as calculate by the MPR, with adherence
defined as a ratio of at least 0.8. The majority of patients (66%), were not adherent to
medication during the 12 months following discharge and 20.7% were readmitted for
symptomatic PTSD. However, non-adherence was not significantly associated with relapse
(p=0.91).
Additionally, the authors reported that the larger the total number of drugs prescribed for
a Veteran, the higher the level of adherence (p=0.014). Age, substance abuse, combat service,
and service connection were not associated with medication adherence.
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Table 3 contains a summary of adherence and persistency measures found in the
literature which demonstrated a distinct difference between adherence and persistence. Whereby
the MPR calculates adherence through assessing medication availability over multiple refill
cycles, persistency denotes the duration of time a patient remains on chronic medication for a
specified surveillance interval. Therefore, MPR in isolation may not impart information on the
consistency of refilling behavior, i.e. persistency.
Persistency as a function of the MPR
As previously discussed, MPR is a measurement of adherence based on the patient's
possession of a medication. A comparable concept, proportion of days covered (PDC), is also
found in the literature and is as frequently chosen as the MPR to measure both compliance and
persistency (Ho et al., 2009). MED-TOTAL and CMA can also be relegated to this category. The
selection of a threshold of .80 to indicate adherence is arbitrary. In the paper written by (Sikka et
al., 2005), it was argued that a patient could be considered persistent with an MPR of .80 because
it would be reasonable to assume that individuals with this score were continuously refilling
medication over a defined time period. (Vink, Klungel, Stolk, & Denig, 2009) conducted a study
using automated databases to calculate both MPR and a gap measure of persistence for 3,877
patients. The findings illustrated that both equations yielded similar products.
(Sikka et al., 2005) stressed the importance of using the same measurement endpoints for
all subjects to ensure accurate results. Such that, patients with shorter observation periods could
generate an MPR that is higher than it actually is when compared to other patients with longer
surveillance intervals.
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Persistency as a function of medication availability at a fixed point in time
Persistency as a function of medication availability at a fixed point in time measures the
availability of medication on hand or the presence of a medication refill on a fixed date after
filling the initial prescription. This measure is insensitive as it regards persistent based on one
refill and is comparable to MED-INT and CSA where persistent occurs at 2 years if a patient has
a single day's supply of medication or a refill available at the end-point of 2 years. This measure
is applicable in very short periods of observation since this would improve its accuracy.
However, this measure does not reflect changes in refill behavior that occur over multiple refills.
The Anniversary Model is another example of a persistence measure calculated based on a fixed
point in time (Caetano, Lam, & Morgan, 2006). In the Anniversary Model, a patient is persistent
at 1 year if a prescription fill occurs within a specified interval surrounding the anniversary of the
first fill (i.e. 30 days). This is a dichotomous measure.
The Minimum-Refills Model is also a measure of persistence based on a fixed point in
time, 1 year. Such that, a patient is considered to be persistent at 1 year if a minimum number of
refills are dispensed during the year (Caetano et al., 2006). This too is a dichotomous measure.
Persistency as a function of gaps between fills
The most broadly used method for assessing persistency is a tool that examines gaps in
treatment. This calculation contains an allowable grace period in which patients can refill
medications and is equivalent to MED-OUT and CMG. The Refill-Sequence Model represents
another persistency measure that takes into account gaps between refills (Caetano et al., 2006).
The Model calculation uses the time between the date of the first fill and the point at which an
undesirable gap between refills occurs. Whereby, non-persistence results if the prescription refill
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Table 3
Summary of Refill Adherence/Persistency Measures
Definition

Single Interval
Medication
Availability

Analogous Concepts

Formula Calculations

Medication-Interval
MED-INT
Continuous, Single-interval
measures of medication
Availability
CSA

(# of pills dispensed) / (Pills dose X doses per
day)/Days in refill interval
Days' supply obtained per interval / Total days
in interval

Dichotomous measure in which a patient is
deemed persistent for 1 year if a prescription is
filled within a defined anniversary date of the 1st
fill (i.e. 30 days)

Anniversary Model

Medication Total
MED-TOTAL

Medication
Possession Over
the Entire
Surveillance
Period

Sum of days’ supply dispensed / Sum of days in
all refills

Continuous Measure of
Medication Acquisition
CMA

Cumulative days' supply obtained / Total days
from beginning to end of time period

Medication Possession Ratio
MPR

Sum of days’ supply / Number of days between
first and last fill + Days’ supply of last fill

Medication Possession Ratio
Modified
MPRm

Total days’ supply / Sum of number of days
from first fill up to, but not including, the date of
last fill + Days’ supply obtained at last fill X 100

Medication Refill Adherence
MRA

Total days’ supply / Number of days of study
participation X 100

Proportion of Days Covered
PDC

Number of days patient has medication / Total
days in dispensing period

Compliance Rate
CR

Sum of days’ supply – Days’ supply at last fill /
Number of days from first up to, but not
including, last fill

Refill Compliance Rate
RCR

Total days’ supply X 100 / Number of days from
first to last fill

Minimum-Refills Model

A patient is considered to be persistent at 1 year
if a minimum number of refills are dispensed
during the year
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Table 3 (continued)
Summary of Refill Adherence/Persistency Measures

Gaps in Treatment

Medication-Out
MED-OUT
Continuous Multiple Interval
Measure of Oversupply
CMOS

Sum of days without medication/Sum of days in all
refills

Continuous, Single-Interval
Measures of medication Gaps
CSG

Days in interval – Days' supply obtained/Total days
in interval

Days Between Fills
Adherence Rate
DBR

1 - (Day between fills – Today days’ supply) X 100
Number of days between fills

Refill-Sequence Model

Is calculated as the interval between the date of the
first refill and the point at which an unacceptable
gap between refills occurs.

Total number of days' surplus
Days of study participation

Continuous Measure of
Medication Gaps
CMG

Total number of days in treatment gaps/Duration of
the observation period

does not occur within a predetermined number of days. This Model generally recognizes
switching of medication as an indication of persistence.
The principal challenge encountered when calculating persistency based upon gaps in
treatment is to define the permissible gap that specifies length of the grace period between refills.
The researcher decides the appropriate length of a grace period by considering a variety of
factors that may include the following influences: medication half-life, dosage titration, and
number of days in a refill period (i.e. 30, 60, or 90 days). For example, the permissible gap may
be one-half the number of days in the previous prescription supply. Such that, a patient who
refills a medication for 30 days would be given a 15 day grace period in which to obtain the next
fill. Therefore, non-persistence does not occur until day 46.
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Innumerable methods for measuring gaps between refills exist in the literature reported
dichotomously, persistent versus non-persistent (Vink et al., 2009). The most frequently cited
permissible gap in the literature is 30 days. Ultimately, sound clinical validation informs the
choice for the permissible gap threshold. However, the rationale for choice of persistency
calculation is rarely transparent in published papers. Few studies examine multiple methods of
persistency in the same investigation (Vink et al., 2009).
Conversely, a study conducted by (Hudson, Rahme, Richard, & Pilote, 2007) examined
refill records of over 20,000 patients who were administered a statin. The authors calculated
persistence using three different measures for each patient: (1) MPR, (2) persistency as a
function of medication availability based on a fixed point in time, and (3) persistency as a
function of gaps between fills. The rates of persistency were variable in the range of 5-94%
depending on the calculation used. Kaplan Meier analysis illustrated rates of persistency as a
function of a wide variety of gaps between fills, from one to 120 days. As hypothesized, the
results demonstrated that longer grace periods increased the level of persistency. Results
emphasize the importance of defining a consistent allowable gap for all patients in a study that is
scientifically sound. The findings of a study conducted by (Van Wijk, Klungel, Heerdink, & de
Boer, ) provided further corroboration of the results from the (Hudson et al., 2007) investigation.
Additional Measurement Considerations
About the same time, (Andrade, 2006) also completed a comprehensive review of the
literature to examine methods of measuring adherence and persistence using automated
databases which included appraisal of 136 articles. The results of this evaluation identified
methods previously presented. In addition, this assessment revealed several other considerations
when working with pharmacy refill data that includes switching, retentiveness, and turbulence.
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Switching
This review included 34 studies that took into consideration a change to a different drug
within the same class during the observation period, i.e. switching. The literature contains a
myriad of definitions of switching, for example, (Chan, Walker, & Yood, 1993) defined
switching as dispensing of a different drug within the same class within 120 days following the
initial fill of the drug. Whereas, (Walker, Chan, & Yood, 1992) defined switching as
administration of a different drug within the same class within 60 days of the initial fill.
The deliberation of switching when examining treatment compliance has been encouraged.
However, it should be noted that unless the requisite administrative database utilized for the
study makes a specific provision for noting the reason why switching occurred, it would be
difficult to discern the reason for a medication switch outside of a reported adverse drug event.
Alternatively, a manual chart review may clarify the rationale for the switch. This approach
would likely prove too labor intensive in large studies.
Retentiveness
Retentiveness is an additional concept of consideration when switching has indeed
occurred. Retentiveness has been defined as "the number of repeat pairs for that drug divided by
all the pairs in which the drug was the first one dispensed” (Walker et al., 1992). Retentiveness
accounts for the repeat dispensing of the same medication, though not necessarily at the same
dose, within the identified timeframe.
Turbulence
Turbulence generates a calculation based on the total number of changes that occur
during an observation interval. (Caro, Speckman, Salas, Raggio, & Jackson, 1999) defined
turbulence as "the number of changes (i.e. addition of a new drug, dropping of 1 or more drugs,
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or a switch to 1 or more other drugs) occurring in 6-month intervals from the time of index
prescription” p. 44. Patients noted to have turbulence are less likely to be persistent with
prescribed drug regimes. The usefulness of this calculation will depend on the goals of the
study.
Standardization of Measurement
A call to action occurred in 2008 for uniformity of medication compliance calculations
using administrative data. By this juncture, uncertainty over what constituted compliance versus
persistence had emerged from scientific consideration since MPR creates the same discordance
as MED-TOTAL and CMA. Whereby Patient A and B can have the same calculated compliance
score and yet the rate of continuous refilling (persistence) is not the same for these two patients.
Therefore, making it difficult to conclude that Patient A and B are adherent to a drug regime in a
similar fashion. Hindrance of scholarship in the field occurred from an inability to compare
results across studies.
In an attempt to advance the knowledge of this methodology by generating
standardization, the International Society for Pharmacoeconomics and Outcomes Research
(ISPOR) published a paper in this regard (Cramer et al., 2008). A discussion of these
developments follows.
The work produced by ISPOR was conducted over a three year period and involved a
review of the literature that spanned nearly four decades, from 1966-2005. The goal of the
workgroup was to provide uniform definition and operationalization of the constructs
compliance, adherence, and persistence relating these terms to measurement using administrative
databases.
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The authors concluded that the terms compliance and adherence can be utilized
synonymously and may be defined as follows: “the extent to which a patient acts in accordance
with the prescribed interval and dose of a dosing regime” (Cramer et al., 2008). A further
detailed definition of the concept generated from the ISPOR report will inform the definition of
adherence for this study found in Chapter 1.
The ISPOR paper operationalized compliance using the MPR as defined by retrospective
assessment of the number of doses dispensed in relation to the dispensing period. Refill of
medication equates with compliance. MPR is calculated with the following formula:
Number of days supplied X 100
Days of observation
The lack of daily dosing detail using this equation is a limitation of this method.
Persistence is acknowledged by ISPOR as a construct distinct from compliance that considered
the consistency with which a medication is taken during a given surveillance period. In this
review, persistence was defined as “the duration of time from initiation to discontinuation of
therapy” (Cramer et al., 2008).
Persistence is operationalized by counting the number days of medication availability
from initiation of the prescription, or a define point in time during chronic treatment, to the end
of the observation period. This calculation must define the permissible gap allowed between
refills based on the pharmacodynamics of the medication under consideration (Cramer et al.,
2008). Such that, the maximum amount of time a patient could go without taking the medication
and not encounter adverse consequences is distinguished. However, currently, no allowable gaps
exist for any prescribed medications (Andrade, 2006). The literature contains reports of
persistence as both a continuous and a dichotomous variable.
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In a separate document, ISPOR presented a systematic approach to study methodology
when using pharmacy refill data to assess compliance (Peterson et al., 2007). This paper
represents an international consensus on the standardization of study design created to improve
the quality of research conducted in the field. The following is a brief overview of these
proceedings meant to function as a guideline for research process in this study. The paper should
address the suitability of data sources to answer specific research questions as well as the
reliability and validity of the source. Procedures for protection of personal health information
exist. Conversion of continuous data to categorical data is discouraged and a discussion of the
limitations of retrospective data occurs.
There are several inconsistencies in the two papers provided by ISPOR. Both the
(Peterson et al., 2007) report as well as the (Cramer et al., 2008) paper advise that a persistence
analysis be contained in the methodology as separate from compliance and must include a gap
determination. However, there are inconsistencies in the definitions of various adherence
constructs found in both works. Therefore, misrepresentation of the terms persistence and
compliance continues. Furthermore, the (Peterson et al., 2007) article, also produced by ISPOR,
does not specifically endorse the use of a defined allowable gap as a requisite when measuring
persistence. Additionally, the authors assert that very few medications have a defined
permissible gap in which patients could safely forego taking a prescribed medication and not
experience adverse events. Therefore, calculation of tolerable gaps using retrospective pharmacy
data remains a challenge. This is the case with all medications prescribed for IBD. For patients
with IBD in remission, a scientifically established “drug holiday” that would avoid disease
reactivation, has not been ascertained (Regueiro, 2012c). In an effort to achieve remission in
IBD patients with active disease, no advisable gap in treatment exists making calculation of
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persistence using a permissible gap in this cohort impossible with the state of knowledge that
currently exists.

Summary
It is appreciated that medication adherence has a substantial bearing on clinical outcomes
and utilization of healthcare resources. As a result, much discourse exists regarding the
establishment of the appropriate mechanism for assessing this variable. While many methods for
measuring adherence in chronic illness subsist, all have inherent benefits as well as
shortcomings. After decades of research, no consensus on how best to measure this construct has
been forthcoming. The purpose of the investigation should be the driving force behind the choice
of a data collection method in medication adherence research.

Medication Adherence in Patients with IBD
Medication is a key component to controlling disease in IBD. Non-adherence to
treatment regimens should be the first issue suspected in patients who are not responding to
therapy as poor adherence is the primary reason for suboptimal clinical outcomes (World Health
Organization, 2003).
Universally, regardless of disease type or severity, medication adherence is problematic
in all situations requiring self-administration of treatment, as is the case in IBD. Despite the
availability of effective medication to control the condition, adherence remains a challenge since
IBD is an illness at high risk for poor adherence due to onset at a younger age, relapsing and
remitting disease course, as well as prescribed difficult to follow therapies (Lopez San Roman,
Bermejo, Carrera, Perez-Abad, & Boixeda, 2005a) Rates of non-adherence in IBD mirror those
found in other chronic diseases. Adherence to long-term medication treatments in the most
common chronic illnesses are in the range of 17% to 80% (Krueger et al., 2005)
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Correspondingly, a recent systematic literature review revealed rates of non-adherence in IBD to
be between 7% and 72% (C. A. Jackson et al., 2010).
Earliest published reports to improve adherence in gastrointestinal diseases recognized
the complex nature of this construct and encourage healthcare provider assessment of patient
participation in treatment (Levy & Feld, 1999). This widely referenced paper, published about
the time of CCM promulgation, weighed in well before the majority of adherence research in
IBD was completed. Thus, chronic diseases other than IBD provided a benchmark to create
discipline recommendations.
Although not explicated stated, (Levy & Feld, 1999) ascribed most of the CCM
elements, such as proactive healthcare teams, informed activated patients, self-management
support, the health system, and decision support as strategies to expand adherence. Papers of an
editorial nature by (Kappleman et al., 2011) and (Shah et al., 2011), provided additional support
for examining these CCM components in patients with IBD within the context of the health
system and the quality of care delivery in this population.
Therefore, in accordance with the CCM, interpretation of IBD adherence results occurs
from the perspective of the health system in which data collection takes place, because at least
one-half of all investigations transpire outside the U.S. in countries that have socialized
medicine. A study conducted by (Robinson, 2001) demonstrated the potential influences of the
health system on adherence in IBD in a study conducted to examine the rates of non-adherence
in European countries. Reported rates of non-adherence varied widely between countries: France
13%, Italy 25%, UK 33%, and Germany 46%. Similar variations in adherence rates exist in other
countries and disease states (Bovet, Burnier, Madeleine, Baeber, & Paccaud, 2002; Reid,
Abramson, Raven, & Walters, 2000). The large disparities in levels of non-adherence in

57

countries with government-sponsored healthcare, as noted in above studies, supports the need for
further research examining the effects of other government operated healthcare systems, such as
the VA, on medication adherence in patients with IBD. Without assessment of systematic
influences on adherence and resource utilization, engendered population health outcomes are in
danger of failure (World Health Organization, 2003).
Despite this, clinical inertia exists regarding assessment of medication adherence in
patients with IBD since research in the discipline did not begin until the early 1980s, while
adherence research began decades earlier in many other chronic disease states. Furthermore,
authorities in the specialty, generating IBD clinical guidelines, fail to propose formal
recommendations to screen for medication adherence, inclusive of comprehensive chronic illness
care in this population (Kornbluth & Sachar, 2010).
Yet, a study survey of Gastroenterologists (n = 395) in the U.S. who care for patients
with IBD demonstrated a large portion of those surveyed (77%) screen for adherence to
medication but only 19% used a valid method to do so (Trindade, Ehrlich, Kornbluth, & Ullman,
2011) This may be prejudiced by the fact that only one validated medication adherence survey
for use in patients with IBD currently exists, the Morisky Medication Adherence Scale -8
(MMAS-8) (Trindade et al., 2011). Nevertheless, 95% of the physicians in the aforementioned
study recognized the importance of determining a patient's level of medication adherence to
guide treatment.
Furthermore, the gastroenterology discipline as a whole comprehends the importance of
medication adherence in this population as the literature contains five review articles, published
in the last five years, regarding rates and factors associated with non-adherence in patients with
IBD. Four of the reviews were non-systematic in nature and served to examine the current state
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of relevant publications in this regard and to initiate discussion about research methodologies
and study findings (Hawthorne, Rubin, & Ghosh, 2008; S. Kane, 2006; Lakatos, 2009;
Robinson, 2008) .
One review, the most recent (C. A. Jackson et al., 2010), was the only review that used
systematic criteria both in searching for and in evaluating articles, thereby providing a critical
assessment of the status of knowledge in this arena. The results of which are addressed below.
In all, the paper included 17 studies, 76% of which were cross-sectional, with a total sample of
4,322 subjects over the age of 18, recruited principally from IBD specialty clinics (92%). None
of the reviewed studies used a power calculator to estimate sample size and only one study
reported procedures for handling missing data. Europe was the country in which 65% of the
studies originated with the remaining conducted in North America. Measurement of adherence
occurred using an assortment of methods: self-report (interview, questionnaire, VAS, and
diaries), serologic and urine samples, as well as administrative pharmacy data and was reported
in the range of 7-72%. The highest rates of non-adherence (30-43%) appear with use of selfreport tools.
While no variables consistently demonstrated an associated with non-adherence, the
following primary factors related to non-adherence were identified: younger age, employment,
single status, shorter disease duration, active disease, patients in remission, poly-pharmacy, pill
burden, immune modulator medication, lack of confidence in physician, and psychological
distress. Intriguingly, non-adherence was not associated with the number of primary care visits,
time since last outpatient visit, and time since last colonoscopy.
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Further discussion of IBD medication adherence research ensues. The passages that
follow provide further detail regarding rates and factors of adherence as well as methods used to
measure adherence.
Rates and Predictors of Adherence in IBD
(Linderberg, C. S., Solorzano, R. M., Vilaro, F. M., and Westbrook, L. O., 2001) argued
that the initial step in building science is qualitative inquiry. Remarkably, the two qualitative
adherence studies conducted in patients with IBD occurred simultaneous to the discipline’s
quantitative work.
(A. Hall & Porrett, 2006) interviewed six patients from an IBD specialty clinic in the
United Kingdom, in a study designed to explore factors affecting medication adherence in
patients with IBD. The authors discovered ten categories encapsulating the experiences of
patients regarding factors that affected compliance. These included beliefs regarding medication,
side effects, length of time and experiences since diagnosis, social support, medication regimen
and routine, practicality of the administration of medication, costs of prescription and
communication regarding a change in medication, supportive medical staff, access to healthcare
services, and information resources. The findings of this study mirror results of quantitative work
simultaneously performed by the researchers of the discipline. The authors conceded that factors
influencing medication adherence in this cohort are multifactorial, contemporaneous, and fluid.
(Moshkovska, Stone, Baker, & Mayberry, 2008) directed the only other qualitative study
to examine medication adherence in IBD. The authors used grounded theory approach to
explored patients’ experiences and rationale for medication taking behavior in 17 ulcerative
colitis patients from specialty clinics in the UK. Analogous with quantitative findings, this study
demonstrated the impact of patient information on medication adherence as reflected by two key
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determinants: patient beliefs about medication and the quality of the doctor-patient relationship.
Lack of perceived benefit and paucity of disease information were barriers to adherence. Factors
identified as associated with an increased risk for non-adherence included: complicated dosing
regimens, less active disease, younger age, new patient status, forgetfulness, and inadequate
information from healthcare providers. All of which have been identified as risk factors for nonadherence by quantitative measure.
Researchers considering findings from quantitative investigations examining IBD
medication adherence need to consider the origin of the rates and factors presented, i.e. rates and
factors associated with adherence versus non-adherence, as there is no consistency in reporting
across studies. Additionally, IBD adherence researchers will report adherence rates as complete
or partial, creating further complexity when interpreting results across studies. Because
ultimately, accurately identifying barriers to adherence, influences creation of intervention(s) to
improve rates targeted to the appropriate audience.
The literature suggests that generation of effective adherence interventions may have a
greater impact on the health outcomes of a population than any improvement in medical
treatment (Haynes, Ackloo, Sahota, McDonald, & Yao, 2008). Interventions should be tailored
to a particular illness as well as healthcare system as no single intervention has proved effective
across all patients, conditions, and settings (World Health Organization, 2003). In this case,
veterans with IBD receiving care for this disease in the VA healthcare system.
Another consideration of IBD adherence study findings is the fact that very few
investigations report use of a power calculation to estimate required sample size. Therefore, there
is a risk that some non-significant findings occur due to a lack of power rather than a lack of
effect. Generalization of study conclusions due to omission of power analysis occur as well.
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Additionally, variables mentioned in the methods segment of publications did not appear in the
results section, making it difficult to assess if any significant findings resulted from this data
collection.
There were no studies in this review conducted solely to report rates of medication
adherence in this population. Intuitively, factors associated with non-adherence provided further
insight into the medication taking behavior of this cohort. Reports of adherence rates and factors
associated with adherence/non-adherence make up the vast majority of medication adherence
investigations in IBD, a summary of which is located in Table 4. As found extensively
throughout the literature, organization of adherence factors in IBD for this review is by patient
factors, health system factors, and condition factors.
Patient factors
Patient factors regarding adherence include employment status, educational attainment,
socio-economic status, treatment cost, race, age, social support, community service utilization,
gender, illiteracy, patient beliefs and perceptions, knowledge of condition, marital status,
confidence in treatment, patient/provider relationship, disease stigma, comorbidities, and
attendance at follow up appointments (S. V. Kane, 2008).
Race
A decade ago, world experts in chronic disease adherence recognized race as an
independent predictor of adherence (World Health Organization, 2003) . Conversely, a metaanalysis of the last 50 years of adherence research performed about that same time (DiMatteo,
2004) reported age, gender, level of education, and socioeconomic status as having a significant
impact on medication adherence. However, race was not acknowledged in the analysis as a
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Table 4
Summary of Non-Adherence Rates and Factors Associated with Adherence and
Non-adherence in IBD
Factors Associated with
Adherence (A) &
Non-Adherence (NA)

Author

Year

Country

Sample
Size

NonAdherence
Rate

Baars

2009

Netherlands

1,067

13%

A: shorter disease duration(< 8
years), older age, CD diagnosis

Bermejo

2010

Spain

107

69%

NA: lack of information about
disease, > 3x daily dosing

Bernal

2006

Spain

214

43%

A: complicated disease course

Bhatt

2009

India

127

81%

NA: taking >4 meds daily

Bokemeyer

2007

Germany

65

9%

NA: fear of adverse drug reaction,
employment

Cerveny(a)

2007

Prague

396

32%

NA: > disease activity

Cerveny

2007

Prague

177

39%

NA: higher levels of education,
disease > 10 years, younger age, lack
of confidence in treatment

D’Inca

2008

Italy

485

39%

NA: younger age, employment

Ediger

2007

Canada

326

25%M
37%F

Horne

2009

UK

1,871

29%

NA: doubts about need for
medication, younger age, shorter
disease duration (<5 years), fewer
outpatient visits (<3 a year)

Kane(a)

2000

U.S.

98

<25%

NA: male gender, shorter length of
remission

Kane(b)

2001

U.S.

94

60%

NA: less extensive disease, male,
single, left sided disease, taking > 4
medications daily
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NA Men: diagnosis of UC, full time
employment; NA Female: younger
age

Table 4 (continued)

Summary of Non-Adherence Rates and Factors Associated with Adherence and
Non-adherence in IBD
Author

Year

Country

Sample
Size

NonAdherence
Rate

Kane(c)

2003

U.S.

99

12%

NA with meds increases disease
recurrence

Khan

2013

U.S.

13,062

43%

NA: increased risk of disease flare

Lachaine

2013

Canada

1,681

72%

A: male, older age (>60yo), current
use of steroid.

Lopez san
Roman

2005

Spain

40

72%

NA: lower quality of life scores, less
active disease, high depression scores,
high patient MD discordance, longer
duration of disease, lack of treatment
info, lack of trust in MD

Mantzaris

2006

Greece

28

64%

NA: male gender, single status, taking >
5 meds daily

Mitra

2012

U.S.

1,693

72%

NA: increased healthcare costs

Moshkovska

2009

U.K.

169

32%

NA: younger age, doubts about need for
medication, South Asian ethnicity

Nahon

2011

France

1,069

10%

A: older age, treatment with TNF,
membership in support group NA:
constraints r/t treatment, anxiety,
smoking, and moodiness

Nguyen

2009

U.S.

235

35%

A: trust in MD, increasing age, lower
QOL, white race

Nigro

2001

Italy

85

18%

A: shorter disease duration, NA: disease
severity and psychiatric diagnosis

Robinson

2013

UK.

1,200

39%

Selinger

2013

UK

356

28.7%

NA: greater risk of relapse, switching >
risk of relapse
NA: doubts about need for medication

Sewitch

2003

Canada

153

41%

NA: less active disease, shorter disease
duration, no scheduling f/u, with MD < 1
year

Shale

2003

U.K.

98

43%

NA: 3x daily dosing, full time
employment, depression
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Factors Associated with Adherence (A)
&
Non-adherence (NA) in IBD

variable having considerable influence on this construct. Similar opinion purveys the vast
editorial work published on IBD adherence in the last five years and race was not purported to be
a mediator of consequence in any of these papers (Bernick & Kane, 2010; S. V. Kane, 2008;
Lakatos, 2009; Lichtenstein, 2008; Selinger, Robinson, & Leong, 2011).
Meanwhile, a systematic review was done to examine racial and ethnic disparities in
patients who utilize VA health services. (Saha et al., 2008), found inequalities in VA across
many clinical areas and service types. Discrepancies were most prevalent for medication
adherence, patient-provider communication, and shared decision-making suggesting that
intervening may improve outcomes in these subjects. Results of the Saha study provided
additional support for further study into the impact of race on non-adherence in veterans with
IBD who use the VA to access healthcare.
Literature promulgated by IBD experts suggested focusing efforts on modifiable
components of adherence, such as patient/provider relationships, versus emphasizing the impact
of a non-modifiable risk factor such as race. Consequently, there was only one study in this
review conducted specifically to examine the effect of race on adherence in this cohort. IBD
subjects from a specialty clinic (n = 120 Black and 115 White) were included in a crosssectional, prospective cohort to determine whether medication adherence differed among Black
and White IBD patients (Nguyen, Munsell, & Harris, 2009). Overall rate of adherence in this
study was 65%. Blacks had significantly higher rates of non-adherence than White counter-parts
(50% versus 80%, OR 0.25, 95% CI 0.14-0.48) which persisted after adjustments for
confounders had been made (OR 0.29, 95% CI 0.13-0.64).
The only other study in this review that discussed race was conducted by (Moshkovska et
al., 2009) in a sample of patients (n = 151) with ulcerative colitis from the UK. The only
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demographic variable independently associated with non-adherence was South Asian ethnicity
(OR 2.940, 95% CI 1.303-6.638) which made up only 19% of this sample.
Interestingly, an additional goal of the Moshkovska study included assessment of the
correlation between adherence and the patient/provider relationship, which was the risk factor
concentrated on in the aforementioned editorials as having the utmost impact on improvement of
medication taking behavior in this population. Patient trust in the physician displayed the
strongest correlation independently associated with adherence (R = -0.30) with no observed
differences between Blacks and Whites noted (R = -0.25 versus -0.30, p = 0.8).
Lack of data concerning the influence of race on medication adherence in patients with
IBD represents a gap in the literature. The literature suggests that treatment disparities based on
race, found in other chronic disease states, may also exist in IBD but this relationship is not
readily understood (J. F. Jackson & Kornbluth, 2007). Furthermore, research suggests that racial
disparities exist in the VA system (Saha et al., 2008) However, little is known of how race
influences chronic illness care in veterans with IBD.
(Sewell, Yee, & Inadomi, 2009) provided support for further investigation of the
influences of race on adherence in a study done to assess the trends of hospitalization among
minority patients with IBD, which showed statistically significant increases in admissions among
all race groups, particularly Asians, as non-adherence has been implicated in increased
healthcare utilization. Additionally, a systematic review demonstrated a rise in the incidence rate
of IBD among Hispanics (from 2.6 to 7.5 per 100,000 and Asians (from 0.22 to 3.62 per
100,000). This study also showed that minorities have a more complicated disease course. Both
of these issues provided support for further inquiry regarding the effects of race on medication
adherence, in this growing patient population, for which little is known (Ho et al., 2009).
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Age
In other chronic disease states, younger age is widely accepted as a risk factor for nonadherence (DiMatteo, 2004). This too appears to be the case in IBD as demonstrated by many
studies in this review (Cerveny et al., 2007; D'Inca, Bertomoro, Mazzocco, Vettorato, &
Rumiati, 2009; Ediger et al., 2007; Horne, Parham, & Robinson, 2009; Moshkovska et al., 2009;
Sewitch et al., 2003; Shale & Riley, 2003) . Higher rates of non-adherence among younger
individuals may be exceptionally problematic in IBD because the onset of disease most often
occurs in the late teens and early 20s.
Remarkably, four studies revealed older age as a significant independent predictor of
adherence ((Lachaine et al., 2013)) (OR=1.6, CI 1.3-2.0), (Nahon et al., 2011) (p < 0.01),
(Nguyen, Tuskey, Dassopoulos, Harris, & Brandt, 2007) (p = 0.01, R = -0.19), and (Baars et al.,
2009) (p = 0.01, OR 1.57, 95% CI 1.2-2.02). However, these results are not surprising given that
as age increases, so does adherence until the seventh decade when treatment adherence levels off
or begins to decrease (Mehta, Moore, & Graham, 1997). This study helped fill a gap in the
literature regarding the impact of age on medication adherence in veterans with IBD for which
little data exists.
Gender
A meta-analysis conducted to analyze rates and predictors of adherence across disease
states in the last 50 years showed a lack of correlation between gender and adherence (DiMatteo,
2004). Additionally, international recommendations to improve adherence to long-term therapies
(World Health Organization, 2003), a widely referenced medication adherence paper (Osterberg
& Blaschke, 2005), as well as two recent systematic reviews (Gellad, Grenard, & Marcum, 2011)
and (Ingersoll & Cohen, 2008) all fail to recognize gender as having significant impact on
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medication adherence. However, a comprehensive review done to catalog barriers to medication
adherence, demonstrated conflicting results regarding the influences of gender on adherence in a
variety of conditions (Krueger et al., 2005).
Similarly, the consequences of gender on adherence in IBD are mixed. Several studies
showed no impact of any demographic variable inclusive of gender (Cerveny et al., 2007; Lopez
San Roman, Bermejo, Carrera, Perez-Abad, & Boixeda, 2005b) . Men were more likely to be
non-adherent in four studies ((D'Inca et al., 2009; S. Kane, Cohen, Aikens, & Hanauer, 2001;
Lachaine et al., 2013; Mantzaris et al., 2007)). Whereas, (Waters, Jensen, & Fedorak, 2005)
demonstrated women were more likely to be non-adherent in an interventional study.
Noteworthy results were produced by (Ediger et al., 2007) who reported different
predictors of low adherence for men and women. For men, predictors of low adherence included
a diagnosis of UC (OR 4.42, 95% CI 1.66-11.75), being employed full-time (OR 11.27, 95% CI
2.05-62.08) having high scores on obstacles to medication assessment, and having a low level of
personality agreeableness. For women, predictors of low adherence include younger than 30
years of age (OR 3.64, 95% CI 1.41–9.43), high scores on obstacles to medication assessment
(OR 3.89, 95% CI 1.90–7.99) , and low level of agreeableness (OR 2.03, 95% CI 1.12–3.66).
Research suggests that addressing the impression of non-modifiable demographic variables such
as gender, on adherence, are not as important as concentrating on modifiable elements (Albaz,
1997). However, a lack of clear understanding about the impact of gender on medication
adherence in patients with IBD warrants further investigation, particularly due to the potential
deleterious effects of non-adherence with medical therapy during pregnancy (Katz & Pore,
2001).
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Employment, marital status, and education
IBD tends to onset at a younger age when decision regarding employment and education
are considered. IBD can have a labile course interfering with fulfillment of pursuits, a course
exacerbated by non-adherence to treatment. A review demonstrated that patients with IBD have a
higher rate of nonparticipation in the labor force (Marfi & Buchman, 2005). This same review
found similar levels of educational attainment among those with IBD when compared to the
general population.
Studies conducted by (Ediger et al., 2007) (OR 11.27, 95% CI 2.05-62.08) and (Shale &
Riley, 2003) (OR 2.7, 95% CI 1.1-6.9) revealed full-time employment as a risk factor for nonadherence. Whereas, (Bernal et al., 2006) demonstrated that unemployment was a risk factor for
non-adherence but was noted to not have reached statistical significance. A weakness of the
Bernal study was a lack of reporting of the set level of significance for the analysis.
Only one study in the review found any correlation between non-adherence and level of
education. Higher levels of education were associated with increased levels of non-adherence
(p = 0.046) in a Czech Republic sample (Cerveny, Bortlik, Vlcek, Kubena, & Lukas, 2007).
Likewise, only one study found any correlation between marital status and nonadherence. Single status was a predictor of non-adherence in the 2006 Mantzaris study.
Intriguingly, being married was supportive of adherence (OR, 95% CI 0.39-0.57) (S. Kane et al.,
2001) .
These contradictory findings across a variety of demographic factors, speaks to the
complex nature of medication adherence in this cohort. In addition, the lack of knowledge related
to demographic factors and medication adherence represents a gap in the literature and need for
further study.
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Health System Factors
Patient/provider relationship, medication access, patient education, patient follow up,
interventions to improve adherence, organization and coordination of healthcare services,
utilization of healthcare resources, and healthcare costs are all examples of variables categorized
as health systems factors in regard to medication adherence (World Health Organization, 2003).
Each of these are discussed below.
Patient/provider Relationship
Two studies explored the influence of patient/provider relationships on medication
adherence in IBD. Instinctively, lower rates of adherence occur when patient/provider
interactions are less than ideal.
Ten gastroenterologists and 153 of their adult IBD patients were the subjects in a
prospective, Canadian study performed to identify determinants of non-adherence in IBD and
assess the impact of patient-physician discordance on adherence (Sewitch et al., 2003) .
Discordance describes physician and patient perceptions of the patient’s health status and of the
clinic visit, as measured by a survey completed independently immediately after the office
encounter. The outcome variable was medication adherence as measured by the validated MAS4. Results showed total non-adherence to be 41% or 63 of the patients. Patient-physician
discordance (OR = 1.59, p = 0.0120), consulting a health professional and new patient status (OR
2.80, p = 0.0239) were predictors of non-adherence. Interestingly, patients treated by the
physician for < 1 year had an 84% higher risk of non-adherence than those treated by the same
physician > 1 year.
An IBD specialty clinic in Spain was the setting for a 2005 study conducted by (Lopez
San Roman, Bermejo, Carrera, Perez-Abad, & Boixeda, 2005a) designed to investigate the
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degree of adherence to therapy and to identify factors affecting medication adherence in this
cohort (n = 40). The authors also collected data on depression, patient-physician discordance,
QOL, and disease activity. Medication adherence measurement took place using the MAS4.Total non-adherence was 72%. However, to keep this high rate of non-adherence in context,
the MAS-4 does not quantify the amount of medication omitted. It merely denotes if the patient
had ever missed a dose of medication. The results showed a higher degree of non-adherence was
associated with patient-physician discordance scores (p = 0.01) and those who trusted their
physicians less (p = 0.03).
Coordination of Care
The literature suggests that organizational variables, such as number of provider visits,
both to primary and specialty care, as well as continuity of care, may have a far greater impact
on medication adherence than demographic variables (Albaz, 1997). Furthermore, coordination
of care between primary and specialty care is requisite to improve adherence (MacColl Institute
for Healthcare Innovation, 2010). However, the results from a Cochrane review (S. M. Smith et
al., 2009) conducted to assess the effectiveness of care coordination between primary and
specialty care, in chronic disease management, were conflicting. Overall, no consistent
improvement in outcomes across disease states materialized with the exception of medication
adherence that indicated significant benefit with coordination of care in this realm.
(Herrinton et al., 2007) conducted a study to explore the variations in IBD practice
patterns and outcomes over a decade (1998-2005) across medical centers in an integrated
healthcare plan in the U.S. in 2,892 adults with CD and 5,895 with UC. Health plan
administrative data provided information for this study. The healthcare system under
investigation had many similar features of the VA such as a closed pharmacy system housed
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within multiple medical centers campuses that include inpatient care, outpatient clinics,
laboratory, and x-ray services. Most medical centers had GI services but no specialty IBD
clinics. No endorsement of IBD practice guidelines existed. Primary care providers had
privileges to write for all drugs to treat IBD, save anti-TNF medications. The results showed a
striking shift of IBD care from specialty care to primary care with GI consultation provided as
deemed necessary.
The notion of coordination of care is widely endorsed by the VA healthcare system (Asch
et al., 2004; McQueen, Mittman, & Demakis, 2004). Yet, coordination of care in the VA has not
been systematically assessed (Neugaard et al., 2011). The primary care service line in VA acts as
a gatekeeper for access to specialty care thereby, coordinating care, such that veterans cannot
obtain specialty care without submission of a specialty consult by the primary care provider.
Although a multidisciplinary approach to chronic illness care in IBD is suggested
(Hernandez-Sampelayo et al., 2010), IBD management by primary and specialty care has not
been critically evaluated (Herrinton et al., 2007) as there were no studies in this review that
examined this conception. This may be due in part to the fact that while the discussion of IBD
care organization adopts the input of many disciplines, the focus remains on the contributions
made from other specialties such as surgery, radiology, pathology, dermatology, rheumatology,
and ophthalmology and not primary care (Mikocka-Walus et al., 2012; Ricci, Lanzarotto, &
Lanzini, 2008). The dearth of information regarding coordination of care between primary and
specialty care in the management of IBD in the VA system supported the need for further inquiry
in this realm.
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Healthcare Utilization
Direct healthcare costs estimates are $3.1 billion for CD and $2.1 billion for UC.
(Kappleman et al., 2008). A disease flare, perhaps compelled by non-adherence to therapy, could
influence the need for health services.
World adherence experts (World Health Organization, 2003) provide support for
examination of the variables associated with healthcare utilization concurrently with medication
adherence rates as this data works synergistically to accurately inform health outcomes and
future interventions. Furthermore, the authors encourage exploring these constructs using a
systems model such as the CCM as a guide. Therefore, this study began to explore the
relationship between medication adherence and healthcare utilization in veterans with IBD who
use the VA healthcare system. Healthcare utilization in this study included outpatient visits to
primary and Gastroenterology (GI) specialty care, ER usage and inpatient admissions for IBD
related illness.
(Kappleman et al., 2011) conducted a study aimed to describe the healthcare utilization
associated with IBD in an insured U.S. population 2003-2004 using the administrative databases
of 87 health plans in 33 states to identify those with IBD using ICD-9 code 555.x for CD and
556.x UC. The mean number of office visits per 100 patients with CD was 167 primary care and
179 GI-specialty, and for UC, 151 primary care and 128 GI-specialty. Overall, the results
demonstrated that healthcare utilization was higher in the IBD population when compared to
non-IBD controls. This is consistent with a paper by (Shi & Singh, 2012) which also reported
healthcare utilization rates to be much higher in IBD than for other Americans who on average
who make three visits a year to see a provider. A lack of healthcare utilization data in veterans
with IBD supported analyzing this topic.
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Similarly, (Ananthakrishnan, McGinley, Saeian, & Binion, 2010) conducted a study
exploring the trends in outpatient and ER visits for IBD in the U.S. 1994-2005. While cohort
generation for this study was the same as the (Kappleman et al., 2011) study, other differences in
study design make comparison of investigational results difficult. The (Ananthakrishnan et al.,
2010) study data source originates from surveys within the National Health Care Survey that is
used to inform the conceptual definitions for this study. The results demonstrated a 55% increase
(95% CI, 1.4-2.2) in outpatient visits as well as a 165% increase (95% CI, 42,498-112,257) in
ER visits in this population during the observation period. The authors advised further
investigation into the influences on increased healthcare utilization in patients with IBD. This
study began to close this information gap by initiating exploration of the relationship between
medication adherence and healthcare utilization in the VA population.
A U.S. based study conducted by ((Mitra, Hodgkins, Yen, Davis, & Cohen, 2012))
examined the association between medication adherence and healthcare utilization in 1,693
subjects using administrative data. Adherent subjects had 31% fewer hospitalizations (p =
0.0025) as well as 34% fewer ER visits (p = 00016) when compared to non-adherent
counterparts.
Most recently, researchers in Australia (Sack et al., 2012) conducted a study using the
CCM as a template for implementing a formal IBD Service in 100-200 patients with IBD to
examine the effects of the Service on healthcare utilization. This is the first study in patients with
IBD to use the CCM. While the authors did not declare the specific Model elements tested,
application of the Model for this study is counterintuitive as the Model has origins in primary
care, not specialty care as the authors present. Use of the Model in this manner is also
asynchronous to knowledge building, as the descriptive work in this field is not accomplished.
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However, the authors did note that 30% of subjects received IBD care from nongastroenterologists again, exploration of this relationship did not occur, a critical missing piece
to the use of the Model. The intervention consisted of a team approach led by a
gastroenterologist, an IBD nurse, surgical team, and radiology. Formal protocols tracked chronic
illness care in this cohort. The results demonstrated a lower number of inpatient admissions in
the treatment group (1.53) compared to controls (2.54, p < 0.0001). The costs of the admission
were also lower in the treatment group ($12,857) versus controls ($30, 467, p = 0.005). The
researchers concluded the intervention a success.
Four studies in this review reported on healthcare utilization variables in relationship to
medication adherence. None of the reviewed studies declared healthcare utilization as the
primary outcome variable.
The first study, conducted by (Horne et al., 2009) reported on the effects of outpatient IBD
visits on medication adherence in 1,871 (63% female, 45% CD, 49% UC, mean age 50)
members of the UK National Association for Colitis and Crohn's Disease (NACC) who were
randomly chosen from the organization's database. This is the only IBD adherence study to
catalog data on the annual number of IBD related visits to the patient's PCP, as well as the
number of outpatient and inpatient IBD related visit in the previous year. Roughly, 33% of
subjects had three or more IBD related PCP visits in the last year, and an equal percentage of
subjects, had no PCP visits in the last year for IBD related illness. While another third, claimed
three or more annual IBD specialty visits. Interestingly, the vast majority of subjects (80%) did
not have any hospitalizations in the year for IBD related illness. This data is suggestive of
quiescent disease in this cohort. Logistic regression showed that younger age, disease duration >
5 years (OR 1.96, 95% CI 1.43-2.69, p = 0.000) and fewer outpatient visits were significantly
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associated with rates of low adherence. The findings of this study support the need for
forthcoming research to examine more fully the effects of healthcare follow-up on mediation
adherence in this population.
The second study in this review reporting an association between non-adherence and
increased healthcare utilization was done by (Waters et al., 2005) who randomized 69 IBD
patients to a nurse-lead education interventions and standard of care. Over the four- week
observation period, the subjects had 44 outpatient visits, 16 for symptom control and 33 for
follow-up. Patient diaries provided medication adherence information. Subjects also had four ER
visits and five inpatient admissions. Although not statistically significant (t = 1.06, p = 0.294),
the educational group had lower rates of healthcare use (M = 0.63) than the control group
(M = 0.95). Those who reported missing medication in their diaries had significantly higher rates
of outpatient visits (p = 0.01).
(Sewitch et al., 2003) conducted the third study in this review to identify determinants of
non-adherence in IBD. The outcome variable was medication adherence as measured by the
validated MAS-4 showed total non-adherence to be (n = 63) 41%. Scheduling a follow-up
appointment (OR = 0.30, p = 0.0059) and new patient status (OR 2.80, p = 0.0239) were
significant predictors (p < 0.05) of non-adherence. Interestingly, patients treated by the
physician for < 1 year had an 84% higher risk of non-adherence than those treated by the same
physician > 1 year.
Data for the final study in this review to examine healthcare utilization and medication
adherence originated from a community health insurance program database. This sample
represents the largest retrospective cohort of patients with IBD year to date (n = 4,313) which
assessed medication adherence using the MPR to determine the association between adherence
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and healthcare costs from the payer's perspective (S. V. Kane, 2008). Overall, just over half
(57.2%) of the subjects were adherent to treatment (i.e. MPR > 80%). Adherence was associated
significantly (p < 0.05) with 62% lower costs for hospital admissions (p < 0.001), 13% fewer
outpatient visits (p <0.05), 45% fewer ER visits (p < 0.001), and 49.8% lower total healthcare
costs (p <0.001). The authors also controlled for comorbidity during multivariate analysis. A
CCI was generated with ICD-9 codes from administrative data as posited by the (Deyo et al.,
1992) algorithm. Study results demonstrated that higher levels of comorbidity were associated
with increased healthcare costs (p < 0.0001).
Results of these studies demonstrate the impact of non-adherence on healthcare
utilization in patients with IBD. However, a lack of information in this regard in VA represents a
gap in the literature and endorsed auxiliary exploration into the effects of adherence on
healthcare utilization in this cohort.
Interventions to improve adherence in IBD
Ultimately, the results of this study would support future generation of interventions to
improve medication adherence in patients with IBD. Therefore, although this is a descriptive
study, it was important to establish the state of interventional knowledge promulgated in the field
to address adherence issues in this population as this data will apprise the generation of future
endeavors.
There was only one interventional study, conducted specifically to examine the effects of
an intervention to improve medication adherence in patients with IBD. Stable patients (n = 81)
from a specialty IBD clinics were randomized to either a 23 week independent ,community,
nurse-delivered patient support program (n = 21) or standard of care (n = 60).
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Patients with an MPR > 80% were deemed adherent to treatment as measured at 3
months and 6 months in the Moss study. At three months, the rate of adherence was 39% for the
control group and 44% for the experimental group. At six months, rates of adherence increased
to 50% in the control group and 67% for those in the patient support group. However, the
differences in adherence for the two groups was not statistically significant (p = 0.3).
Furthermore, there was no association between the community educated group and adherence at
3 (OR 1.2, 95% CI 0.4-3.8) or 6 months (OR 2, 95% CI 0.6-7). The authors concluded that a
nurse-delivered patient-support program did not significantly improve adherence when compared
to standard of care.
Condition Factors Affecting Adherence in IBD
Several condition factors were identified as affecting adherence in IBD. Condition
related factors were disease recurrence, severity of disease, illness duration, disability,
availability of effective treatment, pill burden, duration of treatment, and side effects are
condition factors under consideration discussed as follows.
Pill burden
Pill burden refers to the total number of pills an individual takes in a day. Pill burden may
also refer to the number of pills and doses required daily for each specific medication regime.
Universally, higher pill burden is associated with decreased medication adherence. A systematic
review done to examine the impact of regime factors on medication adherence in a variety of
chronic illnesses confirmed this notion (Ingersoll & Cohen, 2008).
Pill burden is of particular consequence in IBD as some of the medications used to treat
the illness require two or more tablets to be taken up to four times daily with the worst case
scenario of a total of 12 tablets to be taken daily for one medication to treat IBD. The impact of a
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complex medication regime on adherence, not only because of the number of tablets taken per
day, but also dosing frequency, is obvious. This study will provide insight into the impact of pill
burden on veterans with IBD by using refill data to measure medication adherence, not only to
collate the types of medications taken for this condition, but also to explore the number of tablets
and dosing patterns prescribed and the effects of such on adherence.
The literature produced mixed results regarding pill burden. Two studies did not include
any information about the influence of pill burden on medication adherence in the results section
of the papers (Bokemeyer et al., 2007; Lopez San Roman, Bermejo, Carrera, Perez-Abad, &
Boixeda, 2005b). Three studies found no relationship between the type of drug, number of
drugs, and the number of pills administered and medication adherence (D'Inca et al., 2009;
Ediger et al., 2007; S. Kane, Huo, Aikens, & Hanauer, 2003) .
Two studies showed a relationship between pill burden and medication adherence. (Shale
& Riley, 2003) examined adherence in 98 patients from a specialty practice in the UK and found
that three-times-daily dosing was the only significant independent predictor of partial nonadherence (p = < 0.01, OR 3.7, 95% CI 1.8-8.9). Similarly, (S. Kane, Huo, Aikens et al., 2003)
conducted a study to determine adherence rates and predictors of non-adherence in 94 patients
from a specialty IBD clinic. The overall rate of adherence was 40%. The results demonstrated
that a history of taking more than four concomitant medications was associated with a two and a
half times increased chance of non-adherence (OR 2.5, 95% CI 1.4-5.7).
Disease Recurrence
Disease recurrence in patients with IBD, as impacted by medication non-adherence, was
the primary variable of interest in several studies published in the last decade (S. V. Kane &
Hanauer, 2000; S. Kane, Huo, Aikens et al., 2003; Khan, Abbas, Bazzano, Koleve, & Krousel-
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Wood, 2012; Robinson, Hankins, Wiseman, & Jones, 2013). All investigations measured
medication adherence using pharmacy refill data. The largest cohort was found in the (Khan et
al., 2012) study that had 13,062 subjects, followed over a 10 year period and demonstrated a 1.17
times increased risk of disease flares in non-adherent subjects.
(S. V. Kane & Hanauer, 2000) documented adherence rates and disease recurrence at 6
and 12 months. At 6 months, 12 patients (12%) had clinical recurrence all of which had
medication compliance <75%. The median amount of medication consumed was statistically
significant, 26% versus 83% for those still in remission (p = 0.001). At 12 months, an additional
19 patients had recurrence, 68% (n = 15) of which were non-adherent. The median amount of
medication taken was 80% for those in remission and 45%% with recurrence (p = 0.02).
As well, in the (S. Kane, Huo, Aikens et al., 2003) study, at 6 months, 12 patients had
recurrence of disease, all of which were non-compliance with medication. The median
percentage of mesalamine refilled was 51% for those who were non-compliant compared to 77%
for those still in remission. By 12 months, 19 additional patients had disease recurrence, 68% of
which were non-compliant. Patients who were non-adherent had more than a fivefold greater risk
of recurrence than patients who adhered (hazard ratio= 5.5, 95% CD 2.3-13, p = <0.001).
Robinson used pharmacy data from the UK to examine the relationship between
non-adherence, medication switches, and disease recurrence in 1,2000 subjects. The results of
logistic regression revealed that patients who switched mesalamine maintenance preparations
had a 3.5 fold greater risk of relapse than those who did not switch (95% CI = 1.16-10.62, p =
0.008). Although not the primary outcome variable, patients with non-adherence were three
times more likely to develop disease recurrence (OR 3.389, 95% CI 1.29-8.88, p = 0.012) in a
study conducted with 127 patients with IBD (Bhatt et al., 2009).
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Methods Used to Measure Adherence in IBD
All of the studies in this review examining medication adherence in IBD occurred in the
last decade. Table 5 contains a summary of tools used to measure medication adherence in this
population. The majority of investigations (9) used non-validated, study specific instruments to
collect adherence data. The method utilized to measure adherence was not transparent in three
additional studies. Several studies contained less commonly used adherence measures such as
drug serology (1), visual analog scale (VAS) (2), urine drug level (2), and patient diary (1). Five
studies contained variations of the same self-report measure, the Medication Adherence Report
Scale (MARS): MARS-4 (2) and the MARS-5 (1). The MARS eventually became the Morisky
Medication Adherence Scale (MMAS-8). Five studies, all conducted by the same author (Kane)
used pharmacy refill data to gather adherence information. Retrospective data analysis was the
method of choice in three studies. Further discussion of adherence measurement in IBD will
focus on the MMAS-8 as this is only validated self-report tool in IBD and assessment of
adherence using pharmacy data as this is the method utilized for this study.
MMAS-8
(Trindale, Ehrlich, Kornbluth, & Ullman, 2011) conducted the first study to validate the
MMAS-8 in IBD using gastroenterologists (n = 13) and 110 inpatient subjects on a specialized
IBD service. The study aim was to determine the level of agreement for adherence between the
MMAS-8 and perceptions of the treating physician as well as agreement between the MMAS-8
and pharmacy refill data. Although the cohort consisted of inpatients, the resulting assessment
was of outpatient medication adherence.
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Table 5
Summary of Tools Used to Measure Medication Adherence in IBD
Author

Year

Measurement Tool

Baars

2009

Unclear, used cut off of > 80% = adherent

Bermejo

2010

Medication Adherence Report Scale (MARS-4)

Bernal

2006

Non-validated study specific self-report survey

Bhatt

2009

Non-validated study specific self-report survey

Bokemeyer

2007

Drug serology/Visual Analog Scale (VAS)

Cerveny(a)

2007

Non-validated modified MARS-4

Cerveny

2007

Non-validated modified MARS-4

Ediger

2007

MARS-5

Horne

2009

MARS-4

Kane

2000

Pharmacy Refill Data

Kane

2001

Pharmacy Refill Data: MED TOTAL

Kane

2003

Pharmacy Refill Data: MED TOTAL

Kane

2012

Morisky Medication Adherence Scale (MMAS-8)/MPR

Khan

2012

Refill data: MPR, CSA, CMG

Lachaine

2013

Prescription and medical claims: MPR

Lopez
San-Roman

2005

Non-validated study specific self-report survey

Mantzaris

2006

Unclear, used cut off of > 80% = adherent

Mitra

2012

Insurance Claims

Moshkovska

2009

Non-validated study specific self-report survey/Urine drug level

Nahon

2011

Unclear, used cut off of > 80% = adherent, VAS, patient diary

Ngugen

2009

Modified Hill-Bone Compliance Scale (HBCS)

Nigro

2001

Non-validated study specific self-report survey

Robinson

2001

Non-validated study specific self-report survey

Robinson

2013

Refill data: MPR

Trindade

2011

MMAS-8/pharmacy refill data: CSA/MPR

Shale

2003

One non-validated self-report question/Urine drug level
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The foundation for the MMAS-8 stems from the MARS that views non-adherence in the
context of forgetting, avoiding, stopping medication, or altering drug dosages. The MARS-4
expanded into the MMAS-8 that includes dichotomous scoring of the following domains:
forgetfulness, missing doses, decreasing medication without physician input, forgetting to take
medications while traveling, decreasing medication when well, and the inconvenience of taking
medications. One Likert scale question regarding remembering to take medications rounds out
the questionnaire. A score of 8 on the Scale indicated perfect adherence; scores of 6-7 indicate
medium adherence; and scores < 6 indicate low adherence. The results of the MMAS-8 and
calculated adherence using the CSA and MPR from refill data were compared. Non-adherence
was denoted for subjects with CSA or MPR <0.8.
Results identified 54 patients as low adherers and 56 as either medium or high adherers.
Correlation between pharmacy refill data and scores on the MMAS-8 were found as 85% of low
adherers had CSA and MPR scores <0.8. Meanwhile, only 11% of medium and high adherers
had pharmacy refills scores suggestive of non-adherence. Furthermore, physician perception of
adherence correlated with the MMAS-8 for medium and high adherers (95%) but was only 33%
for low adherers. Physician overestimation of adherence was statistically significant (p =
0.0001).
(S. Kane et al., 2012) sought to build on Trindade's work by conducting a study aimed at
determining if a correlation existed between a self-report measure, the MMAS-8, and pharmacy
refill records in 150 (59% female) IBD patients from the Mayo Clinic. Unlike most of the
adherence studies in IBD, this investigation used a power estimate to calculate sample size.
Refill data collected retrospectively, 3 months before the study began as well as prospectively, 3
months and 6 months after the study started, furnished information on medication adherence
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using the MPR, recognized by the authors as the gold standard for measuring adherence in this
population. Patients were given an allowable grace period between 80-120% of the expected
time for a refill. For example, if a refilled date was 30 days, the grace period was between 24-36
days. Procedures for handling patients falling outside the allowable grace period are unclear.
Calculation of MPR occurred separately for each drug the patient took, up to three drugs per
patient. Patients with MPR > 80% were considered adherent. A 5-ASA product was taken by
47% of subjects, 54% on a thiopurine, 15% on Infliximab along with oral therapy, 8% on an
injectable biologic, and 6% on budesonide. This was the first adherence study in IBD to provide
adherence data on most of the agents used to treat the disease.
Median MPR scores were as follows: 5-ASA 50%, thiopurines 60%, Infliximab 75%,
injectable biologic 0, budesonide 33%. Scores of < 6 on the MMAS-8 indicated non-adherence,
while scores > 6 indicated adherence. The median score on the MMAS-8 was 7 indicating
roughly two-thirds of the population fit the definition of adherence. The tool identified a third of
patients classified as non-adherent by MPR. However, using a repeated-measures linear
regression analysis, the authors demonstrated only one drug class, thiopurines, had an MMAS-8
score significantly associated with refill data (p = 0.02, correlation 0.26). While the correlation
between refill data and the MMAS-8 was not noteworthy, use of such a self-report tool in the
outpatient gastrointestinal setting, may help clinicians identify those at greatest risk for nonadherence so that generation of individualized patient education and counseling in this regard
occurs.
Pharmacy Refill Data
Kane produced three U. S. based articles in the last decade using pharmacy refill
information to measure medication adherence in patients with IBD. The first (S. V. Kane &
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Hanauer, 2000) examined the effect of non-adherence on disease recurrence in patients with
quiescent ulcerative colitis who take mesalamine. A "valid calculation" provided information for
medication adherence using pharmacy refill records. Adherence was defined as consumption of
<75% of prescribed medication. Patients (n = 98) were interviewed at 6 and 12 months. At 6
months, 12 patients (12%) had clinical recurrence all of which had medication compliance
<75%. The median amount of medication consumed was significant, 26% versus 83% for those
still in remission (p = 0.001). At 12 months, an additional 19 patients had recurrence, 68% (n =
15) of which were non-adherent. The median amount of medication taken was 80% for those in
remission and 45% with recurrence which was statistically significant (p = 0.02).
The second study provided information regarding prevalence of medication adherence as
well as risk factors for non-adherence in 94 IBD patients with inactive ulcerative colitis (S. Kane
et al., 2001). Pharmacy refill data provided adherence information to calculate the MED
TOTAL. Consumption of 80% of prescribed medication equated with adherence. The rate of
non-adherence was 40%. Those who were male (67% versus 52%, p < 0.05, OR 2.06, 95% CI
1.17-4.88), single (68% versus 53%, p = 0.04), and had left sided disease versus pancolitis (83%
versus 51%, p < 0.01) had statistically significant higher rates of non-adherence. Interestingly,
two variables, which were statistically significant, were found to be protective against nonadherence included colonoscopy within the last 2 years (p = 0.03, OR 0.96, 95% CI 0.93-0.99)
and being married (p = 0.01 OR 0.46, 95% CI 0.39-0.57).
The final study conducted by this author using administrative data to measure adherence
assessed patient satisfaction with once daily dosing of mesalamine versus multiple dosing (S.
Kane, Huo, & Magnanti, 2003). Stable UC patients (n = 22) were randomized to once daily
dosing (n = 12) or conventional therapy (n = 12). The MED-TOTAL formula supplied

85

information on adherence at 3 and 6 months. Adherence again equated with consumption of
>80% of that prescribed. At 3 months, no patients experienced symptoms of relapse and the rate
of adherence was 100% in the daily dosing group and 70% for those taking conventional therapy.
At 6 months, one patient from each group experienced symptoms of disease relapse. Both were
non-adherent to treatment. The average amount of medication taken in the once daily group was
90% compared to 76% in the conventional group. Patient satisfaction was 83% for the once daily
dose group at the end of the pilot compared to 60% for those taking multiple doses daily.

2.6 Veterans Health Administration
Providing benefits for veterans is unique in the world. The United States has done so in
some fashion for centuries. The Veterans Health Administration (VHA) is a multifaceted agency,
with origins in the 1600s, that governs the largest integrated benefits system in the world,
providing services to honorably discharged members of the U.S. Armed Services. VHA’s
primary mission is to enhance the health and wellbeing of those it cares for, emphasizing
functionality of members with service connected injuries (conditions related to military service).
Over time, as circumstances dictated, this country has evolved a complex organization within a
politically charged environment, to meet the needs of those who served. Ever mindful of the
changing demographics of veterans, the many stakeholders associated with veteran benefits, and
the economic climate in which allocation of resources occurs, VA repeatedly transforms to
emerge from these challenges. Investigators conducting research in such a unique atmosphere
will need to be cognizant of how the characteristics of the system affect scientific inquiry.

2.7 Veterans
This study will use a systems model, the CCM, as a foundation for examining
relationships within a closed healthcare system, the VA. While having a tangible appreciation of
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the VA is crucial, equally important to this investigation, will be a working knowledge of the
individuals who use the system under consideration. Veterans are a vulnerable population
because of the presence of multiple disabilities, comorbid mental health diagnoses, substance
abuse histories, and low incomes in substantive numbers (M. W. Smith & Joseph, 2003).
2011 Survey of Veterans
The characteristics of Veterans are ever changing. In an effort to meet the needs of this
divergent population, the federal government has made it a priority to understand the individuals
who utilize VA services and what influences their healthcare decision making and health status.
To attain this objective, since 1999, an annual VHA Survey of Veteran Enrollees' Health and
Reliance upon VA has been conducted by the Office of the Assistant Deputy Under Secretary for
health for Policy and Planning (ADUSH/P&P). Statistics from the survey generate a healthcare
budget for VA. Additionally, this data informs health policy options that affect medical decision
making for Veterans. The annual survey occurs in conjunction with OMB authority that
determines the amount of funding apportioned for Veteran benefits. The survey results represent
data only for Veterans enrolled in VA healthcare.
The demographics discussed are from Fiscal Year 2011, the period of observation for this
study. Therefore, the statistics presented here in should be representative of the population for
this investigation. Data generation occurs by the Healthcare Analysis and Information Group and
the Enrollment and Forecasting Service within ADAUSH/P&P.
Data collection occurred via telephone survey. The observation period was inclusive of
March 4, 2011 through May 27, 2011. Over 45,000 Veteran users of VA healthcare nationwide,
chosen randomly, constituted the sample. Weighted results represent the entire population of
enrollees of approximately 7.8 million Veterans. The survey included the following variables of
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marital status, age, household income, priority level, period of service, combat status, ethnicity
and race, employment status, public and private health insurance coverage. Additional variables
included Medicare coverage, prescription drug benefit or coverage, number and costs of overthe-counter and prescription medications, key drivers of enrollees' healthcare decision making,
perceived health status, smoking status, and perceptions of VA healthcare, and planned future
use of VA (Office of the Assistant Deputy Under Secretary for Health for Policy and Planning,
2012). A summary of key variables are below. Unless otherwise noted, all figures are from the
Office of the Assistant Deputy Under secretary for Health Policy, 2012 report.
Demographic Variables
The average age of the patients was 62. The majority of enrollees were married (62%),
white (80.8%), males (94%) with dependents. Six percent of the population was Hispanic,
11.7% African America, and 4.2% were Native American.
Enrollees served in the military for an average 6.5 years with 43% reporting exposure to
combat during their service. The greater part of veterans (41%) served during the Vietnam War
Era.
Most enrollees (60%) did not work outside the home. The reported median annual
household income was $35,000. This figure is unchanged for the last five years.
Health Status and Future Use of VA
Enrollees under age 45 more often reported positive health status (excellent/very
good/good).Veterans of OEF/OIF had annual incomes greater than $36,000, and were female.
This statistic has remained steady in the last decade.
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Of those enrolled to access VA services, 75% reported that they use VA for at least some
of their healthcare needs. Veterans with annual household incomes of less than $36,000 were
more likely to use VA to meet all of their healthcare needs.
Consistently, for the last five years, at least 45% of enrollees plan to access VA for
primary care only. Less than 5% plan to use VA for specialty care in the future. The reason for
this is unclear. The overwhelming majority of patients who use VA services reported in a
positive manner about their experiences. Predictors of future use of VA benefits were quality,
cost, and availability and accessibility of services.
Health Insurance Coverage
The survey examined availability and use of health insurance by VA enrollees. Health
insurance was defined as "any program that helps pay for medical expenses, whether through
privately purchased insurance, social insurance, or non-insurance social welfare programs funded
by the government" (p.59). Most enrollees (77%) reported some type of public or private health
insurance coverage in addition to VA benefits. This number has been on a steady decline since
2008. Of those with healthcare coverage, 35% are accessing it through an employer.
Younger Veterans, the unemployed, and those with lower incomes are more likely to be
uninsured. This number has grown steadily since 2008 from 34% to 41% in 2011. Medicare
continues to be the most commonly (51%) reported health insurance coverage.
Pharmaceutical Coverage
VA provides both prescription and over the counter drug coverage for all enrollees with
some paying a co-pay ($8/30day supply). Yet 40% of those in the cohort were unaware of the
pharmacy benefit. Individuals with incomes above $36,000 a year and those who were under age
45 were more likely not to have knowledge of these services.
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On average, enrollees take 4.7 different medications in a month with 43% reporting to
have taken five prescription medications in a 30-day timeframe. A comparison with non-veteran
data showed only 11%, age 60 and older took 5 medications per month. This broad difference
exists due to an older, comorbid Veteran population.
Overall, 34% of enrollees do not use VA for prescriptions. The Execute Summary of this
survey does not make clear if these individuals do not take any prescription medications at all, or
if they are obtaining medications elsewhere. Of those who reported private insurance coverage
(77%), only 39% had an associated prescription drug benefit with their health plan. However, it
is not transparent if veterans access to private prescription services influences VA use of the
same benefit. Knowledge of veteran access to pharmacy services outside VA is a recognized
limitation of this study.
In 2006, for the first time, Medicare patients could register for Medicare Part D, a
prescription drug benefit. As expected, VA enrollees with higher incomes who could afford the
premiums were more likely participate. While 36% of VA enrollees have opted to purchase
Medicare Part D, the survey analysis does not make clear the impact of this coverage on VA
drug program usage. This is currently under further deliberation. Furthermore, the effects of the
Patient Protection and Affordable Care Act (PPACA, 2010) on prescription drug coverage for all
U. S. Citizens remains unknown.
VA Reliance.
VA reliance examined outpatient usage and was defined as "the number of visits or trips
in a VA setting reported by an enrollee divided by the sum of all visits in both VA and non-VA
settings" (p. 79). Nationwide, the average reliance on VA for outpatient care was 47%. Drivers
of higher levels of reliance on VA services were: uninsured; reported poor health status; earned
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less than $20,000 annually; 50-64 years of age; service during Vietnam Era; unemployed; single;
and African American.

2.8 Summary of Gaps in the Literature
Significant support existed in the literature for the primary line of injury for this study.
This study addressed several deficiencies in scientific knowledge discovered in this review.
While a substantial amount of research subsists regarding medication adherence in IBD, small
sample sizes and use of unreliable measurement, chiefly that of non-validated self-report
measures, limit the interpretation of study findings. This study provided information on veterans
with this disease, about which little data currently exists. Furthermore, this study assessed
medication adherence using the prescribed "gold standard" for this cohort, pharmacy refill data.
World experts have acknowledged the multifaceted nature of medication adherence, encouraging
assessment of systematic influences on this construct in an effort to improve health outcomes.
However, adherence research in IBD is in early development, with the majority of studies
conducted in the last five years that are descriptive in nature, providing information regarding
adherence rates and predictors of the most common demographic variables. The results of this
review demonstrated persistence in adherence science in IBD in examination of individual
behaviors with very few if any researchers casting a wider net to explore systematic impacts.
Therefore, this study was the first of its kind to assess medication adherence in this cohort using
a systems Model as a guiding framework to explore coordination of care and its relationship to
medication adherence and healthcare utilization in veterans with IBD.
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Chapter 3
METHODS
This chapter includes a description of the study research design. This chapter also
includes a discussion of the population used for this study as well as how the investigational
cohort generation occurs. Additionally, this chapter contains information regarding protection of
study subjects. Furthermore, this chapter incorporates information regarding the databases from
which study variable retrieval occurs, knowledge of data quality housed within these
infrastructures, as well as how study data points are measured. This chapter closes with the
details of data handling procedures, planned statistical analysis, and sample considerations.

3.1 Research Design
The design for this study was a descriptive retrospective data analysis. Medical records of
veterans with IBD provided the information for analysis. Retrospective analysis has been used to
assess medication adherence in patients with IBD using pharmacy refill data retrieved from large
healthcare databases (S. V. Kane & Hanauer, 2000; S. Kane et al., 2001; S. Kane, Huo, &
Magnanti, 2003; S. Kane et al., 2012; Khan et al., 2012; Lachaine et al., 2013; Mitra et al., 2012;
Trindade et al., 2011).(S. V. Kane & Hanauer, 2000; S. Kane et al., 2001; S. Kane, Huo, Aikens
et al., 2003; S. Kane et al., 2012; Trindale et al., 2011)However, few frameworks are available to
guide methodologic decision making in retrospective studies using administrative data (A. K.
Smith et al., 2011; Worster & Haines, 2004) . For this reason, ISPOR generated a consensus
document outlining a systematic approach to designing retrospective database studies of
medication adherence that informed study methodology as well as final manuscript publication
(Peterson et al., 2007).
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3.2 Population
The population for this investigation was enrollees in one northeast Department of
Veterans Affairs Medical Center (VAMC) who sought care for IBD between October 1, 2010
and September 30, 2011 for IBD, FY 2011.

3.3 Procedures for Protection of Human Subjects
Conducting research entails protection of human subjects participating in such an
endeavor, the guidelines for which exist in the Research Act of 1974 (Zucker, 2007). However, it
was not until the passage of Public Law 104-191, the Health Insurance Portability and
Accountability Act (HIPAA) of 1996, that protection of health information (PHI) came to the
forefront. Because PHI access occurred in this study, the implications of HIPAA on study
protocols are reported. Table 6 contains a summary of the procedures used to protect human
subjects for this investigation.
The intent of HIPPA was to improve portability and continuity of health insurance
coverage by allowing chronically ill individuals to change jobs without losing healthcare
coverage (Watts et al., 2003). However, the law also contains a provision mandating health
systems maintaining healthcare information to implement safeguards ensuring the integrity and
confidentiality of PHI that has had consequences for research conducted using administrative
data (Nosowsky & Giordano, 2006). Although not specifically directed at research, HIPPA, also
known as the Privacy Rule, significantly restricts situations in which PHI are used and disclosed.
PHI includes any information collected from an individual, including demographics, related to
the person's past, present, or future mental or health condition as well as payment for such, and
applies to all healthcare plans and providers transmitting this information in an electronic form
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(U.S. Department of Health and Human Services, 2003). This description of PHI applies to all
data used in this study.
Typically, in research, data collection occurs after patients have given informed
consent. However, there is no direct permission obtained in retrospective studies (VonKoss
Krowchuk, More, & Richardson, 1995). The Privacy Rule does allow disclosure of PHI without
permission under limited circumstances, such as when using de-identified and limited datasets,
contingent upon completion of a Waiver of HIPAA Authorization (Watts et al., 2003).
Congruent with 45 CFR 164.512(i)(2), a HIPPAA Waiver is appropriate because this study could
not have been conducted without the waiver or without access to the requested PHI (Department
of Veteran Affairs, 2012). Furthermore, in accordance with the Privacy Rule, patient
authorization is not required for studies using PHI in existence at the time of IRB submission, in
this case, FY 2011 (VA Pittsburgh Healthcare System Research and Development, 2010) . Table
7 contains PHI elements omitted from a dataset considered de-identified or limited (Department
of Veteran Affairs, 2012).
Because this study is examining the relationship between coordination of care,
medication adherence, and healthcare utilization, dates, month and day, of the following
variables are required for data analysis: prescription refills, outpatient visits to primary and
specialty care, ER visits, as well as inpatient admissions for all services related to IBD as
outlined in the measurement section below. While exclusion of all other PHI elements from
study datasets occurs, knowledge of the month and day when service rendering occurs, because it
is necessary to achieve research aims. As a result, this study protocol included a request to the
local VA IRB as well University IRB to obtain a limited dataset through an expedited IRB
process. VA Policy 002, VHA Handbook 1605.1, and VHA Handbook 1605.2 outline
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Table 6
Summary of Procedures for Protection of Human Subjects
1. Use of a Limited Dataset
2. No effort was made to re-identify de-identified data
3. Dataset access occurred only through a password protected VA machine or CAG
through an access restricted SharePoint site
4. All research records were maintained in accordance with the Veterans Health
Administration (VHA) Records Control Schedule. Paper records were disposed of
using methods deemed appropriate by the VAPHS Privacy Officer, and all electronic
data was sanitized using methods rendered appropriate by the VAPHS ISO.
5. Data was only reported in the aggregate
6. The dataset will be retained indefinitely according to policy by the Institution of
Record
7. All research records, as defined by VHA Handbook 1200.05, were stored under lock
and key in the researcher's VA office with the VA PI having the only access
8. The requested dataset was not reused or disclosed to any other person or entity, except
as required by law, for authorized oversight of the research study, or for other research
for which the use or disclosure of the requested information would be permitted by the
Privacy Rule (VHA Handbook 1200.05, p. 66).
9. Any loss or compromise of any VA sensitive information (including research data),
VA equipment or device, or any non-VA equipment or device that is used to transport,
access, or store VA information was reported in accordance with the reporting
requirements outlined in VA Handbook 6500.
10. In accordance with VHA Handbook 1200.05(63)(a), the study was conducted with
a Co-PI
11. Completion of a Waiver of HIPAA Authorization.
12. The PHI requested was the minimum necessary for the stated purposes
13. Data acquisition occurred only for research purposes and future dissemination of
findings
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steps in requesting a limited dataset (Department of Veterans Affairs, 2006b; Department of
Veterans Affairs, 2013).
This study protocol included a VA IRB request to access the limited dataset for use
through remote access provided by the VA, known as Citrix Access Gateway (CAG), that
permitted password protected access to VA information from a personal computer. This study
protocol also included an application submitted to the VA for statistical support through the local
VA Research Office. The dataset was returned to the statistician according to current VA policy
upon final manuscript publication.
A data safety monitoring plan was implemented to ensure that there were no changes in
the benefit/risk ratio during the study and that confidentiality of research data was maintained.
Study personnel met weekly to discuss any issues or concerns. Any instances of adverse events,
protocol deviations, or other problems identified during the meeting were to be reported within
the required timeframes using the standard forms and/or procedures set forth by the IRB. There
was no data compromise during this investigation.
Additional data safeguards included reporting of data in aggregate form to ensure patient
confidentiality and anonymity, as well as storage of all research records, as defined in VHA
Handbook 1200.05, in a locked VA office that only the co-PI had access to. The risks associated
with this study were minimal. Data acquisition occurred only for research purposes and
dissemination of findings.

3.4 Measurement
The following passages contain information regarding measurement of study variables.
The variables included medication adherence, demographic variables, and healthcare utilization.
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Table 7
PHI Data Elements Excluded from De-identified and Limited Datasets
Identifiers Excluded in
De-identified Datasets
Names
All geographic subdivisions smaller than a
state, except for the initial three digits of the
zip code of the geographic unit formed by
combining all zip codes with the same three
initial digits contains more than 20,000 people

Identifiers Excluded in
Limited Datasets
Names
Street Address

All elements of dates except year and all ages
over 89
Telephone Numbers

Telephone Numbers

Fax Numbers

Fax Numbers

E-mail Addresses

E-mail Addresses

Social Security Numbers (SSN)

Social Security Numbers (SSN)

Medical Record Numbers

Medical Record Numbers

Health Plan Beneficiary Numbers

Health Plan Beneficiary Numbers

Account Numbers

Account Numbers

Certificate or License Numbers

Certificate or License Numbers

Vehicle Identifiers/License Plate Numbers

Vehicle Identifiers/License Plate Numbers

Device Identifiers and Serial Numbers

Device Identifiers and Serial Numbers

Uniform Resource Locator (URLs)

Uniform Resource Locator (URLs)

Internet Protocol (IP) Addresses

Internet Protocol (IP) Addresses

Biometric Identifiers

Biometric Identifiers

Full-face Photographs/Comparable Images

Full-face Photographs/Comparable Images

Any other unique, identifying characteristic or
code, except as permitted for re-identification
in the Privacy Rule
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Medication Adherence
Medication adherence was measured using the MPR that was operationalized as: “the
sum of the days’ supply of medication divided by the number of days between the first fill
and the last refill plus the days’ supply of the last refill” Figure 3.1 (Sikka et al., 2005).
Corroboration between dosing instructions and days’ supply of medication did not occur because
this information was not available in the databases accessed for this study.
All individuals had a uniform follow-up period to prevent biases upward in calculating
MPR for individuals with shorter follow up times, for this study, FY 2011 served as the uniform
observation period (Sikka et al., 2005). Adjustment in the denominator of this equation occurred
for subjects with inpatient admissions. Therefore, the observation period for patients with an
inpatient admission, reflected the omission of hospitalized days from the total days in the
observation period (Gellad, 2012).
In the descriptive analysis, MPR was a continuous variable. As found throughout the
adherence literature in a variety of chronic diseases where retrospective analysis of pharmacy
refill data is employed, (Kreyenbuhl et al., 2010; Krousel-Wood et al., 2009; Siegel, Lopez, &
Meier, 2007) further analysis was conducted with the MPR dichotomized so that those with
MPR of >.80 or above were adherent and those with an MPR < .80 were non-adherent. The
origins of these cut off points are based on the principal that loss of >20% of a patient population
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Figure 3.1 Calculation of MPR. “Reprinted from The American Journal of Managed Care,11(7),
Sikka, R., Xia, F., Aubert, R. E., Estimating medication persistency using administrative claims
data, 449-457, 2005, with permission from Managed Care & Healthcare Communications”

in a clinical trial makes the results suspect (Guyan, Sackett, & Cook, D. J. for the Evidenced
Based Medicine Working Group, 1993).
Essentially, an MPR of .80 equates to taking a medication 80% of the time. This means
that 20% of the time, the patient is not taking any medication. Use of this cutoff implicitly
assumes that no change in health outcome occurs as result of this “allowable gap” in treatment.
As reported in this paper, the 80% cut off is used widely throughout the adherence literature for
many chronic disease states, although not supported by any documentation of the clinical validity
of this measure (Ho et al., 2009; Peterson et al., 2007) this includes IBD (Regueiro, 2012c).
Thereby, adding further to the limitations of measuring medication adherence using pharmacy
refill data.
The literature supports the use of adherence cutoffs in IBD as >.80 as adherent and < .80
as non-adherent (Bhatt et al., 2009; S. V. Kane, 2008; S. Kane et al., 2001; S. Kane, Huo, &
Magnanti, 2003; S. Kane, Huo, Aikens et al., 2003; S. Kane et al., 2012; Lachaine et al., 2013;
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Mantzaris et al., 2007; Moss et al., 2010; Nahon et al., 2011; Robinson et al., 2013; Trindale et
al., 2011) . Additionally, the MPR with these cutoffs appears previously in retrospective
adherence studies using a sample of veterans (Khan et al., 2012; Kreyenbuhl et al., 2010).
Therefore, these cutoffs were also employed for this investigation. However, to improve the
robustness of the evaluation, the analysis was repeated using .90 as a cutoff to assess if the
results changed in a statistically significant manner.
MPR calculation occurred for each of the applicable medications in this study for each
patient, because it was conceivable that patients could be taking more than one drug for IBD
simultaneously. Combination of MPR calculations did not occur across patients due to different
denominators for each drug. Therefore, a mean MPR was calculated for each patient taking more
than one medication (Hess et al., 2006; Peterson et al., 2007).
It was acknowledged that the MPR will miss those with primary non-adherence i.e. those
who are prescribed a medication but never pick it up from pharmacy. Additionally, because the
MPR requires at least two medication refills during the observation period, those who filled only
one prescription and never fill again were not included. Therefore, the sample for this study was
limited to subjects who were relatively more adherent than others in the cohort.
While administrative pharmacy data represents a valuable research tool, there are several
confounding elements of this measurement to address such as, over- supply of medication,
persistence, and switching.
Over-Supply of Medication
Over-supply of medication is a consideration when using refill data to measure
adherence. MPR scores typically run 0 to 1.00 with higher values indicating higher levels of
medication adherence (Kim, Agostini, & Justice, 2010). The literature demonstrates a variety of
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procedures regarding MPR values > 1, indicating oversupply of medication. There were no cases
of medication over-supply in this sample.
Persistence
The literature recognizes retrospective measure of persistence as a concept distinguished
from adherence and defined as the length of time from initiation to discontinuation of therapy,
measured in units of time (Burrell et al., 2005). Such that, individuals who are persistent with
therapy, have medication taking behavior that is continuous, filling medications frequently, and
regularly, during a specified period (Sikka et al., 2005). Whereas retrospective measure of
adherence is the total number of days of medication availability for a defined observation period
which does not take into account the consistency with which individuals refill medication
(Burrell et al., 2005).
The mostly widely used measure of persistency is measurement based on gaps between
refills (Sikka et al., 2005). The literature lacks consensus regarding the appropriate length of the
permissible gap (Sikka et al., 2005). Furthermore, there are no allowable gaps in treatment for
IBD (Regueiro, 2012b). Therefore, to contribute to adherence science in a meaningful way,
persistency was not measured for this study.
Switching
Subjects switching between drugs within the same therapeutic class or between a
different therapeutic class were deemed adherent with an MPR of > .80 (Andrade, 2006).
Demographic Variables
The analysis included covariate demographic characteristics that have demonstrated,
although not consistently, an association with medication adherence in IBD. Demographic
variables included age, gender, race, and ethnicity. Age was reported as a continuous variable.
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Gender was a categorical variable, male or female. For regression models, females were
excluded due to low counts in this group.
Race was also a categorical variable with seven levels. The nationally approved race
standardization in VHA originates in Handbook 1601A.01 and Directive 2009-21 and included
the following standardized race values American Indian or Alaska Native, Asian, Black or
African American, Native Hawaiian or Pacific Islander, and White, Unknown by Patient, and
Declined to Answer (Veterans Health Administration, 2012). VA categories for ethnicity
included Hispanic or Latino, not Hispanic, don't know/refused (VA Information Resource Center
(VIReC), 2011) . As such, data collection for race and ethnicity reflected these groups. Report of
descriptive statistics, including frequencies, took place for all races and ethnicities. However, due
to low frequencies in many of the above categories, for further evaluation, race and ethnicity
were collapsed as appropriate. Despite categorical collapse, race and ethnicity were excluded as
variables in multivariate analysis due to minimal occurrences for many categories.
Additionally, IBD diagnosis, CD versus UC, as well as, IBD medication, categorized as 5-ASA,
immunomodulator, were both included.
Healthcare Utilization
Healthcare utilization was the “use of healthcare resources” (Bernstein et al., 2003). The
services chosen for examination in this study were derived from the National Health Care
Survey, a collection of surveys, done to assess how the U. S. healthcare delivery system is being
used and by whom. While the main outcome variable for this study was medication adherence,
research demonstrates a relationship exists between adherence and consumption of healthcare
resources (World Health Organization, 2003). Additionally, while healthcare utilization in IBD
has been studied (Ananthakrishnan et al., 2010; Gibson et al., 2008; Longobardi & Bernstein,
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2006; Mitra et al., 2012; Nguyen et al., 2007), no information regarding the healthcare utilization
of veterans with this disease exists. Therefore, this study began to explore these relationships in
the VA for which a gap in science exists.
Data on healthcare utilization originated from FY 2011 VistA datasets. For this
investigation, the following healthcare services represented healthcare utilization: ER visits,
outpatient department visits that included both primary and specialty GI care clinic visits, as well
as inpatient admissions. The frequencies of each visit type for each patient were included in the
analysis. For further multivariate evaluation, three logistic regression models were created. In
each model, the dependent variable was dichotomous, yes/no. Analysis details of healthcare
utilization are contained in subsequent passages.
Comorbidity
Measurement of comorbidity in research occurs to correct for confounding, to establish
use as a predictor of a study outcome, and for statistical efficacy (de Groot, V., Beckerman,
Lankhorst, & Bouter, 2003). As is established in the literature, healthcare utilization
investigations typically include consideration of comorbidities in the population of interest and
control for this variable during multivariate analysis (Valderas et al., 2009; Vogeli, Shields, &
Lee, 2007) . In turn, this variable was included in this exploratory analysis of healthcare
utilization.
There are over 75 million Americans with two or more chronic conditions (Parekh &
Barton, 2010). Level of comorbidity is of particular concern in the veteran population because
veterans who receive care in the VA are more likely to have multiple chronic health conditions
and higher rates of mortality when compared to the general population or veterans who do not
use the VA for healthcare (Agha, Lofgren, VanRuiswyk, & Layde, 2000; Lee et al., 2007). Of
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further concern, are the results of studies that suggest patients with multiple medical conditions
have poor outcomes and increased healthcare resource utilization (Vogeli et al., 2007).
Similar to medication adherence, no consensus exists in the literature regarding how best to
define and measure comorbidity (Fortin, 2007). As a result, a review article (Valderas et al.,
2009) generated explicit definitions for the nomenclature surrounding comorbidity as well as
measurement considerations of this construct, with the aim of consistent usage of these
definitions and measures in future research to allow for comparison of results across reports and
improve generalizability of study findings. To this end, the recommended definition and measure
emanating from this paper informed the measurement of this construct for this study. Hence, the
definition of comorbidity for this study was the "presence of additional diseases in relation to an
index disease in one individual” (Valderas et al., 2009).
(Valderas et al., 2009) encouraged use of measuring comorbidity with established disease
classification systems such as the one chosen for this study, ICD-9. Choice of the (Deyo et al.,
1992) comorbidity measure took place based on this recommendation. The Deyo algorithm
originates from work completed by (Charlson et al., 1987), who identified 19 medical conditions
associated with increased rates of mortality within 12 months and created a tool to measure this
risk, the Charlson Comorbidity Index (CCI) which has become the most widely used measure to
characterize the risk of death from comorbid disease (Valderas et al., 2009). A comorbidity
index reduces the coexistence of illnesses to a single score that allows for comparison with other
patients in a study as well as subjects across studies.
The CCI assigns a weighted score to each medical condition that ranges between 1-6.
Patients receive a score for each of the medical conditions in the CCI that combined for a total
comorbidity score, with higher values, up to 37, indicating more severe levels of comorbidity. To
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place the scores in context, in the (Charlson et al., 1987) study, a patient in the first cohort (559
patients) with a score of 0 had a 12% 1year mortality rate, scores of 1-2 with a 26% risk, 3-4
with a 52% risk, and those with a score >5 had an 85% risk of mortality at 1 year. The authors
then followed a second cohort (685 patients) for 10 years. The morality risk for the various CCI
scores was similar in that those with a score of 0 had a 12% risk of mortality, scores of 1 a 25%
risk, 2 a 48% risk, and scores > 3 had 59% risk of death. Thereby demonstrating that as CCI
scores increased, so did the cumulative affective of comorbid disease (p < 0.0001). In the second
cohort, age was also a predictor of mortality (p < 0.001).
The CCI was included in a critical review of the measures of comorbidity conducted to
evaluate the validity and reliability of a total of 13 such methods (de Groot et al., 2003). A
correlation coefficient (ICC) exceeding 0.40 supports the concurrent validity of the CCI. The
predictive validity or ability of the CCI to predict future events on an outcome measure of
interest, has been established by the presences of significant relationship of the Index with
various criterion measures such as mortality, disability, hospital readmission rates, and length of
stay (Chalson, Szatrowski, Peterson, & Gold, 1994; Librero, Peiro, & Ordinana, 1999; Rochon et
al., 1996). Data also exists that the CCI has good test-retest as well as interrater reliability
(Extermann, Overcash, Lyman, Parr, & Balducci, 1998; Liu, Domen, & Chino, 1997). Of the 13
comorbidity measures in this review, the authors concluded that only 4 of the 13 are valid,
reliable measures of comorbidity, CCI being one of these measures. More recently, (S. F. Hall,
2006) published a paper in a similar vein producing comparable results.
Building on Charlson’s work, (Deyo et al., 1992) created a method for calculating the
CCI, specifically using administrative data, based on the ICD-9 codes of the 19 medical
conditions in the original Index, see Table 8 (permission located in Appendix D) . The Deyo
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method has 17 chronic diseases in its algorithm. The only difference between the CCI and the
Deyo algorithm is in the category for malignancy. The CCI has three categories for malignancy,
classified as any malignancy, leukemia, and lymphoma. However, the Deyo algorithm places all
three classifications into one category resulting in the creation of 17 medical condition categories
instead of 19. Multivariate analysis in the Deyo (1992) study demonstrated significant
association with outcomes post lumbar spine surgery as well as resource utilization in this cohort
(p <0.0005).
(Quan, Parsons, & Ghali, 2004) sought to validate the Deyo algorithm by examining the
administrative data of 1,200 subjects by comparing algorithm scores using administrative data to
scores generated using the same tool calculated from manual chart review. The authors
calculated a kappa score to determine the extent of agreement between the two sources above
chance. Overwhelmingly, the kappa scores showed moderate (0.41 to 0.60) to substantial
agreement (0.61 to 0.80) between the scores calculated using administrative data and the scores
calculated from manual chart review. Logistic regression models were used to predict in-hospital
mortality using both data sources. While some differences between administrative data and
manually retrieved data occurred, overall the ability to predict in-hospital mortality was the same
for both groups (OR 1.4; 955 CI 1.3-1.5). Recognizing the limitations of administrative data, the
authors concluded that calculation of a comorbidity score using administrative data may
adequately characterize the burden of comorbidity.
Use of the Deyo algorithm in the population of interest provided additional support for its
use in this study. As reported previously, the investigations conducted by (S. V. Kane, 2008)
and (Nguyen et al., 2007) both described in detail previously, are included in this substantiation.
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For example, (Anathakrishnan, McGinley, & Binion, 2008) used the Deyo algorithm to estimate
mortality in a group of hospitalized IBD patients with Clostridium difficile. The results of study
showed that after controlling for comorbidity using the Deyo algorithm during regression
analysis, patients with C. difficile had higher odds of death than those admitted for IBD alone
(OR = 5.7, 95% CI 2.9-11.3), longer lengths of stay (95% CI 0.8-3.2), and were more likely to
undergo bowel surgery (OR = 4.8, 95% CI 2.2-8.1).
(Ananthakrishnan, McGinley, & Binion, 2009) and colleagues again used the Deyo
algorithm in a national sample of hospitalized IBD patients examining the frequency of
complications, requirements for surgery, and outcomes of hospitalization comparing older
patients (>65) to younger patients (<65). Age was recognized as an independent risk factor for
IBD related death. After controlling for comorbidity using the Deyo algorithm in regression
models, older patients persistently had greater mortality than younger comparisons (OR 3.91,
95% CI 2.50-6.11). Regression models also demonstrated that rates of surgery were not
significantly different between the two groups (OR 1.03, 95% CI 0.90-1.18). Additionally, postoperative complication rates were similar in both groups (OR 1.12, 95% CI 0.88-1.43).
Finally, the Deyo algorithm provided information regarding the impact of in-hospital
malnutrition on mortality in a national sample of IBD patients (Nguyen et al., 2009). Predicator
variables in logistic regression models included age, race, sex, IBD diagnosis, primary health
insurance carrier, a comorbidity score calculated using the Deyo algorithm, surgery done during
admission, and hospital characteristics. The risk of mortality in IBD patients with malnutrition
was three times higher than for those who were not malnourished after controlling for
comorbidity, age, sex, health insurance, and hospital factors (95% CI 2.89-23).
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Calculation of Comorbidity
Comorbidity for this study was measured using the following procedures. The statistician
retrieved the ICD-9 codes associated with the CCI located in Table 8 for each patient in the
cohort. The researcher then used the (W. H. Hall, Ramachandran, Narayan, Jani, & Vijayakumar,
2004) age adjusted comorbidity calculator to obtain a comorbidity score that was used in
regression analysis for Specific Aim 3.
(W. H. Hall et al., 2004) developed an online CCI calculator using Microsoft Excel
Macro that rapidly calculates a comorbidity score that originates from Charlson’s original work
(1987) and is downloadable onto a desktop through the following link,
(http://www.biomedcentral.com/content/supplementary/1471-2407-4-94-S1.xls). The scoring
using the Hall calculator as identical to scoring found in the CCI, see Table 8, with a range of 037. Like the CCI, the Hall calculator also makes a provision for an age adjusted comorbidity
which was applied in this study.
Of the comorbidity calculators that have documented reliability and validity (de Groot et
al., 2003), the Index of Coexistent Disease (ICED), Kaplan Index, the Cumulative Illness Rating
Scale (CIRS), and the CCI, only the ICED and CCI have easy to use electronic calculators
available for clinical use. The ICED has not been used in the population of interest. Whereas the
CCI, translated by the Deyo algorithm has been applied in IBD (S. Kane & Shaya, 2008).
Therefore, the comorbidity calculator developed by (W. H. Hall et al., 2004) was the chosen
calculator for this study. Because the majority of subjects had no comorbidity, this variable was
dichotomized yes/no for regression models.
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Table 8
Translation of Charlson Comorbidity Index (CCI) elements into ICD-9 codes
Diagnostic Category

Myocardial infarction
Congestive heart failure

ICD-9 Codes

410-410.9
412
428-428.9

Assigned
weights for
diseases
1
1

Condition Description

Acute myocardial infarction
Old myocardial infarction
Heart failure

109

Peripheral vascular
disease

443.9
441.441.9
785.4
V43.4
procedure
38.48

1

Peripheral vascular disease, includes intermittent claudication
Aortic aneurysm
Gangrene
Blood vessel replaced by prosthesis
Resection and replacement of lower limb arteries

Cerebrovascular disease

430-438

1

Cerebrovascular disease

Dementia

290-290.9

1

Senile and presenile dementia

Chronic pulmonary
disease

490-496
500-505
506.4

1

Chronic obstructive pulmonary disease
Pneumoconioses
Chronic respiratory conditions due to fumes and vapors

Rheumatolgic disease

710.0
710.1
710.4
714.0-714.2
714.81
725

1

Systemic lupus erythematosus
Systemic sclerosis
Polymyositis
adult rheumatoid arthritis
Rheumatoid lung
Polymyalgia rheumatic

Peptic ulcer disease

531-534.9
531.4-531.7
532.4-532.7
533.4-533.7
534.4-534.7

1

Gastric, duodenal and gastrojejunal ulcers
Chronic forms of peptic ulcer disease

Table 8 (continued)
Diagnostic
Category

ICD-9
Codes

Assigned
weights for
diseases
1

Condition Description
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Mild liver disease

571.2
571.5
571.6
571.4571.49

Alcoholic cirrhosis
Cirrhosis without mention of alcohol
Biliary cirrhosis
Chronic hepatitis

Diabetes

250-250.3
250.7

1

Diabetes with or without acute metabolic disturbances
Diabetes with peripheral circulatory disorders

Diabetes with
chronic
complications

250.4-250.6

1

Diabetes with renal, ophthalmic, or neurological manifestations

Hemiplegia or
paraplegia

344.1
342-342.9

2

Paraplegia
Hemiplegia

Renal disease

582-582.9
582-583.7
585
586
588-588.9

2

Chronic glomerulonephritis
Nephritis and nephropathy
Chronic renal failure
Renal failure, unspecified
Disorders resulting from impaired renal function

Any malignancy,
including
leukemia and
lymphoma
Moderate or
severe liver
disease
Metastatic solid
tumor
AIDS

140-172.9
174-195.8
200-208.9

2

Malignant neoplasms
Malignant neoplasms
Leukemia and lymphoma

572.2-572.8

3

Hepatic coma, portal hypertension, other sequelae of chronic liver disease

196-199.1

6

secondary malignant neoplasm of lymph nodes and other organs

042-044.9

6

HIV infection with related specific conditions

“Reprinted from Journal of Clinical Epidemiology, 45(6), Deyo, R. A., Cherkin, D. C., Ciol, M. A., Adapting a clinical comorbidity
index for use with ICD-9-CM administrative databases, 613-619, 1992, with permission from Elsevier”

Emergency Department Visit
For this study, the number of all ED visits, with any diagnosis code, represented by clinic
stop code 77, during FY 2011, represented healthcare utilization of ED services as represented in
the literature in this population (Gibson et al., 2008; Motheral et al., 2003).
Outpatient Department Visit
OPD visit measurement consisted of clinic stop codes for primary (323, 301, 322, 348,
350, 170, 634, and 172) and specialty (Gastroenterology, 151) care. OPD visits did not require a
corroborating ICD-9 code for IBD. All OPD visits for the above primary care stop codes and 151
for GI in this cohort, were included for analysis because it is conceivable that IBD patients are
seen in either venue for IBD related issues and the diagnosis code for IBD not be rendered
(Motheral et al., 2003; Regueiro, 2012a).
Inpatient Admission
Inpatient hospital admissions for any illness, during FY 2011, afforded inpatient
admission information (Ananthakrishnan et al., 2010; Kappleman et al., 2011; Motheral et al.,
2003; Nguyen et al., 2007; Regueiro, 2012a; Sewell et al., 2009; Sonneberg, Richardson, &
Abraham, 2009).
Care Coordination
Care coordination was the “deliberate organization of patient care activities between two
or more participants (including the patient) involved in a patient’s care to facilitate the
appropriate delivery of healthcare services. Organizing care involves the marshaling of personnel
and other resources needed to carry out all required patient care activities, and is often managed
by the exchange of information among participants responsible different aspects of care”
(McDonald et al., 2007).
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The literature characterizes the term “shared care” as tantamount with coordination of
care, as was the case for this study (Starfield, 2003). Identification of coordination of care
occurred with use of “a clinic stop code, a required field in the VA OPC Hospital Location file
that assigns a number representing a type of care or Service/treating Specialty” (Zivin et al.,
2010). For this study, stop codes for primary care (323, 301, 322, 348, 350, 170, 634, 172) and
gastroenterology (specialty care, 151) represented coordination of care (Regueiro, 2012a). Care
coordination was assumed when the patient had clinic stop codes for both primary and specialty
care. Care coordination was a critical element of this study, originating from the theoretical
model for such, the CCM, that posits improved outcomes when use of healthcare resources are
coordinated between primary and specialty care, in this case, gastroenterology.
In VA, primary care serves as the gatekeeper for specialty care access (Kizer, 1996). As a
result, patients should be unable to make appointments with a specialist without a consultation
placed into the electronic medical record by the PCP for said specialty. However, it is
conceivable, due to systematic influences, that patients will access specialty care without
intersession by primary care. For example, the institution under investigation serves as a regional
GI referral center for four other VAMCs. Therefore, patients seen at the VAMC of interest for
GI specialty care will have no records regarding primary care use because this care delivery
occurs elsewhere. Additionally, patients may receive a referral for specialty care services through
the ER.

3.5 Data Handling Procedures
None of the IBD adherence studies in this review, contained information regarding data
handling. To address this issue, a discussion of data handling procedures for this study follows
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which included assessment of missing data, normality, linearity, homoscedasticity,
multicollinearity, and outliers.
Missing Data
Frequency evaluation yielded eight cases with missing race/ethnicity data that was
confirm by the statistician who pulled the data from the local VA database. Eight missing cases
corresponds to 5% of the sample, which is an allowable amount of missing data (D. F. Polit,
2010b; Tabachnick & Fidell, 2007). Therefore, no attempt was made to correct this missingness.
No other variables had missing data.
Normality, Linearity, Homoscedasticity, and Multicollinearity
Evaluation of univariate normality was assessed using histograms, stem and leaf plots,
box plots, as well as skewness and kurtosis. While the outcome variables for this study,
medication adherence and healthcare utilization, were not normally distributed, all were
dichotomized for logistic regression analysis.
Linearity and Homoscedasticity
Linearity and homoscedasticity between two variables was evaluated using bivariate
scatterplots (Tabachnick & Fidell, 2007). Generation of an oval shaped scatter takes place with
normally distributed data. Otherwise, data transformation addressed problems with heterogeneity
of variance (univariate) and heterogeneity of variance-covariance (multivariate) (Tabachnick &
Fidell, 2007).
Multicollinearity
Bivariate and multivariate correlation took place to assess Multicollinearity. Variance
inflation factor (VIF) greater 10 and the tolerance values <.10 were considered representative of
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Multicollinearity (Bowerman & O'Connell, 1990) . No variables met this statistical definition of
collinearity.
Univariate and Multivariate Outliers
Univariate outliers were assessed via visual screening through histograms and boxplots.
If the value remained a true outlier after screening, standardized z scores were generated for each
group and those with scores greater than 3.29 (p<.001, two tailed) were considered potential
outliers (Tabachnick & Fidell, 2007). Multivariate outliers were detected through Mahalanobis
distance at p<.001 (X2 df = to the number of variables) as this is currently the best method for
multivariate outlier detection (Tabachnick & Fidell, 2007).
Expected outliers for healthcare utilization variables were present. However, all
healthcare utilization variables were dichotomized yes/no for regression models. Therefore, no
additional treatment occurred to these variables.

3.6 Analysis
The Statistical Package for the Social Sciences (SPSS) version 21.0 (Chicago, IL, 2012)
was used for data analysis. To control for Type I error, a two-tailed test of significance was used
with an alpha set at .05.
Descriptive Statistics
Variable relationship exploration began with descriptive statistics. Frequencies were
provided for the categorical variables of comorbidity, IBD diagnosis, care coordination and IBD
medication.
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Primary Study Aim
Described medication adherence, healthcare utilization, and care coordination of
veterans with inflammatory bowel disease (IBD) who employ Veterans Affairs (VA)
healthcare at one Veterans Affairs Medication Center (VAMC).
Measures of central tendency characterized medication adherence rates of veterans with
IBD as measured by the MPR. An MPR for each drug was calculated as a continuous variable.
However, based on the literature, MPR was dichotomized into non-adherent (<.80) and adherent
(> .80) for further analysis. Frequencies and percentages for adherent and non-adherent patients
were computed. The total number of occurrences for the healthcare utilization variables of ER
visits and inpatient admissions during the one year observation period were collected. Care
coordination measured by total number of occurrences for both primary and GI specialty care
during the one year observation period were also collected.
Secondary Study Aim 1
Examined the association between medication adherence adjusted for care
coordination, age, IBD diagnosis, comorbidity, and IBD medication in veterans with IBD
who employ VA healthcare.
Bivariate Analysis.
Bivariate analysis was assessed using Chi-square test of independence to make inferences
about the existence of a relationship between the dependent variable, medication adherence and
independent study variables. Phi coefficient and Cramer’s V were examined as appropriate. The
continuous variable of age was examined through an independent samples t-test. Additionally, in
an effort to facilitate future meta-analysis, the odds ratio (OR), 95% confidence intervals (CI)
were reported (D. F. Polit, 2010a).
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Multivariate Analysis.
Logistic regression yielded information about the probability of an IBD patient being
adherent or non-adherent to a medication regime for said disease based on a subscribed set of
factors: age, IBD diagnosis, IBD medication, as well as care coordination and comorbidity.
Inclusion of all independent variables for regression analysis occurred owing to parsimony in
choosing predictors based on study framework, literature, and data availability (Norusis, 2012).
The variables of gender, race, as well as ethnicity were not included in the final analysis due to
homogeneity of the sample. Main effects were determined by simultaneously entering all of the
variables into the model to determine the predictive ability of the overall model. The odds ratio,
95% CI were reported. The Nagelkerke R2 portrayed effect size of the analysis.
Specific Aim 2
Began to explore the relationship between healthcare utilization adjusted for medication
adherence, care coordination, age, IBD diagnosis, IBD medication, and comorbidities in
veterans with IBD who employ VA for healthcare.
To examine the relationship between variables in preparation for further regression
analysis, similar bivariate analysis occurred as described above. Logistic regression yielded
information about the probability of an IBD patient having healthcare utilization measured by
ER or inpatient admissions based on the following predictors: medication adherence, age, IBD
diagnosis, IBD medication, care coordination, as well as comorbidity.
The dependent variable for the two healthcare utilization regression models was
dichotomized (yes/no). The variables of gender, race, and ethnicity were not included in final
models due to homogeneity of the sample. Main effects of each model were determined by
simultaneously entering all of the variables into the model to determine the predictive ability of
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the overall model. As explained previously, all variables from the bivariate analysis were
included in this model regardless of the relationship with the dependent variable. The odds ratio
and 95% CI were reported. Generation of interaction terms for subsequent models was based on
the significance of predictors. The Nagelkerke R2 portrays effect size of the analysis.

3.7 Sample Considerations
Many studies have been conducting examining medication adherence in IBD using
logistic regression. However, little information exists regarding formal sample size consequences
that could provide a benchmark for this investigation (S. Kane et al., 2012). Therefore, sample
size deliberation took place using statistical text references.
Sample size calculations for logistic regression require consideration based on the
number of predictors in the models (Bartlett, Kotrlik, & Higgins, 2001) . One simple
recommendation exists regarding sample size that advised the use of at least 10-20 subjects for
each predictor to reduce the risk of a Type II error (D. F. Polit, 2010c). (D. E. Miller & Kunce,
1973) as well as (Halinski & Feldt, 1970), provided additional support for the use of ten
observations per independent variable. One source cited the use of not less than five observations
per independent variable to ensure generalizability of study findings (Hair, Anderson, Tatham, &
Black, 1995).
Therefore, based on 10-20 patients per predictor, an appropriate sample size for Specific
Aim 2 that included five predictors would be in the range of 50-100. The study sample met this
requirement. Using the above metric, a sample size of the same caliber was required for the
regression analysis of Specific Aim 3 that also included five predictors.
However, to test that the regression model was significant overall, the researcher also
needed to contemplate the size of the effect of the independent variables to predict the outcome.
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(Cohen, 1988) established as a benchmark, an effect size of .80 to achieve a high level of power.
Cohen further suggests "standard effect sizes" for regression: .02 (small), .13 (medium), and .26
(large). Applying this rubric, using G Power, a sample size of 77 is appropriate, with up to 20
predictors, to achieve a large effect (Field, 2013) . Whereas, a sample of 160 patients, using up to
20 predictors, is required for a medium effect, and the minimum number of subjects of 100 is
required with six or fewer predictors for medium effect size (Field, 2013). As noted above, the
study sample met these sampling requirements.

3.8 Study Limitations
Overall, compared to primary data collection, secondary data analysis is less time
consuming, labor intensive, and cost producing. Furthermore, patient non-response or recall bias
does not occur with administrative data because data collection is independent of patient
participation (Schneewiss & Avorn, 2005).
However, while secondary data analysis is recognized as a valid investigational
methodology for assessing medication adherence (Andrade, 2006), nearly three decades have
lapsed since researchers began assessing healthcare practice using retrospective analysis. Yet, the
fundamental issues of using administrative data for research remain. Matching study
conceptualizations with data element definition is challenging since the collection of database
information did not occur for research purposes (Waltz, Strickland, & Lenz, 2010).
Knowledge of the quality of many data elements housed in a variety of administrative
databases infrequently exist, inclusive of VA, creating concern about the reliability and validity
of this methodology (Waltz et al., 2010). Rarely, can researchers comment on the reliability of
original data (Worster & Haines, 2004) . However, by Congressional mandate in 2002, through
Section 515 of the Treasury and General Government Appropriations Act, VA is bound to
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maximize the quality of the information it disseminates (U. S. Department of Veterans Affairs,
2003) .
VA researchers have been major contributors to the methodological literature in the area
of administrative data use during the last 20 years. Nevertheless, VistA, the chosen database for
this study, has more than 1,940 files and 44,960 data fields, generating massive amounts of
information available for systematic inquiry, which has limited the science, as few are expert in
translating this data into usable information for investigation (Hynes, 2012) . However,
investigators who do make use of automated databases, facilitate the translation of data into
information, thereby influencing clinical practice and health policy.
VA informatics and analytics professionals at VA Central Office in Washington, D.C.
share concerns about the quality of VA data because the ability to capture clinical concepts using
standardized data elements found in VA databases remains limited (Francis, 2012) . As a result,
VA pays more than $12 million a year to have national manual chart abstractions done instead of
electronic data pulls to estimate performance on Healthcare Effectiveness Data and Information
Set (HEDIS) measures (Francis, 2012).
Clearly, the impact of poor data quality can have widespread deleterious effects on patient
care. To address data quality concerns, the VHA Data Quality Program exists within the Health
Information Governance Office of VHA's Office of Informatics and Analytics, whose mission it
is to ensure data accuracy for all VHA stakeholders (U. S. Department of Veterans Affairs,
2007). Additionally, each VAMC also has a Clinical Application Coordinator (CAC) who is an
authority on the meaning and utility of local VA data (VA Information Resource Center
(VIReC), 2012) .
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Concerns regarding quality of VA data, lent further support for the goals of this study
using local VA data only, to begin examination of coordination of care, medication adherence,
and healthcare utilization in a population in which little data currently exists. Some of the largest
contributions VA researchers are making currently using administrative data is to provide
documentation of the limitations of many widely used variables, as was the case with this study
(Atkins, 2012) .
Completeness of data commands attention. Not all variables in VA datasets are of equal
quality, as measured by completeness and accuracy of information entered into the system.
Missing or erroneous values are possible.
The information about data quality presented below represents information on data
quality from a national VA database perspective. To this researcher’s knowledge, no data quality
information exists on the elements housed in the local VistA modules used for this study.
Systematic evaluation that occurs through the research process strengthens database
quality. The passages that follow contain information about processes used for this study to
maintain methodologic rigor and include database source for research in VA, cohort generation,
clinic stop code quality, pharmacy data, measuring medication adherence and race data quality.
Database Sources for Research in VA
VA represents one of the largest self-contained healthcare systems in the world. For
decades, systems data captured and storage has occurred in a variety of administrative databases
utilized in health services research. Although VA databases do not exist specifically for research
purposes, informational access ensues to measure patient outcomes particularly when chart
review would prove too labor intensive and cost prohibitive.
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It is important to note, that in accordance with VHA Handbook Policy 1605.1, only VA
employees conduct VA research (Department of Veterans Affairs, 2006a). Furthermore, access
to any VA data for research purposes, requires prior IRB authorization from the investigator's
VA facility, where scrutiny of the application takes place for protocols that address privacy and
security concerns.
VA Databases
While many VA databases exist, for this study, only databases that contained variables
under examination were accessed which included local VistA and CPRS, as well as local and
VISN level pharmacy databases. Data collection for a VA fiscal year (FY) runs October 1September 30. When retrieving data for a FY, it is advised to wait until January 1 st of the
following calendar year to ensure that a complete FY dataset can be obtained (Hynes, 2012).
Additionally, from a systems perspective, because VA datasets are under constant amendment, it
is imperative for growth in database research, to review the most current VA dataset, as
interfacing with databases even just a year ago, could provide vastly different information when
compared to current database configuration (Mark, Dirani, Slade, & Russo, 2002).
VistA
VistA is an integrated system of software applications that directly supports patient care
at VHA healthcare facilities by tying together workstations and personal computers (Hynes,
George, & Pfeil, 2002) .VistA provides system management tools that provide uniformity of data
across the VA system and yet permit customization of each software package to meet local VA
requirements (Brown, Lincoln, Groen, & Kolodner, ). The majority of data found in VistA exists
due to manual entry of information (VA Information Resource Center (VIReC), 2012) .
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Each VistA application generates clinical and administrative data that support the day-today operations of VA facilities and contain patients' medical and healthcare utilization histories
(Hynes, Perrin, Rappaport, Stevens, & Demakis, 2004). VistA contains the most clinical detail of
any VA database and as such, captures many data points that are not currently available in any
other national VA data source (VA Information Resource Center (VIReC), 2012). Specifically,
information on patient demographics (age, race, ethnicity, and gender), coordination of care,
pharmacy refill records, and service utilization (ER visits, inpatient admissions) are examples of
some of the variables housed within VistA's powerful applications (Department of Veterans
Affairs: Office of Enterprise Development, 2008).
Additionally, located within VistA, are International Classification of Diseases (ICD-9)
and Current Procedural Terminology (CPT) codes that are required for use by all VHA sites to
map local data, facilitating the origination of patient cohorts for use in health services research
(Hynes et al., 2004). VistA contains several mechanisms that allow data analysts to identify
unique individuals and subsequently link the identifier to ICD-9 codes during cohort generation.
Such was the case for this study.
A saying is proliferated in VA, that “when you have seen one VA, you have seen one
VA”. Opponents of comparing patient care across hospitals profess that it is not possible to
control adequately for the way patient care varies from hospital to hospital, let alone across an
entire healthcare system (Temple, 1990). Variations in clinical care among individual VAMCs
was of particular concern since a systems framework provides the investigational foundation.
VistA is a good example of the individualized character perpetuated by each VAMC. All
VA data housed in VistA originates at the local level of each individual VA site of operation
(Justice et al., 2006). Local data is subsequently stored at the VISN (regional) level by
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combining information from multiple facilities into a data warehouse. Finally, consolidated data
from local and VISN levels, processed through the National Patient Care Database System
(NPCD), is made available for research in a central location in Texas, the Austin Information
Technology Center (AITC) (Hynes et al., 2004). Therefore, VistA provides the foundation for all
VA databases and is the best source of clinical data (M. W. Smith & Joseph, 2003).
However, while each VAMC has VistA, not all modules are available at each facility
creating differences in data fields varying across medical centers (VA Information Resource
Center (VIReC), 2012). Additionally, because of the large amounts of information generated by
VistA, facilities regularly purge data, further adding to the hazard of heterogeneous data pulls.
Furthermore, local VA procedures may differ in the manner data collection and
recordings occur, causing data elements to have slightly different meanings at various VA sites
(VA Information Resource Center (VIReC), 2012) . This is true of the outcome variable for this
study, medication adherence, as variations exist across facilities in processing pharmacy data (M.
W. Smith & Joseph, 2003). Therefore, knowledge of a local VistA system is required to ensure
the information obtained is what is requested (Maynard & Chapko, 2004). As a result, this study
provided preliminary information regarding systematic VA influences of one VAMC on
coordination of care, medication adherence, and healthcare utilization that segway into regional
and national investigations examining the relationship of these variables.
CPRS
VistA is comprised of more than 100 applications under constant revision. A keystone
VistA application is the Computerized Patient Record System (CPRS), part of the revolution in
patient care within VHA in the 1990s and remains the software package most often accessed by
clinical personnel throughout the VA healthcare system today (Kizer, 1996). As such, CPRS
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generates a large portion of data found in VistA and can provide longitudinal statistics for an
individual patient (VA Information Resource Center (VIReC), 2012). Information culminating
from CPRS provided foundational elements for the dataset used in this study.
Pharmacy Databases
VA pharmacy data is an important resource for understanding medication adherence
because refill data can stratified prescription drug use by patient characteristics, such as age,
gender, or race. While inpatient and outpatient pharmacy information exists, this study only
captured outpatient pharmacy data as previously outlined.
There are three sources for VA pharmacy data: VistA, the Pharmacy Benefits
Management (PBM) package, and DSS NDE Pharmacy SAS datasets. Because this study used
local and VISN level VA data only, this discussion will focus on the database used for local as
well as VISN level data capture, VistA. An important aspect of VA pharmacies is that they only
fill prescriptions promulgated by VA providers with prescriptive privileges. Customarily, the
provider enters medication orders into CPRS.
VistA Pharmacy
The VistA pharmacy package is comprised of 13 elements that function synergistically to
assemble all pharmacy data at the local level relative to prescriptions filled in the VA
(Department of Veterans Affairs: Office of Enterprise Development, 2008). VistA contains both
inpatient and outpatient prescription data from 1997 onward and features information on the
prescribing origin of the prescription such as primary or specialty care, National Drug Code
(NDC), VA product name, VA drug class, prescription fill date, total quantity of medication
dispensed, dispensing units (mg, ml, etc.), and days’ supply of medication given (M. W. Smith &
Joseph, 2003).
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To improve the quality of pharmacy data capture, ideally, the days’ supply is corroborated with
the actual dosing instruction as well as the price per unit of drug. However, dosing instructions
are only available in national data warehouses that were not accessed for this study. Due to
resource constraints, the price per unit of medication was not retrieved.
Cohort Generation
The literature acknowledges that administrative data is usually of unknown validity. Due
to feasibility and cost, validity in secondary data analysis occurs by a diagnosis code (ICD-9
code) and a particular strategy (Harris, Reeder, Ellerbe, & Bowe, 2010). In the case of this study,
corroboration between an ICD-9 code and refill of a precise list of medications used to treat IBD,
equated as a reliable method for identifying care of interest (Quan et al., 2004). The International
Classification of Diseases, ninth revision (ICD-9) codes represent a nosology, an official system
of assigning codes to diagnoses and procedures associated with healthcare in the U.S.
ICD-9 codes are frequently used to identify patients for administrative database studies in
a variety of chronic illnesses including IBD (Motheral et al., 2003). The inherent limitations of
this measure, including the possibility of coding errors that pose a challenge to the credibility of
data accuracy, due to institutional variations in data input, are appreciated (Baker, 2007; Waltz et
al., 2010). To minimize the threat of institutional variation, this study only retrieved data from
one VA facility because local VA data managers possess detailed knowledge of the clinical and
administrative processes used to produce various data elements (VA Information Resource
Center (VIReC), 2012) .
While VHA uses ICD codes to set resource allocation for its beneficiaries, the validity of
using ICD-9 codes as a measure of patient status continues to be widely debated (VA
Information Resource Center (VIReC), 2012). Suggestions exist that clinician payment for
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services drives the assignment of a diagnosis code (Sarrazin & Rosenthal, 2012). However, in
VA, direct reimbursement for care to the provider does not occur, making this a less influential
factor. Another argument against using ICD-9 codes in research is the evolution of diagnoses
codes overtime (Sarrazin & Rosenthal, 2012). This study controls for this impact by examining
only one FY, 2011.
To improve the accuracy of patient selection, a technique validated previously in the
study population is used. The study sample consisted of all veterans enrolled in one northeast
VAMC between October 1, 2010 and September 30, 2011 with an ICD-9 code of 555.x for CD
and 556.x for UC, validated previously in the VA IBD population (Khan et al., 2012; Lachaine et
al., 2013; Mitra et al., 2012; Thirumurthi et al., 2010). See Figure 3.2 for study variable
extraction. The possibility of selection bias exists in administrative database studies due to lack
of randomization. To account for this, all factors utilized in the selection of subjects for this
study were clearly delineating as described below.
Inclusion Criteria
Individuals with at least one of the above outpatient ICD-9 codes at any time during FY
2011, with at least one outpatient prescription of the following oral medications used to treat
IBD, and who refilled the medication at least twice during the observation period, were included
for final analysis: medication (mesalamine 250mg (NDC: 54092-0189-81), mesalamine 375mg
(NDC: 65649-0103-02), mesalamine 400mg (NDC: 00149-0752-15) mesalamine 1,200mg
(NDC: 54092-0476-12), olsalazine (NDC: 68220-0160-10), balsalazide (NDC:, 00054-0079-28),
sulfasalazine (NDC: 43353-0495-80) , azathioprine (NDC: 00054-4084-25), mercaptopurine
(6MP) (NDC: 00054-4581-27).
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At least two refills of medication were required to calculate the adherence measure for
this study, the MPR. Any patient with a 555.x for CD and 556.x for UC, on any occasion in FY
2011, as well as a prescription for any of the above medications confirmed the diagnosis of IBD
(Kappleman et al., 2008; Kappleman et al., 2011; Waltz et al., 2010). For patients with ICD-9
codes for both UC and CD, disease assignment occurred according to the majority of codes
presented (Kappleman et al., 2011).
Exclusion Criteria
Because of a whole host of treatment specific confounders with oral steroids, biologic
medications, rectal preparations, and injectable methotrexate, these drugs were excluded from
analysis (Cooper, Hall, Penland, Krueger, & May, 2009; Kappleman et al., 2008). Moreover,
exclusions included prescriptions filled prior to October 1, 2010, thereby limiting "carry in"
prescriptions filled prior to the measurement period (Cooper et al., 2009). Patients with ICD-9
codes for IBD but who were note prescribed medications for said disorder were also
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Figure 3.2 Extraction of Study Variables

excluded from analysis, as the aim of this study was to describe the medication adherence rates
in this population (Gellad, 2012).
Additional exclusions are the above IBD medications administered while the veteran was
an inpatient, since the aim of this study was to describe adherence to long-term therapy in IBD
and not adherence to acute medication needs dictated by an inpatient admission. Therefore,
adjustment of the denominator in the MPR calculation occurred to reflect the number of days
between the first fill and the last refill plus the days’ supply of the last refill minus the days of
inpatient admission.
Furthermore, patients seen in Gastroenterology not seen by primary care were also
excluded from analysis because a critical component of this study was to examine the
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relationship between medication adherence and healthcare utilization among subjects cared for in
the primary care setting in isolation, versus subjects who received coordination of care. Further
discussion of these excluded patient follows. Information on patients receiving GI care alone was
included in the final report.
Clinic Stop Code Quality
The study used clinic stop codes, 323, 301, 322, 348, 350, 170, 634, and 172 for Primary
Care, 151 for Gastroenterology, and 77 for ER. The literature contained only one study that
examined the accuracy of a VA clinic stop code. While the clinic stop code under investigation
was not the one used in this study it is the only data that exists that speaks to the validity of using
this method to identify points of care. Because the quality of data in VistA is largely uncharted,
reviewing a study containing pertinent variables of interest may be the best place to discover
information on data quality (VA Information Resource Center (VIReC), 2012) . As a result, the
details of this study follow.
(Harris et al., 2010) conducted a study that included over 2,600 subjects, to validate the
substantiation with specialty clinic stop codes used to designate treatment for a substance use
disorder (SUD) and receipt of SUD care as documented in clinical progress notes. Two raters
independently reviewed records and classified them as either documenting or not documenting
SUD. The results demonstrated that 14.1% of the progress notes reviewed did not contain a note
supporting the diagnosis SUD the day of code entry. Approximately 92% of progress notes
contained evidence of SUD treatment when both a clinic stop code and CPT code for such
accompanied the medical record. However, the VISN ranges of concordance were variable
between 57-100%, which are exacerbation at the local facility level as has been supported in the
literature previously (Tarlov & Stroupe, 2010).
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The results of this study demonstrate the inability to ascertain data quality in national VA
datasets with discordance found between national and local information. National level VA data
discrepancies provided further support for the use of local VA data for this investigation.
Additionally, as the above study demonstrated, diligence in the actual process of data
mining is required. For example, the use of two independent raters to review data results is
suggested to improve the accuracy of data pulls. While resources for this study did not allow for
a second data reviewer, concretely defining study variables by creating a coding index served to
improve data retrieval accuracy as well as internal validity (Gearing, Mian, Barber, & Ickowics,
2006) and inter-rater reliability (VonKoss Krowchuk et al., 1995) as displayed in Table 9.
While VA databases provide the most comprehensive patient-level clinical data in VHA,
the size and complexity of these databases requires in depth understanding to ensure accurate
data extraction (VA Information Resource Center (VIReC), 2012). Therefore, VA researchers
who wish to use retrospective data for research are strongly encouraged to work closely with a
local VA data manager who has expert knowledge of the information contained in each database
because extracting data in a structure that can be analyzed using statistical software can be
arduous (Maynard & Chapko, 2004). The statistician for this study was the in residence local
data expert.
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Table 9
Coding Index
Dependent Variables

Definition

Level of Measure
Dichotomous

MedAdhere1

Medication Adherence
0 = Non-adherence (MPR < 0.80)
1 = Adherence
(MPR > 0.80)

MedAdhere2

Medication Adherence

Dichotomous

0 = Non-adherence (MPR < 0.90)
1 = Adherence
(MPR > 0.90)
HealthCareU1

Utilization primary + GI

Dichotomous

0 = no GI outpatient, primary care only
1 = yes primary care + GI outpatient
HealthCareU2

Utilization primary + ER

Dichotomous

HealthCareU3

0 = no ER visits, has primary care only
1 = yes primary care + ER visits
Utilization primary + inpatient admission

Dichotomous

Independent Variables

0 = no inpatient, primary care only
1 = yes primary care + inpatient
Definition

Level of Measure

Demographic
Age
Gender

RaceEth

Age
Gender
0 = Male
1= Female
0 = White
1 = Non-White: Black, American Indian or
Alaska Native, Asian, Native Hawaiian or
Pacific Islander, Hispanic or Latino, not
Hispanic
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Continuous
Dichotomous

Dichotomous

Table 9 (continued)
Coding Index
Independent Variables

Definition

Level of Measure

Medication
MPR

Medication Possession Ratio (MPR)

Continuous

Pharmacy refill records to calculate the
MPR: the sum of days’ supply of
medication divided by the number of days
between the first fill and the last refill plus
the days’ supply of the last fill

Fill Date

Date of fill, date

Date

Days’ Supply

Day Supply of medication (30, 90)

Continuous

Tablets Dispensed

Number of tablets dispensed

Continuous

Diagnosis: 555x. CD, 556.x UC

Categorical

IBD
IBD Diagnosis

0 = UC
1 = CD

IBDMED

IBD Medication

Categorical

0 = 5-ASA
1 = Immunomodulator
2 = Both
IBD Medication: 5-ASA
Dichotomous
Balsalazide

Balsalazide
0 = no
1 = yes

Mesalamine

Mesalamine
0 = no
1 = yes

Dichotomous
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Table 9 (continued)
Coding Index
Independent Variables

Definition

Level of Measure

Olsalazine

Olsalazine
0 = no
1 = yes

Dichotomous

Sulfasalazine

Sulfasalazine
0 = no
1 = yes

Dichotomous

IBD Medication: 5-ASA

IBD Medication: Immunomodulator
Azathioprine

Azathioprine
0 = no
1 = yes

Dichotomous

Mercaptopurine (6MP)

Mercaptopurine
0 = no
1 = yes

Dichotomous

Comorbidity

Continuous

Comorbidity
Comorbidity

Deyo (1992) with Hall (2004) Calculator
ComorbidityII

Comorbidity

Dichotomous

0 = no
1 = yes
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Table 9 (continued)
Coding Index
Independent Variable

Definition

Diagnostic Category
(All comorbidities are dichotomous coded yes/no for each diagnostic category by ICD-9)
MI

Myocardial Infarction: 410-410.9, 412

CHF

Congestive Heart Failure: 428-428.9

PVD

Peripheral Vascular Disease:443.9, 441, 441.9, 785.4, V43.4, 38.48

Cerebro

Cerebrovascular Disease: 430-438

Dementia

Dementia: 290-290.9

Lung

Chronic Pulmonary Disease: 490-496, 500-505, 506.4

Rheum

Rheumatologic Disease: 710.0, 710.1, 710.4, 714.0-714.2, 714, 81, 725

Peptic

Peptic Ulcer Disease: 531-534.9, 531.4-531.7, 532.4-532.7, 533.4533.7, 534.4-534.7

LiverMild

Mild Liver Disease: 571.2, 571.5, 571.6, 571.4, 571.49

Diabetes

Diabetes: 250-250.3, 250.7

DiabetesCom

Diabetes with Chronic Complications: 250.4-250.6

Paralysis

Hemiplegia/Paraplegia: 344.1, 342-342.9

Renal

Renal Disease: 582-582.9, 582-583.7, 585, 586, 588-588.9

Malignancy

Any Malignancy: 140-172.9, 174-195.8, 200-208.9

LiverMoSev

Moderate/Severe Liver Disease: 572.2-572.8

MalignancyMets

Metastatic Solid Tumor: 196-199.1

AIDS

HIV Infection: 042-044.9
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Table 9 (continued)
Coding Index
Independent Variable

Definition

Level of Measure

CoordinationCare

Coordination of care, FY 2011
0 = Primary Care only
1 = Primary Care + GI Specialty Care

Dichotomous

PrimeCare

Total primary care visits, FY 2011

Continuous

Healthcare Utilization

stop codes 323, 301, 322, 348, 350, 170,
634, and 172
GIOutpt

Total GI specialty visits, FY 2011

Continuous

stop code 151
ERVisit

Total ER visits, FY 2011: stop code 77

Continuous

InPt

Total inpatient admissions, FY 2011

Continuous

LOS

Length of Stay

Continuous

Pharmacy Data
Data quality is a limitation when using pharmacy refill information in research. While a
large body of literature has been generated using VA pharmacy data, a gap in the literature exists
regarding the exactness of this material (M. W. Smith & Joseph, 2003) . VistA is the primary
source for clinical data in VA for which no record is available against which to validate
information because all data entry occurs directly into the system through CPRS (M. W. Smith
& Joseph, 2003).Pharmacy administrative database have a high specificity, if medications are
obtained from a closed pharmacy system such as in VA and patients are not obtaining
medications from other sources as is assumed for this study (Hynes, 2012). Moreover, pharmacy
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datasets support analysis of population based prescribing habits, drug utilization trends,
unwarranted variations in clinical practice, and estimate drug usage at local, regional, or national
levels (Cunningham, Sales, & Valentino, 2001).
Accuracy of medication identification using VA pharmacy databases was the focus of a
national VA study of 268,774 individuals (Schutte, Hu, Schmitt, & Phibbs, 2011). Subjects with
at least one outpatient or inpatient diagnosis for bipolar disorder between FY02 and FY09 based
upon ICD-9 codes for this mental illness. Eligible patients were then paired with descript list of
medications (26) used to treat this condition. Similar to how cohort generation will take place in
this study.
Subsequently, a systematic review of patient’s medication compared the presence of one or
more of the identifiers noted below in a national VA database using such combinations as: IEN
only, NDC only, IEN + NDC, and IEN + NDC + IPNUM/IPNO. There are four variables in VA
national databases that provide medication name and strength: Internal Entry Number (IEN),
National Drug Code (NDC), Intermediate Product Number (IPNUM/IPNO), Drug Description
(DRUGDESC) (Schutte et al., 2011), the first three of which were used in this study. Omission
of the DRUGDESC identifier occurred since an unknown quantity of misspellings and
abbreviated drug names exist in this file (Schutte et al., 2011) .
Overall, the results established with 99.3% accuracy that the assigned IEN, NDC, and
IPUNUM/IPNO identifying codes were in full agreement about whether a prescription for
bipolar medication existed. Results for all identifiers were statistically significant (p. <0.05) with
higher levels of significance found with multiple identifies (p.<0.001). The authors
recommended the use of multiple-drug identifiers for completeness. To enhance the accuracy of
pharmacy data in this study, the use multiple medication identifiers was deployed when possible.
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Measuring Medication Adherence
Medication adherence is a multifaceted construct, such that any measurement used in
isolation for measurement is a recognized study limitation. Pharmacy data is not a proxy for
adherence it represents just one part of this complex construct.
For example, in this study, the use of pharmacy refill data did not take into account the
additional activities that may influence medication adherence in this regard, such as a visit to the
clinician to obtain said prescription, filling the prescription, taking the medication as prescribed,
as well as refilling the medication. Therefore, this study examined just one of the many aspects
of medication adherence.
Lack of a consensual definition of medication adherence in the literature is another
limitation of this study. Significant enhancement to external validity or reproducibility occurs
with the standardization of data (Jansen et al., 2005). A critical component of secondary data
analysis will be to establish operationalized definitions of chosen measurements to aid in
reclamation of data from databases. To add to the current adherence literature in a meaningful
way, the definition of medication adherence advised by ISPOR (Cramer et al., 2008) in a
consensus document served as the definition of adherence for this study. Additionally, during
methodologic decision-making, every attempt to utilize standard measures as outlined by the
international retrospective adherence experts of ISPOR occurred (Peterson et al., 2007) .
The outcome variable for this study was medication adherence, assessed using VA
pharmacy refill data, measured for one year, FY 2011, for several reasons. One, the theoretical
foundation for this investigation, the CCM, is a systems model. The system under consideration,
the VA, is constantly changing how it organizes care delivery, assigns clinical priorities, and
allocates funding appropriated by Congress. Therefore, examination of recent FY data to
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describe current systematic influences on all variables, specifically the relationship between
coordination of care, medication adherence, and healthcare utilization was consistent with the
CCM. Additionally, to ensure completeness of information, use of FY datasets that are closed is
advised (Hynes, 2012) . At the time of this publication, FY 2011 is the most recent complete
dataset available. Two, VA databases are under constant revision. Therefore, how data
compilation takes place, using current databases, may not be how data aggregation occurred even
a year ago (Hynes, 2012). Additionally, database attributes can vary widely depending on the
research question(s) and analysis performed (Motheral et al., 2003).
Moreover, this study examined only 1 year of medication adherence because medication
adherence changes over time and this study was meant to describe the medication adherence
patterns of a group about which little is known. While the greatest decline in adherence for many
chronic medications occurs over the first year of therapy (Deizii, 2000), it was not the intent of
this study to explore adherence rates of new users versus those with longer disease durations.
The following were assumptions when using pharmacy refill data to measure medication
adherence: medications prescribed were appropriate, pharmacy records were accurate,
medication acquisition from another person or venue did not occur, lack of a refill equated with
medication not consumed during that period, and no healthcare provider treatment interruptions
occurred during the refill period (Williams, Amico, Bova, & Womack, 2012). An additional
assumption was that patients refilling medication were unlikely to pick up medications with no
intentions of taking them (S. Kane et al., 2001).
Local VA databases did not contain any information regarding private insurance
coverage outside of VA. Therefore, it was conceivable that a patient may fill a prescription for
IBD medications outside the VA. This was a study limitation.
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Race Data Quality
All race data originates at the local VA level in VistA and is then compiled into national
VA datasets. Heterogeneity in defining race exists in VA national level race data. For example,
the VHA Office of Informatics and Analytics compared data extraction for race from two
national VA databases, Corporate Data Warehouse (CDW) and the Administrative Data
Repository Reporting Production (ADRRP) that demonstrated a lack of consistency in defining
race across the VA system. Review of four million unique patient records housed in CDW,
revealed 31 non-standard race values with different race values for the same individual across
facilities. A patient may have up to seven race assignments in CDW. Whereas ADRRP, provides
only standardized race values contained in a single demographic record for each patient.
However, race data was missing for 171,000 individual demographic records. These
inconsistencies provided further support for the use of local VA data only to improve the
accuracy of data capture. An additional race limitation of this study was homogeneity in this
cohort that limits generalizability of study findings beyond VHA.
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Chapter 4
Manuscript: Results and Discussion
The results for study aims are below which included the primary study aim: described
medication adherence rates, healthcare utilization, and care coordination of veterans with
inflammatory bowel disease (IBD) who employ Veterans Affairs (VA) healthcare at one
Veterans Affairs Medication Center (VAMC). Secondary study aims included: examination of
the association between medication adherence adjusted for care coordination, age, IBD
diagnosis, comorbidity, and IBD medication in veterans with IBD who employ VA healthcare;
and exploration of the relationship between healthcare utilization adjusted for medication
adherence, age, IBD diagnosis, IBD medication, care coordination and comorbidities in veterans
with IBD who employ VA for healthcare. The manuscript was prepared for submission to a
journal with a GI focus entitled, Inflammatory Bowel Diseases. The title for this manuscript is
“A retrospective data analysis: Using Wagner’s Chronic Care Model to explore predictors of
medication adherence in veterans with inflammatory bowel disease”. ISPOR retrospective
database publishing recommendations informed final manuscript construction. 1
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Abstract
Background
Medication adherence in inflammatory bowel disease (IBD) ranges between
7-72%. Increased healthcare utilization has been associated with non-adherence in IBD.
Wagner’s Chronic Care Model (CCM) posits that care coordination between primary and
gastroenterology (GI) specialty care could improve adherence and healthcare utilization.

Methods
Guided by the CCM, a retrospective analysis was conducted in veterans with IBD to:
describe medication adherence rates; describe healthcare utilization measured by ER visits and
inpatient admissions; and describe care coordination measured by primary care and GI specialty
care use. A secondary study aim was to explore the relationships between those key outcome
variables and select demographic/health history characteristics.
A local Veteran’s Affairs database was used to extract a cohort of individuals with
Crohn’s disease and ulcerative colitis for fiscal year (FY) 2011. Medical utilization and IBD
medication refills were collected. A dichotomized medication possession ratio (MPR .80) was
used in logistic regression to identify factors affecting medication adherence. Logistic regression
was also used to examine factors affecting ER visits, inpatient utilization, and care coordination.

Results
The cohort consisted of 165 White male veterans 75 with Crohn’s disease and 89 with
ulcerative colitis. The overall rate of adherence was 50.9% with a median MPR of .82.
Regression models did not render any statistically significant predictors of adherence. ER
utilization was significantly associated with adherence (OR=.314, 95%CI=.111-.886, p=.029)
and care coordination (OR=45.73,95%CI=9.053-231,p=.001) in multivariate analysis. Inpatient
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admission was associated with: younger age (OR=.108,95%CI:.019-.609,p=.012), adherence
(OR=.113,95%CI=.014-.939,p=.044), IBD diagnosis (OR=.117,95%CI=.017-.784,p=.027), and
care coordination (OR=11.89,95%CI=1.228-115,p=.033). Logistic regression identified
statistically significance associations with care coordinated between primary and GI specialty
care and the following factors: taking both a 5-ASA and immunomodulating medication
(OR=5.122,95%CI=1.874-14.00, p=.001), younger age (OR=.905,95%CI=.871-.940,p=.001),
and having a comorbidity (OR=2.643,95%=1.171-5.965,p=.027).

Conclusions
No predictors of medication adherence emerged. However, the CCM element of care
coordination provided additional insight into the healthcare utilization of veterans with IBD as
statistically significant associations between ER visits and hospitalization were identified.
Further inquiry into the influences of medication adherence and healthcare utilization in this
population is warranted.

key words: adherence to medication, Wagner’s chronic care model, coordination of care,
veterans, inflammatory bowel disease
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Introduction
Ulcerative colitis (UC) and Crohn’s disease (CD) comprise inflammatory bowel disease
(IBD), a set of chronic inflammatory diseases of the GI tract. The financial burden of IBD in the
United States (U.S.) is considerable, in the range of 3-8 billion dollars annually.1 Nearly 1.5
million Americans suffer with IBD.2 However, little is known about the 45,000 veterans with
this disease who access the world’s largest integrated healthcare system, the Veterans Health
Administration (VHA).
Life-long medication administration is required in IBD to control this often tenuous
condition. However, medication adherence for those who are diagnosed is problematic, in the
range of 7-72%.3 Modifying factors affecting medication adherence in IBD are not distinctive,
existing in many chronic diseases and include age, lack of knowledge regarding illness and
treatment, discordance in the physician-patient relationship, low health literacy, pill burden,
employment, and depression.4 Several noteworthy, unique, condition specific factors found to
affect adherence include remission status, disease type (CD versus UC), new patient status,
timing of last colonoscopy, and taking immunosuppressants. 4 No consistent variables that could
be used to direct interventions have emerged as predictors of adherence in this population.
Furthermore, there have been no studies conducted to date that have explored predictors
of medication adherence in veterans with IBD. While two studies have been published
examining medication adherence in this cohort, the studies focused on disease recurrence. The
authors found the adherence rate of veterans to be between 37-48%, with non-adherent patients
at increased risk for a disease flare.49,50

177

Evidence indicates that when chronic illness is sub optimally treated, complications may
worsen leading to increased consumption of healthcare resources such as ER services, inpatient
admissions, as well as office visits, 4 suggesting that higher levels of medication adherence may
reduce healthcare costs.5 Repeatedly, research has demonstrated that those with IBD who do not
follow prescribed medication regimes have higher rates of healthcare utilization.6-8 World
adherence experts provide support for examination of healthcare utilization concurrently with
medication adherence as this data works synergistically to accurately inform health outcomes
and future interventions. 9
Often IBD care is multidisciplinary requiring input from other specialty services and
departments such as the emergency room (ER), inpatient medicine, surgery, radiology,
pathology, dermatology, rheumatology, and ophthalmology. 10 Contributions from primary care,
the gatekeeper to specialty healthcare in the United States, are rarely considered.16 Inquiry into
the effects of a closed system such as VHA, using Wagner’s Chronic Care Model (CCM) may
provide insight into the associations of both primary and specialty care with medication
adherence and healthcare utilization of veterans with IBD. 11 VHA adopted the CCM in the late
1990s as a vehicle for transformation. 12 The CCM element of care coordination became integral
to delivery of chronic illness care of veterans orchestrated by primary care with consultation to
specialists as warranted. Intuitively, coordination of primary and specialty care should equate
with improved health outcomes. However, results from a Cochrane review revealed conflicting
results.13 Medication adherence was the only clinical outcome that demonstrated improvement
with care coordination. The effects of the VHA system on medication and healthcare utilization
in this population are unknown supporting the primary line of inquiry to describe medication
adherence and healthcare utilization in veterans.

178

Study Purpose
Guided by the CCM, a retrospective analysis was conducted in veterans with IBD to:
describe medication adherence rates; describe healthcare utilization measured by ER visits and
inpatient admissions; and describe care coordination measured by primary care and/or GI
specialty care use. A secondary study aim was to explore the relationships between those key
outcome variables and select demographic/health history characteristics.

Ethical Considerations
Approval was obtained from the appropriate institutional review boards.

Methods
Design & Data Source
A descriptive, retrospective data analysis was conducted by extracting information from a
local VA data warehouse, Veterans Health Information Systems and Technology Architecture
(VistA), containing information about patients treated in the VA Healthcare System which is
updated nightly. VistA is an integrated system of software applications that directly supports
patient care at VA healthcare facilities by tying together workstations and personal computers,
providing a system of management tools that create uniformity of data across the VA system.
Each VistA application generates clinical and administrative data that support the day-to-day
operations of VA facilities and contain patients' medical and healthcare utilization histories.

16

VistA contains the most clinical detail of any VA database and as such, captures many data
points that are not currently available in any other national VA data source

10

and was used to

collect the following study measures: International Classification of Diseases, Ninth Revision
(ICD-9) codes, outpatient pharmacy, patient demographics, and healthcare utilization. VistA
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15

and Veterans Integrated Service Network (VISN) data were collected for outpatient medication
refills only to ensure completeness of pharmacy data capture.

Study Population
The population for this investigation consisted of enrollees in one northeast VA who
sought care for IBD between October 1, 2010 and September 30, 2011 for IBD, fiscal year FY
2011. Cohort inclusion and exclusion criteria are located in Table 1.

Study Measures
Medication adherence was measured using the medication possession ratio (MPR). 17
The MPR was the sum of the days’ supply of medication divided by the number of days
between the first fill and last fill including the days’ supply of the last fill. 16 MPR was calculated
for each medication for each patient and a mean MPR was calculated for each patient taking
more than one medication. 18 As is widely used in the literature, the MPR was a continuous
variable for descriptive analysis, dichotomized for logistic regression models so that those with
an MPR >.80 were adherent and those with an MPR < .80 were non-adherent. 19-30 MPR was an
examined both as a dependent variable in a logistic regression model and was then an
independent variable in the regression models for ER utilization and inpatient admission. The
MPR would not include those with primary non-adherence such as those who were prescribed a
medication but had not picked it up from the pharmacy. Additionally, because the MPR requires
at least two medication refills during the observation period, those filling only one prescription
were not included in the final analysis.
Healthcare utilization variables included ER visits and inpatient admissions, represented
by respective clinic stop codes. For descriptive purposes, the total number of occurrences over
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the one year observation period for each visit type for each patient was collected. However, for
logistic regression, all healthcare utilization variables were dichotomized, yes/no.
Care coordination was measured using clinic stop codes for primary care and
gastroenterology (GI) specialty care. For descriptive purposes, the total number of occurrences
over the one year observation period for each visit type for each patient was also collected.
Veterans with IBD were assumed to have care coordination if both primary and specialty GI
clinic stop codes were present.
Demographic variables included age, gender, race, ethnicity, IBD diagnosis (CD versus
UC) and IBD medication (5-aminosalycilate (5-ASA), immunomodulator, or both) were used to
describe the population under study.
The Deyo adaptation 31 of the Charlson Comorbidity Index (CCI) 32 was used to calculate
comorbidity. Deyo identified 17 categories of medical conditions using ICD-9 codes and
assigned a weighted score for each condition that was summed (Table 1). Higher values
indicated more severe levels of comorbidity.

Statistical Analysis
Data analysis was performed using the Statistical Package for the Social Sciences (SPSS)
version 21.0. 33 A two-tailed test of significance was used with alpha set at .05.
Variable analysis began with descriptive statistics for all study variables including
distribution of continuous variables. Chi-squared tests for categorical variables and t-test
(normally distributed) or Mann-Whitney U tests (non-normally distributed) for continuous
variables were conducted to examine bivariate associations between the primary outcomes of
medication adherence and healthcare utilization and remaining study variables. Similar
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procedures were used to explore care coordination as an outcome. All variables were entered into
logistic regression models regardless of bivariate analysis results. 34
Simultaneous logistic regression was used to examine the effect of age, IBD diagnosis,
IBD medication, comorbidity, and care coordination on adherence, dichotomized (yes (MPR
>.80)/no MPR <.80). Medication adherence was then entered as an independent predictor in ER
and inpatient regression models.
Similar logistic regression model construction was used to explore the impact of age, IBD
diagnosis, IBD medication, comorbidity, medication adherence, and care coordination on ER
utilization and inpatient admission (both dichotomized yes/no). Because IBD diagnosis was not a
significant bivariate predictor, the interaction terms: IBD diagnosis * coordination of care; IBD
diagnosis*age; and IBD diagnosis*medication adherence were created and entered separately
into the inpatient regression model. Odds ratio, 95% CI, and P-values were reported for all three
regression models.

Results
A cohort of 247 (Figure 1) patients extracted from a local VA database with at least one
ICD-9 code for 555.x (CD) and 556.x (UC) were identified between October 1, 2010 and
September 30, 2011. Females (n=11) and non-Whites (n=14) were excluded because of minute
representation. Patients receiving GI specialty care alone (n=36) were also excluded because a
critical study component was to examine relationships between patients cared for in the primary
care setting in isolation, versus patients who received care coordination through primary and GI
specialty care. The final study sample consisted of 165 patients who met all inclusion and
exclusion criteria (Table 2).
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Study Population
The final study sample was homogenous, consisting of White males. The mean age was
69.2 years (SD+ 13.4) with 81% of the sample falling between 60 and 89 years. In the study
cohort, 75 had CD (46%) and 89 had UC (53.9%). A 5-ASA product was prescribed for 76% of
patients while 24% of the sample refilled an immunomodulating medication. Comorbidity was
not present in 44.8% of the sample. The median comorbidity score was 3, SD + 2.9. The top
three comorbidities were COPD (23%), malignancy (15.2%), and cerebrovascular disease
(9.1%).

Medication Adherence Descriptive Results
The adherence rate for the entire sample was 50.9%. The median MPR was .82. As
Table 3 demonstrates, the range of adherence for all IBD medications was as high as 78% for
mesalamine 375mg and as low as 60% for those taking both a 5-ASA and an immunomodulator.
Table 4 presents a summary comparison of study variables by adherence in bivariate analysis
which did not reveal any statistically significant factors associated with adherence.

Healthcare Utilization Descriptive Results
ER Utilization
The mean number of ER visits was .37. The median was 0 .00; 83.1% of patients did not
utilize ER services. Seventeen of the 28 patients who used the ER had 1 ER visit. Bivariate
analysis revealed a statistically significant relationship between ER utilization and patients with
care coordinated between primary and GI specialty care indicating that patients with care
coordination were more likely to engage ER services (OR=29, 95%CI=6.67-129.6, p<.001).
Bivariate analysis also identified medication adherence as a predictor of ER utilization
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suggesting that adherent patients were less likely to use the ER (OR=.321, 95%CI=.132-.779,
p=.009).
Inpatient Admission
Only 10 patients (6%) had an inpatient admission, the mean length of which was .71
days, SD + 3.9. The median number of inpatient admissions was zero as most patients were not
hospitalized. Bivariate analysis revealed a statistically significant relationship between inpatient
utilization and care coordination suggesting that patients with care coordination are more likely
to have an inpatient admission (OR=14.64, 95%CI=1.809-118.547, p=.001). Medication
adherence was also a statistically significant bivariate predictor of inpatient admission
demonstrating that adherent subjects were less likely to experience an inpatient admission
(OR=.223, 95%CI=.046-1.082, p=.044). Bivariate analysis likewise revealed a statistically
significant difference in age between patients with an inpatient admission and patients without an
inpatient admission (t (163)=2.654, 95%CI=2.982-19.943, p =.009). Those with an inpatient
admission were younger (M = 57.3) versus those who without (M = 70.6).

Care Coordination Descriptive Results
The final primary study aim was to describe care coordination of veterans with IBD
measured by primary care and GI specialty care visits. Care presumed to be coordinated between
primary and GI specialty care was found in 41% of the sample. A statistically significant
percentage of patients who had care coordination were prescribed both a 5-ASA and an
immunomodulating medication (30%) compared to those managed by primary care alone
(13.2%) X2(14.182, p=.001).
Independent samples t-test demonstrated a statistically significant difference in age
between those cared for in primary care alone and those who received care coordination

184

(t (163)=4.829, 95%CI=.166-.396, p<.001). Those who received care coordination were younger,
(M=62.9, SD +14.1) than those seen in primary care alone (M=74.4, SD+10.3). More patients
with CD (24.2%) than UC (17.1%) had chronic illness care coordinated between primary and GI
specialty care which was statistically significant (OR=2.421, 95%CI=1.283-4.567, p =.006).
The mean number of primary care visits for patients with care coordinated between
primary and GI specialty care was 2.21 (SD + 1.073) compared to 1.40 (SD+ .623) visits for
those seen in primary care alone, which was statistically significant (t(163)= 6.066,95%CI=.5421.066, p=.001). Comparatively, 46% of patients with care coordination had 3 (SD+ 2.76) or more
visits to GI which was also statistically significant (t(163) = 10.724, 95%CI =.2.472-3.587,
p=.001). Interestingly, 58.8% of those with a diagnosis of IBD were never seen in a GI specialty
clinic.

Multivariate Results
Medication Adherence
A secondary aim of this study was to explore predictors of medication adherence and
healthcare utilization. Multivariate analysis showed no statistically significant relationships
between medication adherence and the variables of age, IBD diagnosis, IBD medication,
comorbidity, and care coordination (Table 5).
ER Utilization
The logistic regression model with ER utilization dichotomized (yes = ER and no = no
ER) containing all predictors was statistically significant, X (7, n=165) = 50.218, p<.001. The
model revealed a statistically significant association between ER utilization and care coordinated
between primary care and GI specialty care (p=.001) and medication adherence ( p=.029)
(Table 5).
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Inpatient Admission
The full model with all predictors was able to distinguish between patients who did and
did not have an inpatient admission (X (7, N=165) = 23.681, p<.001). Table 5 shows that four of
the six independent variables had a statistically significant relationship with inpatient healthcare
utilization. Care coordination was the strongest multivariate predictor of inpatient admission
(p=.033). Addition of interaction terms did not produce any statistically significant results.

Discussion
This is the first study known that critically appraised chronic illness care in veterans with
IBD through the CCM lens of care coordination between primary care and GI specialty care
relative to medication adherence and healthcare utilization. Study strengths included: use of a
theoretical framework recognized by IBD experts as a mechanism to improve outcomes in
patients with IBD; 35-37 generation of a cohort using an administrative definition validated in this
population; 38 use of the gold standard for measuring medication adherence in IBD, the MPR; 19
and use of the consensus definition and measure for adherence propagated by the International
Society for Pharmacoeconomics and Outcomes Research (ISPOR). 18,39
The overall level of adherence in this study (50.9%) is congruent with previous
investigations that included other closed government sponsored healthcare systems and continues
to demonstrate adherence levels well below the accepted value of 80%. 3,47 This study used local
and VISN level VA pharmacy data only. Although slightly higher in this study, the level of
adherence was comparable with recent adherence studies that revealed overall levels of
adherence in this population to be between 37-48%.41,42 as evidenced in large national samples of
veterans that used the same administrative definition for IBD and similar MPR calculations.
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However, this is the first study to examine adherence in the IBD population that was not
able to identify predictors. Regression model construction was parsimonious, guided by the
literature. One possible reason for the lack of significance in our adherence model could be
characteristics unique to our sample. Only two studies have been published that examined
medication adherence rates in veterans with IBD, neither had the goal of identifying predictors of
adherence in this population. 48-50 The samples of both studies consisted primarily of White
males with UC, prescribed oral mesalamine. Our study included patients with both CD and UC
who were prescribed a variety of oral 5-ASA products and/or an immunomodulator.
Additionally, a recent systematic review conducted to examine factors associated with nonadherence in IBD demonstrated that patients in IBD adherence studies are younger than the
patients in our study and are an equal mix of males and females. 3
An additional consideration for these results is the power of the study. It is plausible that
these analyses could have been underpowered, even though steps were taken to address this issue
a priori. The only published data that exists related to medication adherence in veterans with IBD
utilized considerably large samples (n=13,062)50 and (n=4,452)49.. However, these same data had
been shown to demonstrate significance using other statistical tests. This provides evidence that
the current sample size provided adequate power. For example, medication adherence
dichotomized as the MPR (.80) was a significant predictor of ER and inpatient utilization which
speaks to adequate power of the study. Nonetheless, our adherence regression model was only
able to explain 2% (Cox and Snell) to 3% (Nagelkerke) of the variance of those who were
adherent versus those who were non-adherent. Future adherence studies in veterans with IBD
should include larger sample sizes and explore additional variables for clinical relevance to
medication adherence.
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There is a lack of scientific agreement regarding measurement and definition of
medication adherence using administrative data in the literature. Measuring adherence using
pharmacy refill data has been deliberated for decades.

40

Notwithstanding, even consensus

documents promulgated by ISPOR contain discrepancies in advised definition and measure of
adherence 18,39. Most recently, Raebel 41 and colleagues, which included Steiner whose sentinel
paper in 1988 42 started the evolution of electronic database measurement, developed a
conceptual model for standardization of adherence measurement using an algorithmic approach.
The model introduces new concepts into the adherence lexicon. Terms such as adequate
secondary adherence, inadequate secondary adherence, later-stage persistence, later-stage nonpersistence are presented. A new measure of adherence based on medication gaps, new
prescription medication gap (NPMG), is also offered. In an attempt to provide a comprehensive
approach to adherence measurement, new layers of complexity appear. One issue that was
beyond the scope of the paper was the acceptance of an MPR of .80 as representative of
adherence. Although the MPR is the most frequently used administrative measure, it too has its
limitations.

43

An MPR of .80 equates to taking a medication 80% of the time. This means that

20% of the time, the patient is not taking any medication. Use of this cutoff implicitly assumes
that no change in health outcome occurs as result of this “allowable gap” in treatment. The 80%
cut off is used widely throughout adherence literature for many chronic disease states, although
not supported by any documentation of the clinical validity of this measure. 44,45 The origins of
these cut off points are based on the principal that loss of >20% of a patient population in a
clinical trial makes the results suspect. 46 In the interim, the .80 value is the acceptable cut off for
measuring adherence in patients with IBD using administrative data.
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As an independent predictor, medication adherence emerged in our study as having a
strong association with both ER visits and inpatient admissions, suggesting that patients more
adherent to their medications were less likely to engage these services. Our findings were
consistent with a recent study (n=1,693) that also used the MPR to measure adherence and
controlled for comorbidity using the Deyo adaptation method, which demonstrated 34% fewer
ER visits (p=.0016) and 31% fewer hospitalizations (p=.0025) in adherent IBD patients. 8 Our
findings also corroborate previous work that demonstrated 45% lower ER (p<.001) and 62%
lower inpatient (p<.001) resource utilization in adherent IBD patients. 7
The percentages of patients who utilized the ER (16.9%) and had an inpatient admission
(6%) in our cohort were small. One explanation for these healthcare utilization figures may be
the limited one year observation period used in this study because many researchers have
investigated utilization in the IBD population over multiple years.

7,8,51-57,,58

However, healthcare

utilization data in this study was part of an exploratory analysis as the influences on healthcare
utilization in veterans with IBD has not been researched.

8,59

Therefore, further inquiry into the

healthcare utilization patterns of veterans with IBD is warranted.
Care was coordinated in 41% of the sample. Our data demonstrated that the CCM
element of care coordination was found to have several statistically significant bivariate
associations between study variables. Patients with care coordinated between primary care and
GI specialty care were less healthy than patients who were not, as represented by the statistically
significant bivariate characteristics found among patients with care coordination that included:
younger age; more likely to have CD compared to UC; had been prescribed a 5-ASA +
immunomodulating medication; had comorbidities; and had an increased propensity for both ER
and inpatient utilization. One explanation for the characteristics of patients cared for in the GI
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specialty setting may be that primary care providers do not feel comfortable providing care for
patients with IBD more affected by their illness which prompts consultation to the specialist.

62

While it is accepted that a majority of patients with IBD are followed on a long-term basis in an
outpatient GI specialty clinic,63 58.8% of patients in our study were never seen in the GI clinic
which may be due to a more quiescent course of illness in patients with IBD seen in primary
care. This corroborates the comorbid characteristics of our patients with coordinated care
suggesting PCP willingness to treat less complicated patients with IBD by referring them to the
GI specialist as necessary. An alternative explanation for the increased propensity of patients
with care coordination to consume ER and inpatient services could be that these services were
accessed for patient comorbid conditions. However, without specific ICD-9 codes for each type
of healthcare utilization, this is unfeasible to discern.

Limitations
A main study limitation is the definition of care coordination. No consensus in the
literature exists regarding how best to define and measure this variable. Often, research reports
do not include information regarding the definition of this variable. 61 Therefore, to contribute to
science in a meaningful way, the definition of care coordination in our study was derived from
the CCM which adopted the definition from the Agency for Healthcare Research and Quality
(AHRQ) Technical Review and was as follows: “the deliberate organization of patient care
activities between two or more participants (including the patient) involved in a patient’s care to
facilitate the appropriate delivery of healthcare services. Organizing care involves the marshaling
of personnel and other resources needed to carry out all required patient care activities, and is
often managed by the exchange of information among patients responsible different aspects of
care” (p.41). 61 Care coordination in our study was assumed when the patient had clinic stop
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codes for both primary and specialty care. Further exploration of the influences of care
coordination on medication adherence and healthcare utilization in veterans with IBD is
warranted.
An additional limitation of our study is lack of consideration of veteran access to
healthcare outside the VA system. An assumption of our study was that veterans did not access
health services outside the VA for IBD chronic illness care. However, a survey of veterans
conducted during the observation for this study, FY 2011, reported that 45% of enrollees have
access to prescription drug coverage outside the VA, the details of which were unavailable for
this study, and may influence many key study variables.

65

More than 65% of our study sample

was age 65 and over qualifying them for Medicare. The use of Medicare services in veterans was
the focus of a 2012 study conducted by Trivedi that reviewed over 1 million records and
confirmed that 50% of veterans used both Medicare and VA for a variety of healthcare services.
All of this said, access to healthcare outside the VA represents a serious confounder that will
need to be addressed in future veteran research.
Finally, there are several study limitations precluding generalizability of study findings.
Our cohort consisted of White males over the age of 65. However, a recent national survey of
veterans suggested these characteristics are representative of the veteran population. 65 Our study
relied on administrative data that were not verified by comparison with health records due to
resource constraints. Furthermore, these data may reflect the specific practice patterns of the
local VA facility and may not be representative of IBD care delivery across VA. Data used in
this study were not originally generated for research purposes and are subject to coding errors
both during data entry phase by hospital staff and during the data extraction process. We created
a coding index containing detailed definitions of each study variable that was used to retrieve
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data elements to ensure accuracy of data capture. Another study limitation is the fact that a
medication refill does not equate with consumption of medication. A prescription may have been
filled but the patient may not have ingested the medication.

Conclusions
The overall adherence rate in this study, which was consistent with the literature,
demonstrates the need for interventions to improve medication use among patients with IBD.
No predictors of medication adherence emerged, yet medication adherence was an independent
predictor of both ER and inpatient utilization which indicated that adherent patients were less
likely to access these services. The CCM element of care coordinated care was significantly
associated with all healthcare utilization variables suggesting those with care coordinated
between primary care and GI specialty care were overall more likely to access health services
compared to patients cared for in primary care in isolation. The solution to non-adherence and
consumption of healthcare resources in patients with IBD will likely be as complex and
individualized as the treatments they receive. To advance knowledge in this area, this study
suggests that Wagner’s Chronic Care Model can provide a solid foundation for further inquiry.
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Table 1
Translation of Charlson Comorbidity Index (CCI) elements into ICD-9 codes
Diagnostic Category

Myocardial infarction
Congestive heart failure

ICD-9
Codes
410-410.9
412
428-428.9

Assigned
weights for
diseases
1
1

Condition Description

Acute myocardial infarction
Old myocardial infarction
Heart failure
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Peripheral vascular disease

443.9
441.441.9
785.4
V43.4
procedure
38.48

1

Peripheral vascular disease, includes intermittent claudication
Aortic aneurysm
Gangrene
Blood vessel replaced by prosthesis
Resection and replacement of lower limb arteries

Cerebrovascular disease

430-438

1

Cerebrovascular disease

Dementia

290-290.9

1

Senile and presenile dementia

Chronic pulmonary disease

490-496
500-505
506.4

1

Chronic obstructive pulmonary disease
Pneumoconioses
Chronic respiratory conditions due to fumes and vapors

Rheumatolgic disease

710.0
710.1
710.4
714.0-714.2
714.81
725

1

Systemic lupus erythematosus
Systemic sclerosis
Polymyositis
adult rheumatoid arthritis
Rheumatoid lung
Polymyalgia rheumatic

Peptic ulcer disease

531-534.9
531.4-531.7
532.4-532.7
533.4-533.7
534.4-534.7

1

Gastric, duodenal and gastrojejunal ulcers
Chronic forms of peptic ulcer disease
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Table 1 (continued)
Diagnostic Category

ICD-9
Codes

Assigned
weights for
diseases
1

Condition Description
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Mild liver disease

571.2
571.5
571.6
571.4571.49

Alcoholic cirrhosis
Cirrhosis without mention of alcohol
Biliary cirrhosis
Chronic hepatitis

Diabetes

250-250.3
250.7

1

Diabetes with or without acute metabolic disturbances
Diabetes with peripheral circulatory disorders

Diabetes with
chronic
complications

250.4250.6

1

Diabetes with renal, ophthalmic, or neurological manifestations

Hemiplegia or
paraplegia

344.1
342-342.9

2

Paraplegia
Hemiplegia

Renal disease

582-582.9
582-583.7
585
586
588-588.9

2

Chronic glomerulonephritis
Nephritis and nephropathy
Chronic renal failure
Renal failure, unspecified
Disorders resulting from impaired renal function

Any malignancy,
including leukemia
and lymphoma

140-172.9
174-195.8
200-208.9

2

Malignant neoplasms
Malignant neoplasms
Leukemia and lymphoma

Moderate or severe
liver disease
Metastatic solid
tumor
AIDS

572.2572.8
196-199.1

3

Hepatic coma, portal hypertension, other sequelae of chronic liver disease

6

secondary malignant neoplasm of lymph nodes and other organs

042-044.9

6

HIV infection with related specific conditions

“Reprinted from Journal of Clinical Epidemiology, 45(6), Deyo, R. A., Cherkin, D. C., Ciol, M. A., Adapting a clinical comorbidity
index for use with ICD-9-CM administrative databases, 613-619, 1992, with permission from Elsevier”
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Table 2

Inclusion Criteria
At least one outpatient ICD-9 code
CD (555.x)
UC (556.x)
At least two refills of any oral IBD medication
Mesalamine 250mg
Mesalamine 375mg
Mesalamine 400mg
Mesalamine 1,200mg
Olsalazine
Balsalazide
Sulfasalazine
Azathioprine
Mercaptopurine

Exclusion Criteria
 Oral steroids, biologic medications, rectal preparations, injectable
methotrexate
 Inpatient IBD medications
 Patients treated in GI specialty care in isolation with no follow up to primary
care
 Patients with only one refill of outpatient IBD medication(s)
CD=Crohn’s disease; UC=ulcerative colitis; IBD: inflammatory bowel disease; GI=gastrointestinal;
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Figure 1

Cohort Generation
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Table 3. Mean MPR by drug

Drug Class: 5-ASA
Balsalazide
Olsalazine
Mesalamine 250mg
Mesalamine 375mg
Mesalamine 400mg
Mesalamine 1,200mg
Sulfasalazine

Drug Class: 5-ASA
Frequency
(n=165)
2(1.2)
1(.6)
11(6.7)
74(44.8)
48(29.1)
7(4.2)
24(14.5)

Mean MPR
.74
.99
.71
.78
.73
.66
.74

Drug Class: Immunomodulator
21(12.7)
18(10.9)
16(9.7)
16(9.7)

Azathioprine
Mercaptopurine
Aza + 5-ASA
Mercaptopurine + 5-ASA

MPR=medication possession ratio;5-ASA=5-aminosalicylate; Aza=azathioprine
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.65
.77
.60
.83

Table 4. Bivariate analysis of study variables in adherent and non-adherent patients (n=165)
Variable

Coordination of Care

IBD Diagnosis
CD
UC
IBD Medication
5-ASA
Immunomodulator

Both
Comorbidity

Age

Adherent
>.80
%
n
30
18

NonAdherent<.80
n
%
38
23

P

Odds Ratio

.144

.629

95%CI
.337-1.17

38
46

23
28

38
43

23
26

.829
.829

.935
.935

.507-1.725
.507-1.725

65
3
16
44
84

39
2
10
27
51

61
5
15
47
81

37
3
9
28
49

.739
.739
.739
.466
.158

----------

OR

.796

----

CD=Crohn’s disease; UC=ulcerative colitis: 5-ASA=5-aminosalicylate; IBD=inflammatory bowel disease
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------------.430-1.472
-.164-.077

Table 5. Logistic Regression Summary
Adherence
Variable

ER Visits

Inpatient Admit

OR

P

95%CI

OR

P

95%CI

OR

P

95%CI

1.014

.322

.986-1.042

1.009

.641

.971-1.049

.108

.012*

.971-1.004

MPR >.80

-----

-----

-----

.314

.029*

.111-.886

.113

.044*

.014-.939

IBDDx

.837

1.070

.564-2.029

.478

.166

.168-1.360

.117

.027*

.017-.784

IBDMed

.666

1.202

.520-2.778

.537

.305

.164-1.762

1.111

.907

.190-6.490

Comorbid

.343

.727

.377-1.404

1.494

.457

519-4.298

3.222

.166

.616-16.839

CareCoor

.372

.713

.339-1.499

45.73

.001*

9.053-231.035

14.862

.022*

1.463-150.245

Age

*statistically significant .05
ER=emergency room; MPR=medication possession ratio; IBD=inflammatory bowel disease; IBDMed=inflammatory bowel
disease medication; IBDDx=IBD diagnosis; Cormorbid=comorbidity; CareCoor=care coordinationOR=odds ratio; 95%CI=95%
confidence interval
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IRB Approval-Initial Review
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Study# Pro00000762
Retrospective data analysis in veterans with inflammatory bowel disease: Using the
Chronic Care Model to explore medication adherence
The following items were reviewed and approved through Expedited Review:

IRB Study Application
Support Letter – Medical Specialty
Email from Research Office – Statistical Support
Appendix A: Comorbidity Index ICD-9 Codes
Waiver of HIPAA Authorization – Full Study
Waiver of Informed Consent – Full Study
Coding Index
Cohort Generation
Student/Trainee Research: Co-PI Certification signed by Dr. Khalid
Expedited Approval was granted on 07/12/2013. Approval is granted from 07/12/2013 to
07/11/2014.
The VAPHS IRB has determined that this project meets the definition of Human
Subjects Research.
This request for initial review was reviewed and approved by the IRB Chairman under
the following expedited review category:
Category 5: Research involving materials (data, documents, records or
specimens) that have been collected (for any purpose, including research), or will be
collected solely for non-research purposes (such as medical treatment or diagnosis).
Research presents no more than MINIMAL RISK to subjects (considering physical,
psychological, social and economic risk)
AND
Identification of the subjects and/or their responses WOULD NOT reasonably place
them at risk of criminal or civil liability or be damaging to the subject’s financial standing,
employability, insurability, reputation, or be stigmatizing, OR reasonable and appropriate
protections will be implemented so that risks related to invasion of privacy and breach of
confidentiality are minimal.
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Risk Assessment: Minimal; IRB Level of Scrutiny: Low (The risk assessment was made
considering Social; Physical; Psychological; and Economic Risk).
AE Reporting: All unexpected/unanticipated, serious adverse events, whether related
or unrelated to the research must be reported to the IRB within 5 business days of the
investigator becoming aware of the event.
Data Security Level: Level 1 – VA Sensitive Information is collected/used and
subjects are unaware of the use/disclosure
The protocol is approved for a sample size of: 2000.
Sincerely,
Linda Fried
Electronically Signed
Click Commerce's Compliance Extranet product meets or exceeds the
requirements in 21 CFR Part 11 for "closed" systems by providing
manageable name/password administration, strong passwords with
rotation options and electronic signature components that are only
executable by, and designed to be used only by, specified individuals for
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Warning: This transmission is intended only for the use of the person or
office to whom it is addressed and may contain information that is
privileged, confidential, or protected by law. All others are hereby
notified that receipt of this message does not waive any applicable
privilege or exemption from disclosure and that any dissemination,
distribution, or copying of this communication is prohibited. If you
received this communication in error, please notify the Research Office
immediately. Thank you.
VA PITTSBURGH HEALTHCARE SYSTEM
7180 Highland Drive
Pittsburgh, PA 15206
412-954-5381
http://www.pittsburgh.va.gov/Research/professionals.asp
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From: Rizzo, Lori K
Sent: Friday, November 15, 2013 9:38 AM
To: 'nbeagin@ajmc.com'
Cc: 'bhaug@ajmc.com'
Subject: Permission

All:
I have unsuccessfully been trying to obtain permission to use a Figure from your publication,
The American Journal of Managed Care.
I am a PhD student. I would like to use Figure 3 on page 453 from the article below in my
dissertation: Sikka, R., Xia, F., Aubert, R. E. (2005). Estimating medication persistency using
administrative claims data. The American Journal of Managed Care. 11(7), 449-457.
I look forward to your reply.
Best,
Lori
From: Nicole Beagin [mailto:nBeagin@ajmc.com]
Sent: Friday, November 15, 2013 9:58 AM
To: Rizzo, Lori K
Subject: Re: Permission

Hello,
Please forgive the delay in reply. The editorial staff is currently out of office at our conference.
You have our permission to use the figure.
Sent from my iPhone
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